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Preface
To bring into focus the rapidly expanding areas of research
associated with the opioid peptides, an Indo-U.S. Symposium was
held in February 1987 at the Central Drug Research Institute
(CDRI), Lucknow, India. This symposium was organized by the
National Institute on Drug Abuse (NIDA) and the CDRI and was
jointly funded by NIDA; CDRI; the Department of Science and
Technology, Government of India. and the National Academy of
Sciences, New Delhi.
A number of individuals were responsible for the success of this
conference. We especially acknowledge the help of Dr. Phil
Schambra, Science attache, U.S. Embassy (India). Mrs Linda A.
Vogel, Associate Director for Management and Program Coordination,
Office of International Health; Dr. George V. Coelho, Chief,
International Activities Program, ADAMHA; at NIDA, Dr. James C.
Cooper, Associate Director for Medical and International Affairs;
Dr. Marvin Snyder, Director, Division of Preclinical Research; and
Dr. Richard L. Hawks, Chief, Research Technology Branch; and at
CDRI, Dr. R. Raghubir and Mr. K.L. Gupta.
Selected papers from this symposium have appeared as a research
monograph published by the CDRI, entitled Recent Progress in
Chemistry and Biology of Centrally Acting Peptides. Other
presentations from the symposium, along with contributions from
invited authors, comprise the present monograph.
We are grateful to all the contributors for their cooperation in
preparing this publication. We hope that this volume will serve as
a useful reference source on various aspects of the medicinal
chemistry, pharmacology, and biochemistry of opioid peptides and
will provide new incentives for drug abuse researchers in the
opioid peptide field.
Rao S. Rapaka
Bhola N. Dhawan
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Neuropeptides, A Personalized History
Sidney Udenfriend, Ph.D.
The full significance of the important roles in neurobiology played
by peptides is still emerging. It seems that each day we read of
the discovery and characterization of new peptides in extracts of
neural tissue. In fact the chemical structures of neuropeptldes are
now elucidated before their biological significance becomes
apparent. What is responsible for this rapidly growing field are
the recent advances in microprotein chemistry and molecular
biology. Therefore a brief history of peptide chemistry is
important to understand how we have advanced in so relatively short
a period of time in our ability to isolate and characterize trace
amounts of peptides in biological extracts. In this review, I will
not differentiate between small peptides and large peptides
(proteins). I will also discuss peptides in the nervous system as
well as in the endocrine system because of the interrelationship of
these two systems.
The earliest neuroactive substances to be characterized were the
amlnes and substituted amlnes--first acetylcholine, then adrenaline,
noradrenaline, and serotonln. Although dopamine was known for some
time, it was considered to be an intermediate rather than a
neuroregulator in Its own right until somewhat later. However, in
some of the earliest studies (late forties and early fifties) it was
recognized that other substances were active in nerve and muscle
preparations that were not amlnes and whose activities were
destroyed by proteases.
In 1950 peptide chemistry was still emerging as a discipline. While
synthetic chemists could synthesize small peptides, methods for
their purification, even from synthetic mixtures, were not yet very
efficient. Sequencing of peptides had not yet been introduced. In
fact, there was still controversy as to whether each peptide and
protein was a stoichlometrlc entity (i.e., had a unique and
invariable sequence) or whether a given protein or peptide was
composed of molecules each varying somewhat from the other but the
average being fairly constant for that peptide. The dlpeptldes
carnosine and anserine had been isolated from muscle. Homocarosine,
the GABA analog of carnosine. was found to be uniquely present In
brain. However. the high concentration (mg of peptide per g of
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tissue) and small size of these compounds required no unusual
methodology. The first findings that specific proteins have an
invariant molecular composition came from end-group analysis when it
was shown that the same protein isolated from highly diverse species
always had the same amino terminus. Not until the late 1950s. after
Fred Sanger had devised a method for elucidating the amino acid
sequence of a protein and applied it to insulin, was it generally
conceded that all proteins and peptides had exact molecular
compositions.
Several years later, Vincent du Vigneaud isolated and characterized
oxytocin and vasopressin from extracts of the posterior pituitary
gland. It should be noted, however, oxytocin and vasopressin are
present in relatively large amounts in the pituitary gland (ca l
Pmole/g). Column chromatography became generally available in the
late fifties, and Edman introduced the manual procedure for
sequencing peptides at about the same time. These procedures were
used in the isolation and characterization of angiotensin and
bradykinin. In the late sixties Roger Guillemin and Andrew Schally
used similar procedures to isolate TRH from hypothalamus. However,
the hormone was so potent that to isolate the amounts needed at the
time for analysis and sequencing (ca 50 nmoles) they had to extract
tons of tissue. This was very costly and time consuming and required
all the patience and skill of these two outstanding scientists. At
about the same time many other biologically active factors that were
apparently peptide in nature were also reported--substance P, many
growth factors, including nerve growth factor, and a host of
lymphokine activities including the interferons. Isolation and
characterization of these had to await newer developments.
Several major discoveries and advances in technology in the late
sixties and seventies, advances that are still continuing today,
completely changed our approach to dealing with biologically active
peptides. High performance liquid chromatography (HLPC) with
ultrasensitive detection systems made it possible to achieve many
thousandfold degrees of purification in a relatively few steps and
with relatively small amounts of material. The continued
improvement in sensitivity and speed of commercial automated
sequenators now make it possible to determine the primary structure
of a modest sized peptide within a day, starting with 100 pmole or
less of pure material. With monoclonal‘antibody techniques, it is
now possible to prepare specific antibodies to a biologically active
peptide while it is still present in a crude mixture. These
monoclonal antibodies can then be used for rapid purification of the
peptide. With monoclonal antibodies it is frequently unnecessary to
actually isolate the biologically active peptide to determine its
sequence. When expression vectors are used for cloning the cDNA
derived from the tissue of interest, monoclonal antibodies can be
used for clone selection. Sequencing is then carried out on
specific cDNA from which the primary structure of the peptide
precursor can be deduced. Having isolated and determined the
sequence of a peptide or its cDNA, the peptide can be readily
synthesized for further study. The synthetic peptide can then be
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used to prepare site directed polyclonal antibodies, which provide
additional tools for studying the localization and regulation of
that peptide.
I would like to briefly discuss some of the developments in the
chemistry and biology of neuropeptides that took place in the Roche
Institute of Molecular Biology over the past 20 years. Although the
structures of oxytocin and vasopressin were already known, it was
Sachs and Takabatake (1964) who first demonstrated that each of
these was produced as part of a larger polypeptide containing the
neurophysin sequence. This information laid the groundwork for the
subsequent cloning and sequencing of the cDNAs for oxytocin-
neurophysin and vasopressin-neurophysin (Richter 1987).
The dipeptide carnosine, which was originally considered to be
restricted to muscle, was found to be present in the olfactory bulb
by Margolis (1974). Carnosine is now considered to be a transmitter
with a presynaptic site of action. This peptide along with the
enzyme carnosine synthetase and the degradative enzyme carnosinase
are now used as markers of olfactory nerves and to monitor nerve
regeneration. Margolis has also isolated, sequenced, and cloned a
protein that is uniquely expressed in the olfactory mucosa (Keller
and Margolis 1976).
In my own laboratory (Bohlen et al 1975) we developed HPLC and
introduced the fluorescent reagent, fluorescamine, for high
sensitivity. These procedures made possible many studies that were
subsequently carried out in our Institute and elsewhere. Shortly
after the discovery of the enkephalins, my colleagues and I used the
fluorescamine HPLC procedure in the discovery of the prescursor of
beta-lipotropin (Rubinstein et al. 1978a). Chromatograms of
pituitary extracts revealed a ß-endorphin-containing peptide that
was larger than beta-lipotropin, about 30K. This appeared
simultaneously with the report of Mains et al. (1977), who found
that the 30K protein also contained within it the sequence of ACTH.
We coined the name proopiocortin for this common precursor of
ß-endorphin and ACTH. Subsequently, to emphasize the sequences of
MSH in the 30K protein, it was renamed pro-opiomelanocortin, now
better known as POMC. In their studies in cell culture, Mains and
Eipper found that POMC was produced as a glycosylated protein. For
this reason it was generally believed that all forms of POMC are
glycosylated and that the latter may have something to do with
biological activity. However, we showed that in vivo glycosylation
is highly variable from individual to individual within a given
species. In pituitaries taken from individual camels, we showed
that in some glands isolated POMC was almost entirely in the
glycosylated form while in others the molecule contained little or
no glycosyl residues (Kimura et al. 1979). Apparently in the case
of POMC as in other proteins and peptides the significance of
glycosylation remains to be determined.
It is of interest that Rubinstein, who had isolated POMC,
subsequently used the same procedures in my laboratory in
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collaboration with Pestka to isolate a-interferon from human
leukocytes (Rubinstein et al. 1978b). This represented the first
purification and characterization of any form of interferon and
quite a feat because the amount of interferon in these cells was
very small. Although interferon was discovered in the early fifties
and many had tried to purify it over the years, it was not until
1978 with the availability of these newer peptide methods that its
purification and characterization were achieved.
Getting back to the enkephalin pentapeptides, many believed that
they were derived from POMC However, we reasoned that POMC could
not give rise to free Leu-enkephalin since it did not contain that
sequence. Furthermore, although the B-endorphin derived from POMC
contained a Met-enkephalin sequence at its amino terminus, there was
no known processing site adjacent to this sequence that could lead
to its processing to Met-enkephalin. For those reasons we decided
to look for other enkephalin-containing compounds that could serve
as precursors. We devised a bioassay that involved homogenizing
tissue, then treating the extract with trypsin followed by
carboxypeptidase B. By analogy with other peptide precursors, we
felt that there was a good possibility that the enkephalin sequence
within its precursor would be bracketed by pairs of Lys and/or Arg
residues, i.e., -Lys-Arg-enkephalin-Lys-Lys. Trypsin cleaves basic
residues at their carboxyl termini and would be expected to cleave
out a hexapeptide. enkephalin-Lys or enkephalin-Arg. The latter
would be converted to free enkephalin by the carboxypeptidase and so
detectable by the binding assay. The first application of the above
procedure to guinea pig and rat striatum revealed many large
peptides from which both Met- and Leu-enkephalin were released on
treatment with the two proteases (Lewis et al. 1978). Following a
report that bovine adrenal medulla is rich in enkephalins
(Schultzberg et al. 1978), we turned to that tissue from which we
isolated and sequenced about ten different enkephalin-containing
peptides, some containing withln them as many as four enkephalin
sequences (Lewis et al. 1980). Others contained both Met- and
Leu-enkephalin. Even before these enkephalin-containing peptides
were characterized, we had demonstrated the presence in brain and
adrenal medulla of a very large peptide which, on treatment with
trypsin and carboxypeptidase B, yielded approximately six
Met-enkephalin residues per Leu-enkephalin residue. This led to the
concept of a multivalent proenkephalin. It appeared that
proenkephalin like POMC was a polyprotein, one containing the
sequences of more than one active peptide, and that these sequences
were designed to be released by processing.
The many enkephalin-containing peptides that we had isolated and
sequenced at the time were like pieces of a jigsaw puzzle. Although
we had most of the pieces, some were still missing and their exact
order was not clear. However, one of the pieces, Peptide F,
contained a sequence that showed no degeneracy at the nucleic acid
level, enabling us to make an excellent cDNA probe. The same probe
was used by us (Gubler et al. 1982) and by Numa and his colleagues
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(Noda et al. 1982) to clone and sequence bovine proenkephalin. The
latter was indeed shown to contain six [Metlenkephalin and one
[Leu]enkephalin sequence as predicted from the peptides we had
isolated. Two of the sequences were designed to be processed out as
heptapeptides.
With POMC and proenkephalin sequenced, there still remained two
[Leu]enkephalin-containing peptides that were present in the
posterior pituitary and whose sequences did not appear in either of
these precursors. These were a-neoendorphin (Kangawa et al. 1981)
and dynorphin (Goldstein and Ghazarossian 1980). It was already
apparent that a third enkephalin-containing precursor must exist.
Before it was characterized we (Kilpatrick et al. 1982) and Fischli
et al. (1982) independently isolated and characterized a third
[Leu]enkephalin-containing peptide (rimorphin) and showed it to be
present in posterior pituitary extracts in amounts comparable to
a-neoendorphin and dynorphin. Using the sequence information
provided by these peptides, Numa's laboratory cloned and sequenced
their precursor. prodynorphin (Kakidani et al. 1982). The
significance of the redundancy of enkephalin precursors is still not
clear, nor are the exact functions of these neuropeptides known.
Later, Howells in my laboratory cloned and sequenced rat
proenkephalin CDNA (Howells et al. 1984) so that we would be able to
study the biology of the opioid peptides in the species that has
been used most in studies on opiate drugs. We used the cDNA,
antibodies, and HPLC in many different ways. Proenkephalin derived
peptides and the corresponding mRNA were found in several nonneural
tissues including the heart ventricles (Howells et al. 1986) and the
testis and ovary (Kilpatrick et al. 1985) as well. They are also
present in the intestine and pancreas. It is apparent that the
biological functions of proenkephalin derived peptides, like those
of many other neuropeptides. are not limited to the central nervous
system. Adrenal proenkephalin transcription and translation are
markedly increased by denervation (Howells et al. 1984; Lewis et al.
1981) and are apparently under the control of glucocortlcoids
(Yoburn et al. 1987; Mocchetti et al. 1985). Brain proenkephalin
transcription and translation are increased by several centrally
acting drugs (Tang et al. 1983; Romano et al. 1987).
Antibodies to opioid peptides had been used to trace the
proenkephalln innervation in the CNS. However, a more precise and
complete localization of proenkephalin neurons in the brain was
recently carried out with the corresponding rat cDNA. The in situ
hybridization studies were carried out by Howells in my laboratory
in collaboration with Pfaff and his colleagues (Harlan et al.
1987). In situ hybridization methods utilizing cDNA are becoming
more sensitive and may even be more specific than
immunocytochemistry. The latter visualizes nerve bodies as well as
fibers, whereas hybridization visualizes nerve bodies exclusively.
When dealing with antibodies directed to small molecules, such as
the opioid peptides or the catecholamines, diffusion may limit the
precision of localization by immunocytochemistry. Localization of
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macromolecules, whether precursors, specific enzymes, or specific
mRNA, is generally more precise.
I will conclude with two recent examples of the advances that modern
biotechnology has brought to the neurosciences. In the late sixties
Guillemin had to use tons of beef hypothalami to isolate hundreds of
nanomoles for characterizing the first releasing factor, TRH. More
recently Guillemin's laboratory was able to isolate a few hundred
picomoles of growth hormone releasing factors from several grams of
human tissue (Guillemin et al. 1982). This was sufficient for
sequencing. Shortly thereafter, in collaboration with Roche
scientists they cloned the corresponding cDNA (Gubler et al. 1983).
A fraction of the amount of tissue was used, and purification and
sequencing were accomplished on far less material and in a much
shorter time.
Horecker, while at our Institute, had shown that extracting tissues
with 6M guanidine hydrochloride prevents proteolysis (Hannappel et
al. 1982). Under these conditions most larger proteins are
denatured and precipitate and supernatant solutions contain peptides
that are characteristic of a tissue and are not experimental
artifacts. A brain extract prepared in this manner yields many
peptides on HPLC. Some of these peptides are present in other
tissues and are probably known. Others are unique to brain. When
Morgan applied this extraction procedure along with HPLC to
different portions of the brain, the resulting chromatographic
eluates contained relatively few peptides. Two of the unidentified
minor components in extracts of cerebellum when isolated and
sequenced were shown to be unique molecules and limited to the
cerebellum (Slemmon et al. 1984). These two related peptides, which
he named cerebellins, are localized in Purkinje cells (Slemmon et
al. 1985). The cerebellins are now used as markers for maturation
of these cerebellar cells. No doubt many other "minor peptides"
present in extracts recovered from specific brain areas will prove
to be of interest.
One of the most interesting developments relating to peptides in the
brain concerns oncogene products. Oncogenes were originally
discovered through their association with tumors, and the
translations products of oncogenes are considered to be aberrant
versions of normal regulatory proteins or peptides. Protooncogenes
code for normal proteins the functions of which are still being
determined. Morgan and Curran in our Institute showed that the
c-fos protooncogene is rapidly and transiently induced by
receptor-ligand interaction and by agents that affect voltage
dependent calcium channels (Morgan and Curran 1986). The magnitude
of these effects is modulated by pharmacologic agents. More
recently they applied immunocytochemical methods to c-fos
protooncogene induction as a means of determining the exact cells in
brain where specific drugs act.
With all the advances that have been made in methodology and
6
instrumentation and with our increasing knowledge of how proteins
and peptides are made, there is still a great future for peptide
research in neurobiology.
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INTRODUCTION
The discovery of enkephalins (Hughes 1975) ushered in a new era in
which peptides emerged as a novel class of potent analgesics. Soon
after their isolation and characterization was reported by Hughes et
al. (1975), the search for other endogenous peptides possessing opioid
activity was further intensified and several of them could be isolated
from different mammalian tissues and fluids within a short span of
time (Rossier 1982). Almost simultaneously, structure-activity relationship
studies on these pentapeptides were undertaken in a number of labora-
tories, primarily with the object of getting a synthetic peptide that
could be utilized as a pain reliever in clinical practice (Morley 1980,
1983; Hansen and Morgan 1984). Endeavors of this sort were also started
at this Institute, and the interesting results obtained by us are being
briefly reviewed in this communication.
RATIONALE FOR THE DESIGN OF ANALOGS
Since the analgesia evoked by enkephalins was found to be only weak
and transient after they were injected directly into the cerebral ven-
tricles (Chang et al. 1976; Belluzzi et al. 1976), our emphasis was mainly
on the design and synthesis of such analogs of enkephalins that would
elicit profound and long-lasting analgesia even after their administration
by the systemic routes. For designing new congeners, special care was
also taken while introducing novel structural features in the molecules
so that the resulting peptides could be synthesized rather conveniently
even on a large scale when required. At the very outset, we were struck
by the finding that -endorphin, which is a 31 amino acid peptide having
the Met-enkephalin sequence at its N-terminus (Li and Chung 1976;
Bradbury et al. 1976), produces a powerful and long-lasting analgesia
even after intravenous (i.v.) injection (Tseng et al. 1976). It is nearly
100 times more potent than morphine by intracerebroventricular (i.c.v.)
route and 3 to 4 times as potent as morphine when administered intra-
venously (Li and Chung 1976; Tseng et al. 1976). Based on a comparison
of the analgesic properties of -endorphin and two synthetic congeners
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of Met-enkephalin whose N- and C- termini were stabilized against
enzymatic degradation (Pert et al. 1976; Bradbury et al. 1977), Bradbury
et al. (1976) and Cox et al. (1976) suggested that the high order of
activity of -endorphin was not merely due to its being impervious
to brain enzymes. According to them, it could be more of a reflection
of its higher binding affinity with the opioid receptors that might be
arising from the sequence of amino acids that extends from its N-
terminal pentapeptide (Bradbury et al. 1977). If that was true, derivatiza-
tion of the terminal carboxy function of Met-enkephalin to get alkyl-
amides could be expected to lead to derivatives that would not only
be resistant to the attack of carboxypeptidases, but would also possess
higher binding affinity for the opioid receptors due to enhanced hydro-
phobicity at the C-terminus (Beddell et al. 1977). Moreover, the presence
of alkyl chains in these derivatives was also expected to increase their
overall lipophilic character so that their penetration through the blood-
brain barrier would be possible (Belluzzi et al. 1978). To investigate
this hypothesis, a series of alkylamides of Met-enkephalin were synthesized
and examined for their morphinomimetic activity. As reported earlier,
all the newly synthesized compounds of this series exhibited marked
opioid activity (Patnaik et al. 1982). The most active compounds were,
however, t h e  n-propyl and isopropyl amide derivatives. Encouraged
by the initial results, we launched the synthesis of another series of
alkylamides in which the N-terminus of the pentapeptides was also
protected against the attack of brain enzymes (Hambrook et al. 1976).
In this series, the Gly2 residue of enkephalins was replaced by D-Ala
as Pert et al. (1976) and Beddell et al. (1977) had already demonstrated
that such a substitution not only protected the Tyr1-Gly2 bond against
cleavage by aminopeptidases but also potentiated the receptor-binding
affinity of the peptides. As expected, all the pentapeptides thus obtained
showed more pronounced and sustained antinociceptive activity following
intracerebral (i.c.) administration (Mathur et al. 1979). The most promis-
ing compounds here again were the isopropyl- and n-propyl derivatives.
With a view to further optimize the morphine-like activity of these
pentapeptide derivatives, we proceeded in two ways. On the one hand,
a few substituted hydrazides of (D-Ala2 , Met5)-enkephalin were synthesized
as we found that the hydrazide derivative (11) was twice as potent
an analgesic as the corresponding amide (compd. 10, table 2). On the
other hand, we decided to substitute Phe4 in peptides 3 and 4 (table 1)
with a MePhe residue so that the Gly2 -Phe4 bond would be stabilized
against the action of enkephalinases (Schwartz et al. 1981; Gorenstein
and Snyder 1980) and the hydrophobic site provided by the phenyl ring
of Phe4 would be retained in the molecules for interaction with the
opiate receptors (Corin et al. 1980).
The incorporation of this modification could be expected to yield highly
potent and systemically active peptides (Römer et al 1977; Römer
and Pless 1979). The sulfoxides of derivatives 5 and 6 were also syn-
thesized (compds. 7 and 8, table 1) for studying their activity profile.
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TABLE  1
Comparative Morphine-Like Activity of New Enkephalin Analogs
S.No. Compound
Relative
Molar Potency
Analgesia GPI
(i.c.)
1.
2.
3.
4.
5.
6.
7.
8.
9.
Tyr-Cly-Gly-Phe-Met-NH.C3H7(n)
C3H7(i)
D-Ala C3H7(n)
C3H7(i)
MePhe C3H7(n)
C3H7(i)
Met(0) C3H7(n)
C3H7(i)
Gly- C3 H7 ( i)
Tyr-Gly-Cly-Phe-Met
0.82 0.52
2.88 0.36
2.53 4.55
8.84 5.60
24.17 30.00
716.08 12.95
20.85 24.78
353.62 19.06
706.09 2.98
0.01 2.00
Morphine hydrochloride
ED50 Morphine analgesia in mice(i.c.): 0.11±0.01 µg;
IC50 (10
-8M):5.7±0.07mg/ml
1.00 1.00
TABLE 2
Analgesic Activity of (D-Ala2, Met5)-Enkephalin Amide and Hydrazides
in mice (i.c.)
S.No. Compound RelativeMolar Potency
10. Tyr-D-Ala-Cly-Phe-Met-NH2 0.31
11. NH.NH2 0.56
12. NH.NH.C6H5 21.52
Tyr-Gly-Gly-Phe-Met 0.01
Morphine hydrochloride 1.00
ED50 Morphine analgesia: 0.10 ± 0.01µg
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It is evident from the molar. potencies of peptides 6 and 8 (table 1)
that the oxidation of Met residue to Met(0) leads to a drastic reduction
of the intrinsic activity of the parent peptide (Raghubir et al. 1982).
An attempt was, therefore, made to substitute the Met side-chain
of analog 6 by other stereochemically equivalent side-chains by replace-
ment of the thiomethylene group of Met with an amide residue and
several analogous peptides were obtained (Sharma 1983). In addition,
the side-chain of Met5 was altogether deleted in one of the analogs.
As discussed in the subsequent sections, some highly potent systemically
active enkephalin analogs could thus be obtained. Finally, a few analogs
in which Nval, D-Nval and Gly residues were incorporated as the fifth
amino acid and their carboxy functions were derivatized as isopropylamide
or phenyl hydrazide were also synthesized in an effort to get an analog
which may be more selective for the -subtype of opiate receptors.
The synthetic strategies and biological activities of some of the more
promising analogs of enkephalin obtained under this study are being
discussed in the following sections.
SYNTHESIS OF PEPTIDES
All the enkephalin analogs were synthesized in the solution phase by
well-established procedures of peptide synthesis. In general, coupling
of amino acids and peptides2 was achieved by the DCC/HOBt, mixed
anhydride and 2,4,5-trichlorophenyl ester methods. Except in the case
of Met-enkephalin alkylamides, where the carboxy function of Met
was initially protected by p-nitrobenzyl group, methyl or ethyl esters
were employed for protecting the carboxyl groups. The -NH2 functions
of amino acids and intermediate peptides were protected either with
a carbobenzoxy (Z) or t-butyloxycarbonyl (Boc) group. The cleavage
of Boc group was accomplished by treatment of the protected derivatives
with TFA, HCOOH or HCl/dioxane in presence of ethanedithiol and
anisole. Z-group was removed either by hydrogenolysis over Pd/C or
by catalytic transfer hydrogenation using HCOOH as the hydrogen donor.
The synthetic strategy for getting alkylamides of Met-enkephalin involved
sequential peptidation of Met-ONBzl with appropriate Boc-amino acid-
2,4,5-trichlorophenylesters to get the protected pentapeptide Boc-Tyr-
Gly-Gly-Phe-Met-ONBzl. Treatment of this pentapeptide ester with
the required amines followed by cleavage of Boc group from the resulting
amides gave the desired analogs (Dhotre et al. 1984).
The synthesis of alkylamides of (D-Ala2, Met5)-enkephalin was also
carried out in a stepwise manner starting from Met-ONBzl in the same
way as described for Met-enkephalin alkylamides (Dhotre and Mathur
1984). An alternate strategy involving (3+2) fragment condensation
technique was also adopted for the synthesis of peptides of this series
as well as for the n-and isopropylamides of (D-Ala2 , MePhe4 , Met5)-
enkephalin (figure 1). In this procedure, the C-terminal dipeptide ester
Boc-Phe-Meta-OMe or Boc-MePhe-Met-OMe was synthesized by either
DCC/HOBt or mixed anhydride method and converted into the required
alkylamides via the free peptide acid. The N-terminal tripeptide fragment
was coupled with the appropriate C-terminal dipeptide alkylamides
via the 2-4-5-trichlorophenyl ester for getting (D-Ala2, Met5)-enkephalin
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alkylamides and via the mixed anhydride for getting (D-Ala2, MePhe4,
Met5)-enkephalin propylamides 5 and 6. Synthesis of Tyr-D-Ala-Gly-
MePhe-Gly-NH.C3H7(i) (compd.9) was also achieved in the same fashion
by coupling the N-terminal tripeptide with . MePhe-Gly-NH.C3Hr(i).
The sulfoxides 7 and 8 (table 1) could be obtained by direct oxidation
of compounds 5 and 6 using approximately IN H202 in acetic acid
(Raghubir et al. 1982).
FIGURE 1
Synthetic Strategy For Various Enkephalin Analogs
Aaa:Phe or MePhe; Bbb: Met or Gly; R: n-propyl or isopropyl
Various (D-Ala2, Met5)-enkephalin hydrazides (table 2) were synthesized
by a slightly modified procedure. The common intermediate Boc-Tyr-
D-Ala-Gly-Phe-Met-OMe, was obtained first by coupling the mixed
anhydride of Boc-Tyr-D-Ala-Gly with Phe-Met-OMe. Treatment of
the pentapeptide ester with hydrazine hydrate directly gave the correspon-
ding hydrazide which was deblocked with HCl/dioxane to give the
compound 11. For the synthesis of the phenyl hydrazide 12, the penta-
peptide ester, mentioned above, was hydrolyzed and the resulting acid
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coupled with phenylhydrazine by the mixed anhydride procedure (Sharma
1983). Cleavage of the Boc group by treatment with HCOOH gave
the final product. Homogeneity of all the peptides was checked by
chromatography including HPLC.
BIOLOGICAL ACTIVITY
Morphinomimetic activity of all the newly synthesized analogs of enke-
phalin was examined both in vitro and in vivo. For in vitro tests, the
electrically stimulated myenteric plexus-longitudinal muscle preparation
of guinea pig ileum (GPI) was prepared from adult guinea pigs of either
sex as described by Kocterlitz and Watt (1968). Graded concentrations
of various compounds were added to the bath and agonist activity cal-
culated from inhibition of the contraction (IC50 values). Morphine hydro-
chloride and Met-enkephalin were used as standard for comparison.
Naloxone antagonism was used to investigate the specificity of action.
For assaying analgesic activity of peptides, the method of Eddy and
Leimbach (1953) was employed using mice of either sex in groups of
10 for each dose. The compounds were administered in graded doses
intracerebrally (i.c.) and the control group received an equal volume
of normal saline by the same route. Percentage of animals showing
analgesia was determined at each dose level and ED50 calculated accord-
ing to Finney’s Probit analysis (1952). Morphine hydrochloride and Met-
enkephalin were used as standard drugs and naloxone was used to anta-
gonize the analgesic effect.
The relative molar potencies of some of the more promising analogs
of enkephalin obtained by us in analgesia and GPI tests are presented
in tables 1 and 2. As mentioned earlier, the most active compounds
among the alkylamides of Met-enkephalin were the n-propyl and isopropyl-
amide derivatives, being 80 and 270 times more potent than the parent
pentapeptide in the analgesia test. Lengthening and shortening of the
alkyl chain was found to have an adverse effect on the antinociceptive
activity. However, the most potent compound of this series in the GPI
test  was the n-hexyl amide, its activity being 12 times higher than
the isopropylamide (Patnaik et al. 1982).
In the (D-Ala2,Met5)-enkephalin alkylamide series too, the highest
order of analgesic activity was exhibited by the isopropylamide (compd.4)
followed by the n-propylamide (compd.3). It can be seen that replacement
of Gly2 with D-Ala has led to a threefold increase in the activity of
these peptides (Mathur et al. 1979). Peptides 3 and 4 are approximately
240 and 800 times more potent than Met-enkephalin on a molar basis.
Here again, there is no correlation in the in vivo and in vitro activities
of compounds. The most active derivative of this series in the GPI
test was the ethylamide. The hydrazide of (D-Ala2, Met5)-enkephalin
was found to be twice as potent as the corresponding amide. When
the hydrazide nitrogen was substituted with alkyl groups, no significant
change in the activity was observed. In the case of phenyl hydrazide,
however, a substantial enhancement of analgesic activity was achieved
(table 2). It is nearly 2,000 times more active than Met-enkephalin.
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When Phe4 was substituted by a MePhe residue in the propylamides
3 and 4, highly potent analogs could be obtained. The antinociceptive
activity of peptides 5 and 6 is nearly 12 and 80 times higher than that
of compounds 3 and 4 respectively. As compared to Met-enkephalin,
(D-Ala2, MePhe4, Met5)-enkephalin isopropylamide is nearly 70,000
times more potent as an analgesic (Raghubir et al. 1982). The correspond-
ing sulfoxide retains only half the activity of the parent peptide. It
has, however, been found to be active even when administered by
systemic routes. This is in conformity with the results obtained by
Römer et al. (1977) and Römer and Pless (1979).The most significant
finding of this study is that the side chain of Met5 in (D-Ala2, MePhe4,
Met5)-enkephalin isopropylamide does not seem to play any role in
the manifestation of the opioid activity of this analog. As such, the
Met residue can
Ala2, MePhe4, Gly5)-Enkephalin isopropylamide is, in fact, a highly potent
be replaced by Gly without any loss of activity. (D-
analog and elicits profound and longer-lasting analgesia even after
systemic administration (Raghubir et al. 1984). Both the systemically
active compounds mentioned above have been taken up for detailed
investigation, and their pharmacological profile is discussed elsewhere
(Raghubir et al. 1988). We have also found that the corresponding phenyl
hydrazide, (D-Ala2, MePhe4, Gly5)-enkephalin phenyl hydrazide, is
comparatively more selective for s-subtype of opiate receptor.
CONCLUDING REMARKS
It is evident from this review that incorporation of such structural
modifications that would inhibit metabolic deactivation of enkephalins
and enhance their receptor-binding affinity leads to peptides that show
a high order of antinociceptive activity after systemic administration.
The aromatic side chain of Phe4  in enkephalins plays an important
role in the manifestation of opioid activity. Stabilization of Gly5-Phe4
peptide bond against the action of enkephalinases, so that the hydrophobic
site for receptor interaction provided by the Phe residue is not lost,
enhances the activity of peptides remarkably. Introduction of hydrophobic
chains at the C-terminus of the pentapeptides certainly has a favorable
effect on their activity, but the presence of such groups that would
lead to an optimum hydrophobicity of the solvent facing part of the
molecule is most desirable. The deletion of Met5 side-chain without
causing any loss in the biological activity of the analog (D-Ala2, MePhe4,
Met5)-enkephalin isopropylamide may be viewed in this context.
It is now well established that enkephalins play several important roles
in the CNS in addition to their role in the process of analgesia. They
are known to be involved in learning and behavior, modulation of other
neuropeptides and putative neurotransmitters, modulation of neuro-
endocrinal activities and central control of autonomic activities. It
will be useful to study the effect of the modified enkephalins on these
central parameters as well. This may provide useful leads for potential
drugs/tools beyond their present significance in analgesia.
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FOOTNOTES
1Communication no.4192 from Central Drug Research Institute, Lucknow,
India.
2Abbreviations for amino acid and peptide derivatives are according
to IUPAC-IUB Commission on biochemical nomenclature, Biochemistry
11:1726,1972; other abbreviations are: DCC,NN-dicyclohexylcarbodii-
mide; HOBt, I-hydroxy-benzotriazole; TFA, trifluoroacetic acid.
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Approaches to Studying Structure-
Activity Relationships in Peptide
Hormones Through the Expression
of Synthetic Genes
John W. Taylor, Ph.D.
INTRODUCTION
The primary structures of a very large number of peptide hormones having diverse
pharmacological properties have now been elucidated. In order to understand the func-
tions of these peptides and to exploit their potential as pharmaceutical agents, it is
essential to study structure-activity relationships in each case. To this end, the tech-
niques of peptide synthesis have commonly been applied, allowing the direct preparation
of deletion analogues and analogues incorporating natural and nonnatural amino acid sub-
stitutions. However, many peptide hormones are too large to consider extensive investi-
gations of the role of individual amino-acid residues, as the preparation of multiple ana-
logues in this way would be too time-consuming and expensive, and even the synthesis of
the natural structure alone may represent a significant synthetic achievement or produce
material that is too poorly characterized to be useful (Clark-Lewis et al. 1986). In such
cases, the alternative approach of employing synthetic genes and recombinant DNA
technology is becoming increasingly more attractive as new methods in this area are
developed. The latter approach consists of three main stages: (a) the assembly from
synthetic oligonucleotides of a gene coding for the peptide hormone being studied; (b) the
preparation of mutant genes coding for the desired hormone analogues; (c) the efficient
expression of the original and mutant genes in overproducing cells from which the hor-
mone analogues are recovered and purified. Compared to peptide synthesis, this
approach has the major advantage that all possible deletion analogues or single residue
substitution analogues may be prepared simply and rapidly, at little extra cost, by muta-
tion of the original gene once it has been assembled. Furthermore, the purity of the final
peptide products prepared in this way, and the likelihood that they will be contaminated
with pharmacologically active impurities, is not a function of the size of the hormone or
its amino acid composition, as it is when direct chemical synthesis is employed. The
purpose of this article is to review the methods that are currently available for preparing
peptide hormones by gene expression in Escherichia coli and to discuss how they might be
employed to perform structure-activity analyses.
OLIGONUCLEOTIDE SYNTHESIS AND GENE CONSTRUCTION
Oligomeric DNA must be synthesized in order to construct a gene that codes for the
desired peptide hormone and can be incorporated into a suitable plasmid vector for
expression. In addition, synthetic oligonucleotides are employed in the subsequent site-
directed mutagenesis of that gene and the sequence characterization of all of the gene
constructs produced, as described below. There are two synthetic strategies in common
use, each involving the stepwise addition of protected nucleotides to the 5’ end of the
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FIGURE 1
Oligonucleotide synthesis by the phosphite method (A) and the phosphate method (B)
Oligonucleotides are built up on a solid phase support through the repetitive application of
these reactions for each base addition. DMT, dimethoxytrityl; MSNT, 1-(mesitylene-2-
sulfonyl)-3-nitro 1,2,4-triazole.
growing oligonucleotide chain which is anchored to a solid support at its 3’ end (reviewed
by ltakura et al. 1984 and Sonveaux 1986). The two methods are distinguished by the
use of either a phosphite analogue of the nucleotide (a phosphoramidite) in the addition
step which is subsequently oxidized to the phosphate form, or the introduction of the
protected nucleotide in the phosphate form directly (figure 1). After completion of the
final synthetic cycle, the base- and phosphate backbone-protecting groups are removed,
and the linkage to the solid support is cleaved to yield the crude oligonucleotide. If an
automated synthesizer is employed under optimal conditions, the synthesis of oligonu-
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cleotides as long as 100 bases may be achieved. However, manual syntheses that
employ apparatus as simple as a small syringe are quite adequate for the preparation of
oligonucleotides up to 20 bases long.
Purification of the correct oligonucleotides from crude synthetic mixtures may be
achieved by HPLC on ion-exchange or reversed-phase columns, or by electrophoresis
through polyacrylamide gels under denaturing conditions (Sonveaux 1986). The HPLC
methods are suitable for oligonucleotides shorter than about 20 bases long and can be
used for larger quantities, but often require the assumption that the major product from
the synthesis is the correct one. In contrast, polyacrylamide gel electrophoresis can
readily provide adequate purification of oligonucleotides 10-100 bases long in sufficient
quantities for the uses described here, and can be performed on multiple samples simulta-
neously in the presence of reliable standards to identify the desired products.
The solid supports that are most commonly used are derivatized silica, which is useful
for preparing relatively large quantities of shorter oligonucleotides, and derivatized con-
trolled-pore glass, which gives higher yields per synthetic cycle and is more useful for the
present purposes (Sonveaux 1986). In addition, however, Helmut Blocker’s group has
demonstrated that paper disks may also be used as a solid support for oligonucleotide
synthesis (Frank et al. 1983). If these disks are used in conjunction with a synthetic
apparatus that incorporates one reaction vessel dedicated to the addition of each of the
four base types, then the simultaneous synthesis of multiple oligonucleotides (as many as
40 is reasonable) having unique base sequences can be achieved by numbering the paper
disks and resorting them between the four reaction vessels after each successive base
addition. Both the phosphite and the phosphate chemistries have been applied to this
process, which can result in considerable savings in time and expensive synthetic
reagents (Frank et al. 1983; Matthes et al. 1984; Ott and Eckstein 1984). In our labora-
tory, for example, we have successfully employed the phosphoramidite chemistry to the
simultaneous manual synthesis on paper disks of 12 unique oligonucleotides that ranged
from 13 to 19 bases in length. These were then purified in a few hours from the crude
synthetic products by simultaneous electrophoresis on a single polyacrylamide gel in
sufficient quantities and purities for use in oligonucleotide-directed mutagenesis or DNA
sequencing experiments. An analysis of the crude and purified products of these synthe-
ses by gel electrophoresis and autoradiography, after 5'-end labelling with ATP-y-32P
and polynucleotide kinase, is presented in figure 2. Since the preparation of each mutant
gene coding for a new peptide hormone analogue requires a unique oligonucleotide of this
size range, the application of Blocker’s approach should be particularly useful in this
regard.
Several semisynthetic approaches to the assembly of the double-stranded DNA com-
prising the synthetic gene and its incorporation into a double-stranded plasmid or phage
DNA vector may be considered. Most commonly, both strands of the gene are synthe-
sized in their entirety as oligonucleotide fragments that have overlapping base comple-
mentarities. These oligonucleotides are enzymatically phosphorylated at their 5’ ends,
and then annealed together and ligated using T4 DNA ligase and ATP. The resulting
segment of double-stranded DNA is designed to have unpaired “sticky ends” that allow
another enzymatic ligation into vector DNA linearized with a restriction enzyme that
produces complementary “sticky ends.” This approach, illustrated in figure 3, can be
refined by (a) the use of two restriction enzymes producing different “sticky ends” so
that the orientation of the inserted DNA is unambiguous, and (b) using the synthetic DNA
in excess over the vector (about five- to tenfold has given us good results) and leaving
the oligonucleotides that provide the 5’ ends of the synthetic gene unphosphorylated so
that ligation of either the insert or the vector to itself is minimized. Using this approach,
synthetic genes can be efficiently assembled into vectors in segments of 100-300 base
pairs, punctuated by unique restriction enzyme sites (for examples, see Ferretti et al.
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FIGURE 2
Analysis of the products from a manual synthesis of twelve unique oligonucleotides. The
oligonucleotides were synthesized simultaneously on individual paper disks using the phos-
phite method. They were then desalted on Sep-Pak C18 cartridges (Waters Co. Ltd.),
and then purified by electrophoresis on a 20% polyacrylamide gel and desalted again, as
before. The crude (left pane/) and gel-purified (right pane/) synthetic products were
analyzed by autoradiography, after 5'end labeling with 32P and electrophoresis on a
15% gel. The oligomers ranged in length from thirteen to nineteen base residues, as
follows (left to right): 18mer; 14mer; 18mer; 17mer; 18mer; 18mer; 19mer; 18mer; 16mer;
19mer; 18mer; 13mer.
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FIGURE 3
Assembly of a synthetic gene and its incorporation into a vector. For best results, the
oligonucleotides at the 5’-end of each strand (in this case, I and V) are left unphosphory-
lated, and the “sticky ends” of the synthetic gene are different, so that the vector must
be cut with two restriction enzymes that produce complementary “sticky ends.”
1986 and von Bodman et al. 1986). Thus, a synthetic gene coding for a given peptide
hormone can usually be assembled in a single step. Oligonucleotides about 50 bases long
and overlaps of about 8-12 bases appear to provide the most reliable combination for
obtaining the correct annealing and ligation and the fewest sequence errors after cell
transformation and characterization of the amplified products. We have also found that
it is quite reliable to perform the two ligation steps simultaneously, by adding both the
vector and ligase directly to the annealed oligonucleotides. The use of longer oligonu-
cleotides can result in more sequence errors, since there will inevitably be more impurities
present from their synthesis even after purification, and the use of shorter oligonu-
cleotides and/or overlaps makes the design of unique overlapping segments difficult and
increases the difficulties of obtaining correct annealing. Nevertheless, synthetic genes
have been successfully assembled from shorter oligonucleotides prepared by the paper
disk method of Blocker described above (Grundstrom et al. 1985; Brodin et al. 1986).
Two other notable strategies have been employed. First, the approach of ligating the
synthetic oligonucleotides one strand at a time was successful in a synthesis where the
presence of a repeated codon made direct assembly of the duplex difficult (Smith et al.
1984). In this case, the oligonucleotides comprising one strand only were phosphorylated
with kinase. These were then ligated together after annealing to the unphosphorylated
overlaping oligonucleotides comprising the opposite strand. After denaturing this mix-
ture, the ligated strand was then purified by polyacrylamide gel electrophoresis. This
process was performed simultaneously for the second strand, and the two purified
strands were then annealed and ligated into the vector in a separate step. The second
alternative strategy is one in which oligonucleotide synthesis is minimized by limiting the
synthesis to longer overlapping single-stranded segments of the gene, so that the gaps
between the overlaps can be filled enzymatically using a suitable polymerase and the
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deoxynucleotide triphosphates (dNTPs), before the segments are ligated. This ap roach
has also been quite successfully employed (see, for example, Bergmann et al. 1986 but is
generally found to be less reliable due to the difficulties of obtaining correct annealing and
strand synthesis.
MUTAGENESIS
The preparation of peptide hormone analogues for structure-function analysis requires
that the synthetic gene coding for the natural structure be mutagenized. This may be
achieved in a random or partially random fashion by a number of chemical or physical
methods, including treatments with sodium bisulfite, nitrous acid, hydrazine or UV light,
that involve damaging the DNA so that its sequence is incorrectly repaired or replicated
upon cell transformation giving rise to mutant progeny (Myers et al. 1985). Alternatively,
restriction enzyme recognition sites purposefully introduced into the synthetic gene at
strategically useful points may be exploited to introduce more specifically chosen muta-
tions. In this case, either the DNA is cleaved in one strand only by restriction enzyme
digestion under suboptimal conditions and then “misrepaired” enzymatically (Shortle et al.
1982), or else two such restriction sites are employed in order to cut out a “cassette” of
double-stranded DNA that can then be replaced by any new “cassette” consisting of
synthetic oligonucleotides (Lo et al. 1984). The most universally applicable methods,
however, involve oligonucleotidedirected mutagenesis (Zoller and Smith 1983). In these
methods, a synthetic oligonucleotide carrying a mismatch near the center of its sequence
to direct the desired mutation is annealed to its partially complementary sequence on a
single-stranded vector carrying the gene or gene fragment to be mutagenized. This
oligonucleotide is then used to prime the synthesis of the entire complementary strand in
vitro, using a DNA polymerase and each of the deoxynucleotide triphosphates (dNTPs).
Competent cells are transformed with the resultant heteroduplex DNA and spread out on
agar plates, giving rise to both forms of the DNA, from which the desired mutant form
must be selected (figure 4a). In principle, all types of mutations of the target DNA
sequence are achievable in this way, including deletions, additions, and substitutions of
one or more bases, and there are no limitations on the sites that are accessible to
change. It is necessary only that the vector carrying the gene can be prepared in the
single-stranded form, and that a suitable mismatched primer oligonucleotide can be
designed and synthesized so that it will anneal specifically to the correct site on the gene.
Since most expression vectors are double-stranded plasmids, the requirement for the
single-stranded form usually necessitates a subcloning step, where the gene or gene
fragment to be mutagenized is cut out by restriction enzyme digestion and transferred to
a single-stranded bacteriophage such as one of the convenient M13 vectors adapted by
Messing and coworkers to contain multiple cloning sites (Messing 1983). Once the mutant
has been prepared, the gene can then be transferred back to the original plasmid for the
purposes of expression. In some cases, however, this process has been simplified either
through the use of phage vectors for expression directly (Wilkinson et al. 1983), or
through the use of plasmid expression vectors of the pEMBL type, which are normally
double-stranded but contain the origin of replication of M13 phage DNA and can readily be
prepared in the single-stranded form upon infection of the plasmid-carrying cells with
phage (Dente et al. 1983). The requirement for specific annealing of the mismatched
oligonucleotide to the desired site usually presents no problems in cases involving the
addition, deletion, or substitution of a single codon. It is usually sufficient to place the
mismatched bases at least eight bases from either end of the oligonucleotide, and the
precise arrangement can be further optimized for specific annealing to the correct site
through the use of commercially available computer programs designed for this purpose.
The major difficulty in oligonucleotide-directed mutagenesis is often the identification,
lafter ce l transformation with the heteroduplex DNA, of the plaques of phage-infected
cells that contain the mutant phage. E. coli cells have a DNA mismatch repair system
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FIGURE 4
Oligonucleotide-directed mutagenesis using M13 vectors. (A) The unmodified procedure
of Zoller and Smith (1983): (1) Mismatched primer extension with the Klenow fragment
of DNA polymerase I and the dNTPs; ligation with T4 DNA ligase and ATP. (2) Trans-
formation of competent cells and colony growth on agar plates. (B) The phosphoro-
thioate method (Sayers and Eckstein 1987): (1) Mismatched primer extension with
Klenow, dATP, dGTP, dTTP and dCTP- -S; ligation with T4 ligase and ATP. (2)
Nicking with Nci I; gapping with exonudease III in the 3’ to 5’ direction, or with A  exonu-
clease or the T7 gene 6 exonuclease in the 5’ to 3’ direction, as appropriate. (3) Repair
with DNA polymerase I, the dNTPs, T4 ligase and ATP. (4) Transformation and
colony growth.
that depends upon the action of the dam methylase, which labels DNA in vivo by methy-
lation of GATC sequences, in order to recognize the original (methylated) viral (+)-
strand and correct mismatches that were introduced into the (-)-strand during synthesis
in vitro (Kramer et al. 1984a). The efficiency of this system is dependent on the type of
mismatch introduced, but it typically reduces the frequency of occurrence of the mutant
phage to about 10% of the plaques, and much lower frequencies are quite common
(Taylor et al. 1985a). Furthermore, most of the plaques containing mutant phage that
were obtained by plating out transformed cells directly are contaminated by the presence
of the nonmutant form and must be replated at least once to ensure that the pure
mutant form is obtained. Since the mutagenesis of a hormone gene in a phage vector
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carried by E. coli cells will not normally result in a recognizable change in plaque pheno-
type, the mutant phage obtained by this method must be identified by screening a large
number of plaques with a hybridization assay using the 32P-labelled mismatched oligonu-
cleotide (which is perfectly complementary to the mutant page DNA). This assay
involves transferring the plaques obtained in a mutagenesis experiment onto nitrocellulose
filter paper, denaturing the phage and then hybridizing the radiolabelled oligonucleotide to
the exposed immobilized phage DNA. Mutant and nonmutant phage are then distinguished
by autoradiography after washing the nitrocellulose paper in a high salt buffer at
successively higher temperatures. The radiolabel is washed off the samples of nonmu-
tant phage at lower temperatures (Zoller and Smith 1983).
In order to avoid the time-consuming hybridization screening step described above and
eliminate the use of high specific activity 32P radiation, a number of modified mutagene-
sis procedures have been developed that increase the frequency of occurrence of the
mutants to a point where they may be conveniently identified and characterized directly
by DNA sequencing. For this purpose, it is necessary to increase the efficiency of the
mutagenesis to a point where the random selection for sequencing of only two or three
plaques from each experiment will result in a high probability of identifying the desired
mutant in a pure form. The relationship between the mutagenesis efficiency and the
number of plaques that must be screened to achieve a satisfactory 90% probability of
success is graphically illustrated in figure 5 (Kramer et al. 1982). Clearly, any method
that will be useful in this regard needs to achieve reliable efficiencies of mutagenesis that
are higher than about 50%. Only a few methods are adequate in this regard. These
methods depend upon either selecting against the original DNA sequence in the (+)-strand
of the heteroduplex in vivo, after transformation, or eliminating the original DNA
sequence in that strand in vitro, before transformation.
Selection against the (+)-strand in vivo has been successfully achieved in different ways.
Kunkel (1985) has shown that single-stranded Ml 3 vectors carrying cloned genes may be
prepared in host cells deficient in dUTPase (dut - ) and uracil glycosylase (ung - ) to
contain several deoxyuridine residues per molecule in place of the normal thymidine
residues. When this DNA is used as the template to produce heteroduplex DNA in the
normal way, transformation into ung + cells results in glycosylation  and excision of the
uracil moieties, creating multiple abasic sites and a consequent strong selection against
the original (+)-strand molecules during the subsequent replication. The result is that
more than 50% of the plaques obtained from these transformed cells contain progeny
phage that are the desired mutants derived from the (-)-strand sequence. In a similar
manner, the amber nonsense mutation or the Eco K restriction site have been exploited
as genetic markers that may be incorporated into the (+)-strand of M13 DNA when it is
prepared in a suitable suppressor-carrying or Eco K- host, respectively (Carter et al.
1985). In these approaches, selection against the (+)-strand of the heteroduplex DNA
that is subsequently prepared in vitro requires an additional mismatch in the (-)-strand
opposite the marker, so that transformation into a suppressor-deficient or Eco K-
restricting host, as appropriate, will select against progeny derived from the (+)-strand
only. The simplest way to achieve this double mismatch is to use two mismatched
oligonucleotides simultaneously to prime the (-)-strand synthesis in vitro. In this case, the
oligonucleotide annealed to the site of the genetic marker would be identical for all the
mutations directed by the second mismatched primer in the normal way, so that little
extra synthetic effort is required. Other, more difficult approaches involving the prepa-
ration of heteroduplex, gapped DNA have also been applied to these selection methods
(Kramer et al. 1984b). Again, the typical mutation efficiencies appear to be about 50%,
although higher efficiencies have been reported, so that all of the preceding methods for in
vivo selection against the nonmutant strand appear to allow the use of DNA sequencing
methods to identify and characterize the mutants generated directly.
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FIGURE 5
Relationship between the number of phage plaques that must be screened to have a 90%
probability of identifying a mutant and the efficiency of the mutagenesis method used.
(Adapted from Kramer et al. 1982. Copyright 1982, IRL Press, Ltd.)
Most recently, my coworkers and I in Fritz Eckstein’s laboratory have developed a very
efficient method for oligonucleotide-directed mutagenesis that takes the alternative
approach of eliminating the original (+)-strand sequence opposite the mismatched primer
in the heteroduplex DNA, before it is used to transform competent cells (Taylor et al.
1985a; Nakamaye and Eckstein 1986; Sayers and Eckstein 1987). In this approach, the
mismatched oligonucleotide primer is annealed to the (+)-strand of the M13 vector DNA
with its cloned insert in the normal wa y, and then the in vitro synthesis of the comple-
mentary (-)-strand is performed with the dCTP in the reaction mixture entirely substi-
tuted by its -thiophosphate analogue, dCTP- -S. The a-thiophosphate analogues of
the natural dNTPs are diastereomeric and all of the DNA polymerases that have been
investigated to date readily accept the Sp diastereomer of each dNTP- -S as a sub-
strate, incorporating it into DNA with inversion of configuration about the phosphorus
atoms almost as efficiently and accurately as for the unmodified dNTPs (Burgers and
Eckstein 1979). The product of this in vitro synthesis is, therefore, heteroduplex cova-
lently closed circular DNA that contains in its (-)-strand the desired mutant sequence, as
well as hosphorothioate internucleotidic linkages of the Rp configuration on the 5’ side of
each dCMP base residue (figure 4b). Phosphorothioate-substituted Ml 3 DNA has similar
physicochemical characteristics to the natural DNA and retains its infectivity upon
transformation of competent host cells, but also has the property of being resistant to
linearization by restriction enzymes, particularly those which cleave their recognition
sequences on the 5’ side of the base type that was substituted by its a-thiophosphate
analogue in the synthesis. Indeed, for about one-third of the restriction enzymes that we
have tested, linearization that requires cleavage of a phosphorothioate linkage appears
to be completely blocked (Taylor et al. 1985b). However, these enzymes are still able to
hydrolyse the unsubstituted (+)-strand of the phosphorothioate DNA quite efficiently in
the normal way, to produce double-stranded DNA with a single “nick” placed specifically
in the (+)-strand at the restriction enzyme cleavage site. We have exploited this prop-
erty of the Nci I restriction enzyme in order to specifically hydrolyse the (+)-strand of the
heteroduplex DNA containing dCMPS-substitutions in the (-)-strand at recognition sites
of the type shown below.
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(+)-strand: 5’-CC/GGG-3’
(-)-strand: 3’-GGC/CC-5’
Nci I normally cleaves the internucleotidic linkage on the 5’side of the central base residue
in both strands of such sequences, as indicated, but in this case cleavage of the (-)-
strand is blocked. The nicks that are generated in the (+)-strand can then be used as
starting points for its digestion in the 3’ to 5’ direction, using the enzyme exonuclease Ill.
This digestion occurs at a reproducible rate of about 100 bases per minute in all of the
DNA sample simultaneously, provided that the correct buffer conditions and excess of
the exonuclease are used. When digestion has proceeded to a point safely beyond the
desired point of mutagenesis (opposite the mismatched primer oligonucleotide), the gapped
DNA can be repaired by polymerization with dNTPs, using the mutated sequence of the
(-)-strand as the template to produce phosphorothioate DNA having the desired mutant
sequence in both strands (figure 4b). In a number of trial base-substitution mutagenesis
experiments, where mutant a 13 DNA prepared in this way was used to transform com-
petent cells, 80% - 90% of the plaques obtained were consistently found to contain the
desired mutant phage uncontaminated by the unmutated form (Nakamaye and Eckstein
1986).
Based on the above results, the phosphorothioate DNA approach promises to be the
most efficient of the enhanced oligonucleotide-directed mutagenesis methods, and it
requires only a few hours of additional manipulations over the basic protocol and has no
special requirements for unusual host cells or vectors. The dNTP- -S analogues are
commercially available and give satisfactory results when used as the racemic mixtures
directly. Furthermore, all of the potential limitations of this approach appear to present
no additional difficulties and it should be applicable to every mutagenesis problem. For
example, other restriction enzymes besides Nci I may be employed for the nicking reac-
tion (in conjunction with the appropriate thiophosphate nucleotide analogue); the exonu-
clease Ill digestion and subsequent repair reactions are efficient over a range of several
thousand bases; and gapped DNA may also be prepared by digestion from a nick in the
opposite, 5’ to 3’ direction, using either exonuclease or the T7 gene 6 exonuclease
(Sayers and Eckstein 1987). Thus, one or more appropriate restriction enzyme recogni-
tion site present at any position in the vector or cloned gene is probably a sufficient
prerequisite for the method and one that is easily satisfied. In the case of Nci I, the
recognition sequence described above is present in all of the M13 vectors and the
alternative Nci I site, where the (+)-strand sequence is 5-CCCGG-3’, does not seem to
interfere when it is also present, because its cleavage in the (-)-strand is also blocked by
the dCMPS substitution (Nakamaye and Eckstein 1986). Initial experiments (Sayers and
Eckstein 1987) indicate that deletion mutagenesis is also just as efficient using these
methods, despite the expected difficulty of digesting the loop of unpaired bases in the (+)-
strand opposite the mismatched primer during the gapping step. (The third alternative of
insertion mutagenesis, in which the heteroduplex phosphorothioate DNA will have an
unpaired loop in its (-)-strand, is expected to be straightforward.) Finally, we have failed
to detect any unexpected mutations in addition to those that were directed by the mis-
matched oligonucleotides during our extensive characterization by sequence analysis of
the mutants generated by these procedures. This indicates that the phosphorothioate
DNA in the (-)-strand is a suitable template for accurate DNA synthesis by DNA poly-
merase I during repair of the gapped DNA in the final step of the in vitro manipulations.
The high efficiency of the phosphorothioate DNA method for mutagenesis suggests that
new approaches to the rapid preparation of large numbers of mutants of a given peptide
or protein might be possible. Nearly all of the DNA that is prepared in vitro contains the
mutant sequence that is determined by the mismatched primer oligonucleotide. There-
fore, the use of oligonucleotides that contain degenerate positions would allow the effi-
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cient single-step preparation of, for example, mutants of an enzyme in which an active
site residue is replaced by all other possible naturally occurring amino-acid residues. The
subsequent identification and characterization of these mutants would be very rapid,
because it could be performed directly by DNA sequencing. Alternatively, multiple spe-
cific mutations at many different sites could be generated very rapidly by combining this
mutagenesis method and direct sequence analysis with the paper disk approach of
Helmut Blocker to synthesize the large number of mismatched oligonucleotides that would
be required. This should be extremely useful in the characterization of structure-activity
relationships in the larger peptide hormones that we are considering here, particularly
when methods are available for the efficient expression and purification of the mutants
generated.
EXPRESSION AND PURIFICATION
The most important aspects of the expression of a synthetic gene in E. coli cells and the
purification of the protein product are the requirements for efficient transcription of the
gene and subsequent translation of the mRNA; the location, structure, and stability of
the peptide product; and the possible methods by which it, and any mutants of interest,
might be separated from the other protein constituents of the host cells. These subjects
have been reviewed extensively elsewhere (Gold et al. 1981; Wetzel and Goeddel 1983;
Marston 1986) and the present discussion will focus on the particular problems that are
associated with the preparation of peptide hormones and their analogues, and the
approaches to solving those problems that have been adopted to date.
Various factors are known to affect the efficiency of transcription and translation,
sometimes dramatically. These include the strength of the promoter, the structure of the
ribosome-binding site and its position relative to the translation start codon (usually
AUG) on the mRNA, the stability of the mRNA, and the presence of transcription atten-
uators near the end of the open reading frame of the message. There are also strong
correlations between codon usage in E. coli genes and the levels to which the correspond-
ing proteins are expressed, which suggest that expression levels are determined by the
codon-anticodon interaction energies and by tRNA abundancies (Grosjean and Fiers
1982). Unfortunately, there appear to be no absolute rules governing the precise choices
that must be made in order to optimize these many factors for efficient expression. The
approach that most researchers have adopted has been to employ the best natural
systems, either directly or through the design of consensus structures. Thus, trp, lac,
Ipp, PL and pho A promoters and ribosome-binding sites have all been employed
directly, or in synthetic combinations such as the tac hybrid derived from trp and lac (De
Boer et al. 1982) or the rac hybrid derived from rrnB and lac (Boros et al. 1986) which
appear to be stronger than their parent structures. The design of hybrid or consensus
promoters and ribosome-binding sites does not, however, always lead to better expres-
sion systems (see, for example, Deuschle et al. 1986). Most of the promoters that are
commonly employed also offer the advantage of being inducible, for example by
temperature shift ( PL) or addition of a metabolite (systems based on trp and lac).
This allows gene expression to be switched on at the most advantageous time, which is
particularly important in cases where the protein produced is detrimental to the cell.
The codons chosen to design a synthetic gene are usually taken from tabulations of the
most abundant tRNAs (Ikemura 1981) or the most abundant codons in highly expressed
genes (Yarus and Folley 1985) although exceptions are often made so that convenient
restriction enzyme recognition sites can be built in. The importance of this consideration
was highlighted by the use of a synthetic gene that had been optimized in this manner to
produce bovine growth hormone (Seeburg et al. 1983). The synthetic gene was ex-
pressed at much higher efficiency than the natural mammalian gene had been. Additional
empirical rules governing codon choice have also been suggested (Yarus and Folley 1985).
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Unfortunately, it is possible that the choices made at this stage of the design of an
expression system may result in quite unpredictable problems that are difficult to identify
or solve: if certain DNA sequences cause the RNA polymerase to slow or stop, this may
result in premature dissociation of the transcription complex and truncation of the mes-
sage; or, if protein folding occurs concomitant with translation, other sequences may
disrupt this process through their effects on the rate of translation of the mRNA on the
ribosome, and incorrectly folded products may result. Even less information is available
regarding mRNA stability and how it can be enhanced. Although stability might be
related to secondary structure formation throughout the message, as well as, possibly,
its overall length, experiments suggest that the structure of the 5’ end is critical. Again,
the approach to this problem has been to employ natural sequences in the 5’ untranslated
region that are taken from stable systems. In the case of the T4 gene 32 message, for
example, the 5’ sequence has been shown to confer stability on unstable sequences that
are fused downstream to it. This property has been exploited in the design of a plasmid
vector employing the promoter region and start codon of that gene and requiring phage
T4 infection for expression (Duvoisin et al. 1986).
In the expression of foreign proteins in E. coli cells, the stabilit y of the product within the
cells is an especially important consideration. Such expression has been shown to turn on
the production of the Ion protease and other gene products regulated by the htp R gene
product associated with the heat shock response, leading to much higher rates of prote-
olytic degradation than normal (Goff and Goldberg 1985), and the use of Ion- and htp R
mutant host strains is certainly helpful in this regard (Buell et al. 1985). Whether these
responses are triggered by particular “foreign” amino acid sequences, or by incorrectly
folded structures, or some other mechanism is responsible is not presently known. In
addition, the half-lives of proteins that are endogenous to the cells vary themselves over
a wide range, indicating that there are mechanisms for targetting proteins for degrada-
tion that are normally in effect and might act on an overexpressed foreign protein also.
E. coli has a large number of proteolytic enzymes that might participate in these pro-
cesses, and are vital to the normal functioning of the cell (Swamy and Goldberg 1981).
Empirical correlations suggest a strong relationship between the half-life of a protein in E.
coli and its N-terminal amino acid sequence. In particular, the “PEST” hypothesis sug-
gests that sequences rich in Pro, Glu, Ser, and Thr will be most highly susceptible to
degradation (Rogers et al. 1986). Alternatively, procaryotic cells may have a mecha-
nism for protein turnover that is similar to the ubiquitin-associated mechanism that
appears to operate in eucaryots, in which case an important determinant of the half-life
will be the N-terminal residue itself, with Arg, Lys, Asp, Leu, and Phe directing the most
rapid degradation, and Met, Ser, Ala, Thr, Val, and Gly dictating the greatest resis-
tance to degradation (Bachmair et al. 1986).
Proteolytic degradation of the desired product is, perhaps, the most difficult problem
attendant to the production of smaller peptides such as the peptide hormones. Their
direct expression is usually followed by their rapid degradation, so that large quantities
can never accumulate. This is almost certainly because these peptides are too small to
fold into a stable globular structure, and their extended flexible conformations can readily
fit into the typical active-site groove of a broad-specificity protease. The first success-
ful solution to this problem, and the approach that is still most commonly applied, was to
express the peptides as part of a much larger fusion protein by splicing the corresponding
synthetic gene in frame to the end of the gene coding for a highly expressed protein that
could act as an intracellular carrier. In this way, somatostatin, -endorphin) and both the
A and B chains of insulin were separately produced, each fused to a point near the C
terminus of -galactosidase (Itakura et al. 1977; Shine et al. 1980; Goeddel et al. 1979).
Expression was directed under the control of the strong inducible lac promoter and the
peptides were recovered from the purified fusion protein by proteolytic ( -endorphin) or
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chemical (somatostatin and the insulin chains) cleavage at specific amino-acid residues
engineered into the structure for this purpose.
The fusion protein approach solves a number of the problems discussed above simultane-
ously, provided that the carrier protein is normally expressed at a high level in E. coli and
it is being used as the N-terminal portion of the hybrid. At the RNA level, the structure
around the ribosome-binding site should already be optimized for transcription, translation,
and mRNA stability, and codon usage for most of the rest of the message should also be
correct. After translation, the N-terminal amino acids should be consistent with the
requirements in that region for a stable protein in vivo. There are additional advantages
in relation to the purification procedures, First, the production of a larger protein aids in
its direct identification by polyacrylamide gel electrophoresis, since the identification and
visualization of small peptides by these techniques is difficult. This usually eliminates the
need for antibodies directed against the desired peptide in order to follow its expression
and purification. If enzymatic carrier proteins such as -galactosidase or alkaline phos-
phatase are used, activity can often be assayed directly on agar plates by calorimetric
methods. Second, affinity columns can often be designed that target the carrier portion
of the fusion protein during purification. Such affinity columns are usually constructed
using antibodies to the carrier protein or, if it is an enzyme, inhibitors may be employed
more conveniently. Affinity chromatography based on the carrier is a particularly
important asset when multiple mutants of the peptide portion are being prepared, since
the purification procedures should be identical in each case. Finally, procaryotic proteins
are synthesized in vivo with N-formyl-Met at the N terminus which is usually cleaved
from the mature protein during posttranslational processing. However, overexpressed
foreign proteins are often produced with the N-terminal Met deformylated but still
attached or incompletely removed, and the factors that govern the processing are not
understood. The fusion protein strategy, with the carrier portion at the N terminus,
therefore eliminates this potential problem also.
To date, many small peptides in addition to those mentioned above have been expressed
using the gene fusion strategy. These include antigenic determinants from hepatitis B
fused to -galactosidase and expressed under control of the lac promoter (Charnay et
al. 1980) or fused to -lactamase (trp promoter; Edman et al. 1981); influenza virus
antigens fused to -galactosidase (lac promoter; Davis et al. 1981); hirudin fused to
galactosidase (lac or PL promoters; Bergmann et al. 1986); TGF  fused to 17
residues of the trp LE protein and promoter (Winkler et al. 1986); calcitonin fused to
interferon-y ( PL promoter; lvanov et al. 1987); and 27-desamidosecretin fused to
galactosidase (lac promoter; Sumi et al. 1984). Frequently, these fusion proteins are
insoluble within the cellular environment, even when produced at low levels, possibly as a
result of incorrect folding of the carrier. This results in the formation of intracellular
aggregates or inclusion bodies consisting predominantly of the fusion protein. These
structures can often be isolated by centrifugation, and subsequently dispersed under
denaturing conditions, as reviewed recently by Marston (1986), with considerable advan-
tages in the purification strategy.
In a number of cases, the fusion approach is unsatisfactory, either because recovery
from the inclusion bodies is difficult, because a soluble fusion protein is desired (when the
peptide is to be used directly as an antigen) or, very commonly, because proteolyic
degradation of the peptide component still occurs, leading to impure products and a low
yield. In these cases, proteins such as alkaline phosphatase, Omp A or -lactamase,
which have N-terminal signal- or leader-peptide extensions that direct their translocation
across the cytoplasmic membrane and subsequent release into the periplasmic space,
have been useful as alternative carriers. When correct transport and processing by
signal peptidase occurs, large quantities of the fusion protein can accumulate in the
periplasm, where precipitation has not generally been encountered, although proteolytic
32
degradation can still be a problem. Since relatively few E. coli proteins are present in the
periplasm, and its contents can usually be selectively released by osmotic shock, secre-
tion to the periplasm is also advantageous in terms of purification (Marston 1986).
Examples of peptides that have been prepared in this way include human proinsulin, which
was fused to N-terminal fragments of -lactamase (Chan et al. 1981) and the Met27
analogue of human GRF, which was fused to the phosphate-binding protein, pho S (Anba
et al. 1987). However, when -neoendorphin was fused to alkaline phosphatase near its
C terminus, transport or release into the periplasm was unexpectedly blocked (Ohsuye et
al. 1983). On the other hand, it is often possible to dispense with the mature carrier pro-
tein entirely and simply connect the synthetic peptide directly to a signal peptide sequence
with its signal peptidase recognition site intact. Thus, for example, human EGF and
hirudin have both been expressed, transported across the cytoplasmic membrane and
released into the periplasm after correct signal peptidase cleavage, through their fusion
to the alkaline phosphatase signal peptide (Oka et al. 1985; Dodt et al. 1986); human
growth hormone was similarly processed under the direction of the alkaline phosphatase
signal peptide or its own (eukaryotic) signal peptide (Gray et al. 1985); and proinsulin was
secreted into the periplasm by fusion to the -lactamase signal peptide (Chan et al.
1981) or through the correct transport and processing of the preproinsulin gene product
(Talmadge et al. 1980). In a small number of cases, the processed peptides have been
found predominantly in the extracellular medium, indicating that they have passed
through the outer cell membrane also. These include -endorphin, which had been fused
to the Omp F signal peptide and an additional 12 amino-acid residues, and was subject to
proteolytic degradation at its C terminus (Nagahari et al. 1985) and human growth
hormone (Kato et al. 1987) and -fibrinogen (Lord 1985) each of which had been fused to
-lactamase signal peptides. In the human growth hormone study, passage across the
outer membrane was promoted by additional weak expression of the kil gene, which
makes the outer cell wall permeable without cell lysis, suggesting that passive diffusion
across this membrane occurred. The large size of -fibrinogen (molecular weight 67,000)
would seem to preclude passive diffusion, indicating that other mechanisms of transloca-
tion across the outer membrane may also be important. However, extensive degradation
of this protein was demonstrated, and the method of detection employed was dependent
only on the presence of a short peptide fragment at its N terminus, so that passive
diffusion across the relatively porous outer membrane might explain the extracellular
presence of all three of these peptides. Whatever the mechanism, transport to the
extracellular medium appears to yield smaller quantities of these peptides than can be
obtained from intracellular fractions, and is not necessarily advantageous in terms of
purif ication.
Unless an endogenous proteolytic cleavage system such as the signal peptide/signal pep-
tidase system described above is accurately exploited, the fusion protein strategy to
peptide production requires that a specific cleavage reaction must be devised for the
release of the target peptide from the fusion protein. This step is performed after cell
lysis and, usually, after some initial purification. Several site-specific methods for such
peptide backbone cleavages have been employed, all of them requiring that a “recognition
site” consisting of one or more residues be engineered into the fusion protein on the N-
terminal side of the scissile peptide bond. In most cases, the structural requirements for
these sites are limited to the N-terminal side of that bond only. Since many biologically
active peptides do not tolerate N- or C-terminal modifications to their natural structures,
and given the additional possibility that peptides may be produced in E. coli with an addi-
tional Met at their N termini (see above), this situation is ideal for recovery of a precise
peptide structure if that peptide is positioned at the C terminus of a fusion construct.
The cleavage methods can be divided into three categories: chemical, enzymatic at a
single specific residue, and enzymatic at sites defined by a specific sequence of residues.
Three chemical methods have been employed. Cleavage on the C-terminal side of Met
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residues using cyanogen bromide has often been used to release peptides that contain no
additional Met residues from fusion protein products (Itakura et al. 1977; Goeddel et al.
1979). Occasionally, the target peptide sequence has been modified in order to meet this
requirement, as in the case of [Thr59] insulin-like growth factor I fused to an eight residue
leader peptide (Peters et al. 1985). The cyanogen bromide reaction is usually carried out
in 70% formic acid, and is therefore often useful for cleavages that must be performed
under denaturing conditions such as those involving insoluble products in inclusion bodies,
although additional denaturating agents such as urea or guanidinium thiocyanate are
often added. A second chemical method, used to cleave Trp E-bovine growth hormone
fusion proteins at Asp-Pro bonds, is acid pH treatment (Szoka et al. 1986). Again, the
conditions require 70% formic acid, and often a denaturing agent is added, but elevated
temperatures are also required. Although this method has the advantage of greater
selectivity because it requires a two-residue site, it results in a cleaved peptide with an
N-terminal Pro and may not always be efficient or specific for the Asp-Pro bond. Fur-
thermore, there are reports that some Asp-Pro bonds are quite resistant to acidolysis,
even under forcing conditions where extensive side reactions are occurring (see, for
example, Allen et al. 1985). The third chemical method is similar to the second, consisting
of cleavage at Asn-Gly bonds by hydroxylamine treatment at pH 9 and elevated tem-
perature. This method was recently used to release human insulin-like growth factor
from the C-terminal end of an IgG-binding domain of staphylococcal protein A, after the
intact fusion protein had been purified on an IgG-Sepharose affinity column (Moks et al.
1987). Its general applicability remains to be determined.
Enzymatic cleavages at single-residue sites include the reported use of clostripain to
cleave C-terminal to Arg in an a-chloramphenicol acetyltransferase-calcitonin fusion
protein (see Marston 1986) and trypsin cleavage of -endorphin from -galactosidase,
also C-terminal to Arg, after the fusion protein had been treated with citraconic anhy-
dride to provide temporary protection of the Lys residues in -endorphin from cleavage
(Shine et al. 1980). In this category, the Staphylococcus aureus V8 protease is also
potentially useful in that cleavage by this enzyme can be limited to sites C-terminal to
Glu residues, even in the presence of Asp residues, under specific buffer conditions
(Houmard and Drapeau 1972). This specificity has not yet been exploited, but might well
be applicable to the production of a wide variety of active hormone analogues that have
been engineered to replace any internal Glu residues with Asp. Such substitutions repre-
sent very minor changes in peptide structure, and they might often have little effect on
pharmacological activities.
There are, at present, only two enzymes having recognition sites comprised of several
amino-acid residues that have been exploited for the recovery of peptides from a fusion
product. Collagenase cleaves collagen at multiple sites having a consensus structure -
Pro-Xxx-Gly-Pro-Yyy-, with cleavage occurring on the C-terminal side of both of the
unspecified residues. In one example of the early application of this cleavage reaction,
Germino and Bastia (1984) designed a plasmid to express a fusion protein consisting of
-galactosidase at the N terminus, connected to the plasmid R6K initiator protein via a
60 residue segment of chicken pro -2 collagen containing several potential collagenase
cleavage sites. They were then able to purify this protein by affinity chromatography
based on the -galactosidase segment and recover the R6K initiator, which is normally
rapidly degraded in E. coli, after collagenase-catalyzed hydrolysis of the linker at multiple
sites. The final product, however, was probably extended from the N terminus of the
R6K initiator by about 10 residues of the linker, and may have been heterogeneous. More
satisfactory results have been obtained by Nagai and Thøgersen (1984) to recover
human -globin from a hybrid with c-II protein, and by Steven Benner’s group (Nambiar
et al. 1987) to cleave -galactosidase-linked ribonuclease A, using the action of blood
coagulation factor Xa to cleave at the C-terminal end of its consensus linker -lle-Glu-Gly-
Arg-. In this case, the enzyme does not appear to require the three-dimensional structure
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of its normal substrate for efficient cleavage, which probably contrasts with the re-
quirements of collagenase, and the products obtained appeared to be homogeneous and
devoid of unwanted N-terminal extensions, although in neither case was any sequence
characterization performed. As one final note, it is worth pointing out that the potential
utility of any enzymatic method is limited by the purity of the enzyme preparation, and
contaminating proteolytic activities are often a problem.
The utility of fusion constructs for enhancing the stability of overexpressed peptides in
vivo and for simplifying their purification has stimulated a number of researchers to
design novel systems for these purposes that do not involve natural carrier proteins. In
several cases, the use of multiple fused copies of the target peptide has been shown to
enhance its stability and recovered yield. For example, three copies of the proinsulin gene
were found to be optimal for resistance to proteolysis when they were fused directly to
the tac promoter, and two copies were optimal when fusion to the lac promoter plus a
small fragment of the -galactosidase gene was tested (Shen 1984). The repeated
proinsulin gene segments were connected by linkers coding for the amino acid sequence -
Arg-Arg-Asn-Ser-Met-, with the expectation that the correct proinsulin peptide could be
recovered by cyanogen bromide cleavage followed by proteolytic digestion with trypsin
and carboxypeptidase B. A similar strategy has been employed for the production of
Met-enkephalin (Hostomsky et al. 1985). This opioid peptide was released from a fusion
product consisting of 11 copies of the peptide connected by -Arg-Arg- linkers and fused to
part of the SV40 small-t antigen, after trypsin and carboxypeptidase B digestion, as
indicated by RIA and guinea-pig ileal assays. A substance P analogue having a C-termi-
nal homoserine amide was also successfully prepared from overexpressed fusion proteins
containing 4, 16 and 64 copies of the corresponding C-terminal Met analogue (Kempe et
al. 1985). These were fused together between part of the cro repressor on the N-
terminal side and ß-galactosidase on the C-terminal side. In this case, the substance P
analogue was obtained by cyanogen bromide cleavage to release multiple copies of the C-
terminal homoserine lactone analogue, which were converted to the desired
[HSe11]substance P with a C-terminal amide, as in the natural hormone, by treatment
with 30% ammonium hydroxide. This last approach is likely to prove useful for the
preparation of many other peptide hormone analogues where a C-terminal amide is
required for activity.
Another approach taken by Sung et al. (1986) to optimize the production of proinsulin was
the addition of different homo-oligomeric peptides at its N terminus. As discussed above,
this tactic is likely to affect the efficiency of expression as a result of modifications to
the 5’ end of the mRNA structure, in addition to affecting the lifetime of the peptide in
vivo as a result of the effects of the N-terminal amino-acid residues on endogenous
mechanisms for targetting protein degradation. In this investigation, hexamers of Ala,
Asn, Cys, Gln, His, Ser, or Thr were found to produce the highest yields, and the yields
for the(Ala)6- and (Ser)6-modified constructs were indeed found to be strongly dependent
on the specific choice of codons used, indicating the importance of the structure of the
ribosome-binding site on the mRNA. The use of poly-Arg fused to the C terminus of an
overexpressed protein has also been explored as an aid to purification (Smith et al.
1984). This method was applied to the production in E. coli of human growth hormone
(urogastrone) as a fused protein with 14 residues of the trp E protein at its N terminus
and a C-terminal tail of 5 Arg residues. After expression, the fusion protein was purified
from the cell lysate by cation-exchange chromatography, where it eluted after the bulk
of the bacterial proteins on a salt gradient. The poly-Arg tail could be removed by
carboxypeptidase B digestion.
In our laboratory, we are attempting to exploit the potential amphiphilic nature of many
peptide hormones and other biologically active peptides, and the general propensity of
these structures to form organized aggregates in aqueous solution (Taylor and Kaiser
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FIGURE 6
Schematic diagram of the structure of a helix bundle protein consisting of four amphiphilic
a helices. Fusion proteins of this type, designed to incorporate amphiphilic peptide hor-
mones at their C termini (shaded segment), might be resistant to proteolysis in E. coli.
1986) in order to generate fusion proteins that are specifically designed to include the
peptide hormone as an integral part of their globular structure. For example, many of the
intermediate-sized flexible peptide hormones can form amphiphilic -helical segments
(Taylor and Kaiser 1986). These peptides might be incorporated into globular fusion
protein structures consisting of multiple near-parallel helices similar to the four-helix
bundles commonly found in natural proteins (Weber and Salemme 1980) if they were
connected to repeated segments of peptide sequences designed to form idealized
amphiphilic helices (figure 6). Such tailor-made structures are expected to be soluble and
more resistant to proteolytic degradation than the randomly connected fusion proteins
usually are. Furthermore, they could be specifically engineered to allow convenient purifi-
cation of the peptide hormone by, for example, ion-exchange chromatography. Eventu-
ally, these simple modifications of the fusion protein approach are likely to result in very
efficient systems for the production of peptide hormones in bacterial cells in high yield.
Combined with the rapid, multiple oligonucleotide synthesis methods of Blocker’s group,
and the high-efficiency mutagenesis methods that we have developed in the Eckstein lab-
oratory, the exploration of structure-activity relationships in peptide hormones through
the expression of multiple mutant genes in E. coli should often be competitive with the
direct chemical synthesis approach, and may have advantages in terms of time, cost of
reagents, and product purity.
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X-Ray Diffraction Studies
Enkephalins and Opiates
of
Jane F. Griffin, Ph.D., and G. David Smith, Ph.D.
The conformation or conformations of the enkephalins responsible for
biological activity, that is, the conformation assumed at the receptor and
resulting in the transduction of a message, has been of enormous interest
since the enkephalins were first isolated by Hughes and Kosterlitz (1975).
These pentapeptides with sequence Tyr-Gly-Gly-Phe-Leu(Met) have many
degrees of conformational freedom due to peptide chain flexibility, centered
in the four and five torsional rotations, and side-chain flexibility from the
rotations of the Tyr1, Phe4 and Leu5 or Met5 residues. How does the
opioid receptor(s) recognize a flexible linear pentapeptide, the relatively
inflexible fused ring morphine-like compounds and the other families of
drugs with which it interacts? What are the chemical moieties recognized by
the receptor(s) and how are they arranged in three dimensions? Do the
different opioid receptor subtypes bind different low energy conformations of
the endogenous compounds or induce them into an “active” conformation?
Since 1975 the conformations of enkephalin have been studied by every
available spectroscopic technique in a variety of solvents and in the solid
state, by more traditional biochemical structure/activity studies, by theoretical
methods and by single crystal X-ray diffraction techniques. These studies
have been reviewed in an excellent chapter by Schiller (1984). A more
detailed review of the crystallographic literature appears in a previous
monograph in this series (Camerman and Camerman 1986). This review will
concentrate on the enkephalin structures determined by X-ray diffraction
techniques since that paper was published, and on certain aspects of the
structures which were not highlighted in the previous review. The results of
X-ray diffraction studies on some morphine analogues with interesting opioid
activity profiles will also be discussed.
INFORMATION OBTAINED FROM X-RAY DIFFRACTION STUDIES
The results of an X-ray diffraction study are a set of atomic coordinates, unit
cell constants and space group. Calculations made from the above
information provide not only geometric details on the compound under
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study, precise bond distances, valency angles and torsion angles, but also
intramolecular and intermolecular hydrogen bond geometry. The interactions
that represent the forces holding molecular crystals together are exactly the
same forces that are responsible for substrate-receptor binding: electrostatic
interactions between charged groups, hydrogen bonds between functional
groups, hydrophobic interactions and dipolar interactions. Thus the bioactive
compound in the crystal lattice is a model of the substrate in a set of
complementary surroundings. Determination of different crystalline forms,
polymorphs and solvates, of the same material show different gross
intermolecular interactions that can be related back to interactions in
solution. Stable patterns of aggregation and even solvation present in
solution persist in the crystalline form. Thus, multiple determinations of the
same compound (either more than one molecule in the asymmetric unit or
different crystalline forms) give information on conformational flexibility,
stable aggregates, patterns of solvation, and intermolecular interactions.
Main-Chain Conformation
There have been three X-ray crystallographic studies of [Leu5] enkephalin
and two studies of the same crystalline form of (Met5]enkephalin. The
crystal data on these structures is given in table 1. The structures labelled
[(4-bromo-Phe4] analogue of [Met5]enkephalin (Doi et al., 1987b) have been
LEE2, MEE2 (Griffin et al., 1985, 1986a), MEE2 and MEBrE2 the
determined since the previous review. Structures MEE2 and MEE2 are two
independent studies on crystals that appear to vary only in the amount of
water present (see table 1). Previously, the crystal structures of the
[(4-bromo-Phe4] analogue of [Leu5]enkephalin and a few other analogues ues
with individual amino acid replacements have also been determined. These
compounds and the main-chain conformations observed in each of these
studies are given in table 2. Two conformations predominate, a turn
centered on Gly2Gly3 and a family of extended conformations.
Solution spectra have for the most part been interpreted as showing that
there are both extended and folded conformations in solution; the folded
conformation most frequently found by interpretation of spectra is a turn
centered on Gly3 Phe4, a conformation not yet observed in the solid state.
Khaled (1986) has pointed out some of the limitations in magnetic resonance
studies of peptides: (1) assignments are complicated in a molecule containing
a recurring amino acid residue such as in enkephalin with two adjacent
glycine residues; (2) a controversy exists regarding the interpretation of the
temperature dependence of NH protons. These assignments are used to
distinguish inter- and intramolecular hydrogen bonds. The presence of the
type I’ -turn conformation of enkephalin, centered on Gly2Gly3 and
characterized by a Phe4 NH to O=C Tyr1 hydrogen bond, observed in the
solid state studies of [Leu5]enkephalin and analogues (table 2) has been
reported in only one spectroscopic study, enkephalin amides complexed with
18-crown-6-ether in chloroform (Beretta et al. 1984).
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TABLE 1
Crystal data on enkephalins.
[Leu5]enkephalin
LE(B)a LE(E4)
b
[Met5]enkephalin
LE(E2)C ME(E2')d ,e  MEBr(E2)dLE(E2)c
Space Group
Z
No. independent
mol./ asym. unit
solvent/ asym. unit
Vol. (A3)
No. observations
No. obs. > 2 sigma
a (A)
b (A)
c (A)
alpha (°)
beta (º)
gama (°)
C2 P21 P2116 8 4
4
6 H2O
13501
8869
5430
24.861
17.084
31.937
95.54 115.9 92.19 91.24 91.23
4 2
8H20, 8C3H7NO, 0.5H2O
8459 2999
10942 3180
5965 3004
18.720 11.549
24.732 15.587
20.311 16.673
P21
4
2
10.6H2O
3448
5056
4725
11.607
17.987
16.519
P21
4
 2
10 H2O
3413
6037
4407
11.592
17.871
16.480
P1
2
2
4.5 H2O
1730
5908
5270
11.619
11.609
12.943
93.92
96.10
86.99
a Smith and Griffin 1978; Blundell et al. 1979.
b Karle et al. 1983; Camerman et al. 1983.
c Griffin et al. 1985, 1986a. Subsequent to this report of structures LE(E2) and ME(E2), Hastropaolo et
al. (1986, 1987) reported the independent structure determination of the same structures using the same
X-ray diffraction data of Blundell. The report that the [Met5]enkephalin crystals were grown from
ethanol/water (Hastropaolo et al. 1986) is incorrect. The experimental details of crystallization and
data collection from Blundell’s laboratory are given in Griffin et al. 1986a.
d Doi et al. 1987b.
e ME(E2) and ME(E2') are tvo independent studies on crystals that appear to vary only in the amount of
water present. Note the almost identical cell parameters, differing by 34 A3 in unit cell volume.
TABLE 2
Conformations of enkephalin and enkephalin analogues
from X-ray crystallographic determinations.
Peptide Conformation
Tyr-Gly-Gly-Phe-Leu- 2H2O 
(Smith and Griffin, 1978)
Tyr-Gly-Gly-Phe-Leu-2H2O,
2C3H7NO,X (Karle et al. 1983)
type I’ ß-bend NPhe to OTyr
(Gly-Gly) NTyr to OPhe
Extended None
antiparallel ß-sheets
Tyr-Gly-Gly-Phe-Leu•0.5H2O
(Griffin et al. 1986a)
Tyr-Gl-Gly-Phe-Met•5.3H2O
(Griffin et al. 1986a) 
Tyr-Gly-Gly-Phe-Met•5.0H2O
(Doi et al. 1987b)
Extended None
antiparallel ß-sheets
Extended None
antiparallel ß-sheets
Extended None
antiparallel ß-sheets
Tyr-Gly-Gly-(4Br)Phe-Leu•2.5H2O type I’ ß-bend
(Ishida et al. 1984) (Gly-Gly)
NPhe to OTyr
NTyr  to OPhe
Tyr-Gly-Gly-(4Br)Phe-Met•2.3H2O
(Doi et al. 1987b)
Tyr-D-Nle-Gly-Phe-NleS•2.5H2O,
C2H5OH (Stezowski et al. 1985)
Tyr-Gly-Gly-Phe•DMSO,2H2O
(Foumie-Zaluskie et al. 1977)
Extended
type II’ ß-bend
(D-Nle-Gly)
NPhe to OTyr
NTyr to OPhe
type I’ ß-bend
(Gly-Gly)
Gly-Gly-Phe-Leu•H2O
(Foumie-Zaluskie et al. 1977)
Extended
BOC-Tyr-Gly-Gly-(4Br)Phe-MetOH
(Doi et al. 1984)
Extended None
antiparallel -sheets
BOC-Aib-Aib-Phe-MetNH2•DMSO
(Prasad et al. 1983)
BOC-Gly-Gly-Phe Ethyl Ester
(Ishida et al. 1983)
310 Helix
type I’ -bend
(Gly-Gly)
Intramolec.
H-bonds
None
NPhe to  OTyr
None
NPhe to OBOC
NMet to Aib
None
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Extended Main-Chain Conformations
The six independent observations of [Leu5]enkephalin, 4 molecules in LEE4
and 2 molecules in LEE2, in the extended conformation are superimposed in
figure la. The two independent molecules of [Met5]enkephaIin (MEE2) are
superimposed in figure lb. The peptide chains observed in LEE2, but
particularly in the three (Met5) structures are unusually planar. This is
apparent by examination of the torsion angles for the [Me5]enkephalin
structures and [Leu5]enkephalin (LEE2) versus the extended conformations
seen in LEE4 (see table 3). The main-chain torsion angles of the dimer of
[4-bromo-Phe4,Met5]enkephalin (MEBrE2) are remarkably similar to those in
MEE2 and MEE2, even though the space group and the amount of solvent
water in the crystal are different. The torsion angles for Gly2 and Gly3
in the three [Met5] structures indicate an unusually extended conformation.
all the values lie between ± 160° and ± 180°, The values for the Phe4
residue in the [Met5]enkephalin structures (six observations) are almost
invariant, -154° ± 4°/155º ± 4°, and lie in the ideal -sheet region; the
values in the [Leu5]enkephalin structures show greater variability, especially
in LEE4 The Met residues are in two slightly different conformations,
 -138°/157° and -155°/170°. These results could be interpreted to indicate
less flexibility in the main chain of [Met5]- versus [Leu5]enkephalin, but the
small size of the data base imposes caution in drawing this conclusion.
Side-Chain Conformation
In addition to the torsion angle values, which define main-chain
conformation, table 3 contains the torsion angles, which describe the Tyr,
Phe, Leu, and Met side-chain conformations in the -sheet enkephalin
structures. The values for the Tyr and Phe side chains in the
(Met5]enkephalin structures are almost invariant. both close to +60° (six
observations of each). This is in contrast to the values observed in the
[Leu5]enkephalin structures: Tyr +60° (three observations), 180° (three);
Phe -60º (five), 180° (one).
If the side-chain conformation observed in the extended structures is
compared with that observed in the type I’ -turn [Leu5] structures, LE and
[(4-bromo)Phe4 ,Leu5]enkephalin, the major difference is in of Tyr: -60°
in the -turn forms and +60º and 180° in the extended forms; of Phe is
-60º in the turn structures, similar to the major conformer in the -sheet
[Leu5]enkephalin structures.
In summary, in this admittedly small sample, the side-chain conformations in
[Leu5]- versus (Met5]enkephalin are distinguished by mutually exclusive Phe
values. The [Leu5] structures have of Phe -60°, 180°, while the
[Met5] structures have of Phe values +60º. The extended versus -turn
structures have mutually exclusive values for Tyr -60º ( turn), and
+ 60°, 180° (extended),
INTERMOLECULAR INTERACTIONS
The [Met5]enkephalin structures consist of dimers forming infinite anti-
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FIGURE 1
(a) A stereo view of a least-squares superposition of the six
crystallographically observed extended conformations of [Leu5]enkephalin.
The 21 main chain atoms were fit. (b) A stereo view of a least-squares
superposition of the two crystallographically observed extended
conformations of [Met5]enkephahn in MEE2. Each methionine residue is
observed in two distinct conformations; one is dashed.
46
parallel -sheets with varying amounts of water molecules per dimer. The
two crystallographically independent molecules of the dimer are remarkably
similar with respect to both main-chain and tyrosine and phenylalanine side-
chain conformations (table 3). In both MEE2, and MEE2 each methionine
side chain is disordered, and the disordered conformations are different in the
two independent molecules (see table 3). The disorder appears to be the
result of close contacts between methionine side chains in adjacent
independent molecules. The amount of solvent in the unit cell appears to
affect the methionine side-chain conformation. In the dimer the nitrogen and
carbonyl of GIy2 and Phe4 of one molecule are hydrogen bonded to the
carbonyl and nitrogen of Phe4 and Gly2,
(figure 2).
respectively, of the other molecule
Additional hydrogen bonds connect adjacent dimers and form
head-to-tail (NTyr to OMet) connections, which loin crystallographically
equivalent molecules related by translation.
The [Leu5]enkephaIin structure LEE2 is made up of planar -sheets arranged
similarly to those in the [Met5] structures. However, the side chains are
oriented differently in the two independent molecules (see table 3). There is
only one molecule of water per dimer of [Leu5]enkephalin versus 10.6 and
10.0 in MEE2 and MEE2 , respectively. The packing is more compact than
is observed in the other two [Leu5] forms. The one water molecule is
tetrahedrally coordinated; it donates two hydrogen bonds to the two
independent leucyl carboxyl groups and accepts two hydrogen bonds from
the hydroxyl groups of two independent tyrosine side chains.
In the [Met5]enkephalin structures MEE2 and MEE2, the distance between
sheets is approximately 9.0 (one-half the b axis), while the value observed
in the [Leu5]enkephahlin structure is 7.8 As a result of this increase in
interplanar spacing, the unit cell of [Met5]enkephalin accommodates
additional water molecules.
Comparison of the -Sheet Forms
The asymmetric unit, that is, repeating unit, is a dimer in structures LEE2
MEE2, MEE2 and MEBrE2 and a tetramer in LEE4 The dimers are similar 
in all four structures; two independent molecules form an antiparallel -sheet
with four hydrogen bonds N(Gly2)A to O(Phe
4)B N(Phe’)B to O(Gly
2)A,
N(Gly2)B to O(Phe
4)A, N(Phe
4)A to O(Gly
2)B, where A and B refer to the
two independant molecules. The dimers are joined in head-to-tail fashion,
with identical dimers related by translation forming infinite ribbons. These
ribbons are joined to adjacent ribbons by antiparallel hydrogen bonds
translated by approximately 1/2 the length of the peptide. Therefore, dimers
adjacent in the plane of the -sheet hydrogen bond across the head-to-tail
connections (see figure 2). The -sheets thus formed are not pleated in the
normal direction, that is, along the peptide chain. Instead the chains are
very flat and extended, and the pleat is perpendicular to the direction of the
peptide chain.
The asymmetric unit in LEE4 is a tetramer; two of the four molecules, A and
B, form a dimer similar to the one described above for the dimeric structures
with respect to hydrogen bonding. The other two molecules of the tetramer.
C and D, are rotated 180º in the plane of the -pleated sheet and form
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FIGURE 2
Packing pattern of [Met5]enkephalin MEE2 showing the -sheet structure.
This pattern is common to the three [Met5] structures. Water is shown as
large circles. The water structure is not common to the three structures.
FIGURE 3
Comparison of the -sheet formed in [Leu5]enkephalin, LEE4, left, and LEE2 ,
right. The dimer common to both structures is outlined.
48
hydrogen bonds with one another and with B and the translationally related
A molecules through the peptide C=O and NH groups. The tetramers form
a continuous -pleated sheet along a. These sheets are connected to
translationally related sheets along c, forming an infinite sheet in the ac
plane. The sheets are separated from one another by solvent, much of it
disordered. The distance between the sheets is 12.4  (1/2 b) and there is no
interaction between the side-chain residues of adjacent sheets.
The side-chain residues pack quite differently in the space between adjacent
sheets in the two [Leu5] structures, LEE4 and LEE2 (see figure 3). In LEE4
there is a layer of solvent molecules separating the side-chains of the -sheets
adjacent along b. The structure is a sandwich layered along b, the bottom
slice is a -sheet. followed by a side-chain layer forming hydrogen bonds
(Tyr) and hydrophobic interactions (Leu and Phe) to the next layer, solvent,
which in turn forms hydrogen bonds and hydrophobic interactions to the
side-chain layer from the top -sheet, the final slice. Because in LEE4, the
dimer formed by molecules C and D is rotated 180° in the plane of the sheet
with respect to the AB dimer. all three side-chain residues from the plane at
0.25 and three from the plane at 0.75 pack in the space between
sheets separated by b/2. In LEE2, on the other hand, the residues between
the planes consist of tyrosyl and leucyl side-chains from one sheet and
phenylalanyl residues from the sheet separated by b/2. These form relatively
tight hydrophobic interactions connecting the B-sheets along b.
Packing of the -Turn Form
The asymmetric unit in the -turn form LE is a tetramer (see figure 4). The
two central molecules form a hydrogen- onded dimer, the N-terminus ofb
each is hydrogen-bonded to the tyrosyl hydroxyl of the other. Molecules one
and three are connected by three water molecules forming bridging hydrogen
bonds between them. Molecules two and four are almost identical to one
and three. These tetrameric units are repeated in three dimensions by the
symmetry operations of the space group. The interactions between separate
tetramers are mainly hydrophobic; the two-fold axis is surrounded by Phe
and Leu side-chains (see figure 4b).
In the -turn structure there are two intramolecular hydrogen bonds that
connect the Tyr and Phe groups of each of the four independent molecules,
N(Tyr) to O(Phe) 2.79-2.84 and N(Phe) to O(Tyr), 2.99-3.10 . The six
water molecules take part in a variety of interactions. Two water molecules
form a bridge between the Phe4 carbonyl oxygen and the Leu5 carboxy
oxygen of one molecule. In each of the four independent molecules, both
the Gly2 nitrogen and the Gly3 carbonyl oxygen are hydrogen bonded to
water molecules.
There are patterns of solvation common to more than one of the enkephalin
crystal structures; that is, water molecules bind to the same atoms even
though the packing in the structures may vary. The waters common to more
than one structure are given in table 4.
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TABLE  3
FIGURE  4
(a) Stereo view of the tetramer that makes up the asymmetric unit in LE
Large circles are water molecules. (b) Stereo view of the packing of a unit
cell, 16 molecules, in LE Note the hydrophobic holes formed by tyrosyl,
phenylalanyl, and leucyl residues.
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TABLE 4
Common patterns of solvation in enkephalin crystal structures:
atoms of enkephalin molecules hydrogen-bonded to water.
LE LEE4 LEE2 MEE2*
CO-(leu5) CO
-(leu5) CO-(leu5) CO
-(met5)
OH(tyr 1) OH(tyr1) OH(tyr1) OH(tyr1)
N+(tyr1) N+(tyr1)
C=O(gly2) C=O(gly
2)
C=O(phe4) C=O(phe4) C=O(phe4)
*The authors do not have the crystallographic coordinates for MEE2, and
MEBrE2, so the solvent structure cannot be calculated.
Conformation of Enkephalin at the µ and   Receptor
Since the demonstration of the existence of multiple forms of opioid
receptors, arguments have been made that the µ  and subtypes bind different
fcon ormations of the endogenous opioids. Soos et al. (1980) suggested this
on the basis of CD spectra on the enkephalins and enkephalin analogues.
Raman spectra was interpreted as showing more folded conformations of
[Leu5]enkephalin than [Met5]enkephalin in aqueous solution and DMSO
(Renugopalakrishnan et al. 1985). The observed solid state conformations
led to the proposal that [Leu5]enkephalin binds to the µ  receptor in a folded
conformation and [Met5]enkephalin to the s in an extended conformation
(lshida et al. 1984). Recently Doi et al. (1987b) suggested that a pair of
bend molecules of enkephalin can mimic the -sheet dimer, placing similar
functional groups in the same regions of three-dimensional space, and bind
to the receptor. In a subsequent paper the same group (Doi et al. 1987a)
suggested that the -turn monomer and the extended dimer could each bind
to both µ  and subtypes of the opioid receptor. They based this conclusion
on computer graphics and empirical energy studies of the two conformations,
adjusting the tyrosyl and phenylalanyl side chains on both conformations to
superimpose the analogous residues in the same regions of three-dimensional
space. This hypothesis requires further testing by biochemical techniques.
The -turn structure of [Leu5]enkephalin was initially proposed to be the
biologically active conformation (Smith and Griffin 1978). The conclusion
was based on a least-squares superposition of the -turn conformation of
enkephalin with the structures of morphine, etorphine and PET, 7-(1-phenyl-
3-hydroxybutyl-3]-endoethenotetrahydrothebaine, the latter two superactive
agonists. In addition, the fact that the torsion angles of Gly2 place the
conformation in a region of conformational space allowed for D-amino acids,
and D-Ala2 substituted enkephalins had been shown to be very active,
supported the proposal. These arguments were made before the existence of
opioid receptor subtypes was demonstrated and the selectivity of the
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individual subtypes shown experimentally. The activity of etorphine and the
tetrahydrothebaines at both u and s opioid receptor subtypes, however, has
not been accounted for in the suggestion that u and s subtypes bind different
conformations of the enkephalins.
The fully extended conformation of a small peptide can form the maximum
number of intermolecular hydrogen bonds. In going from the extended form
to the type I’ -turn conformation centered on Gly2Gly3, the enkephalin
molecule decreases the number of hydro en bonding groups available for
receptor interactions and increases the surface hydrophobicity. This may be
relevant to the conformation assumed at the receptor(s), since the morphine-
and tetrahydrothebaine-like molecules are more hydrophobic than enkephalin.
OPIATE DRUGS
Naltrexone Derivatives
FUNALTREXAMINE
- and -Funaltrexamine ( - and -FNA) are naltrexone derivatives differing
only in chirality at C6. Both compounds bind to the µ opioid receptor in
mouse vas deferens (MVD) and guinea pig ileum (GPI) preparations, but
only the -epimer binds irreversibly, presumably by forming a covalent bond
to the receptor. For this reason, -FNA has been used to irreversibly block u
receptors in order to isolate the binding characteristics of receptors in GPI
and MVD preparations, and Sites in brain homogenate preparations.
A two-step recognition process had been proposed to account for the
different binding characteristics of  and -FNA for the µ receptor; both
bind in the first recognition step but only the -epimer is in the proper
orientation for the second recognition step which results in alkylation. The
crystal structures of - and -FNA suggested a possible explanation for the
observed differences (Griffin et al. 1986b). The two compounds have almost
identical conformations in the fused rings with the exception of the C ring;
the -epimer has a chair conformation and the -epimer a twist-boat
conformation, resulting in the fumaramate side chain being equatorial to the
C ring in both cases. Analysis of the superposition of the two structures
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FIGURE  5
Stereo view of the superposition of the crystallographically observed
structures of - and -funaltrexamine, with the proposed sites of receptor
interaction. The first recognition step involves the phenol ring. the phenol
hydroxyl, and the charged nitrogen. The second recognition step involves
the fumaramate group and possibly the amino nitrogen at C6 (from Griffin et
al., 1986b, Copyright 1986, American Chemical Society).
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revealed that the fumaramate groups occupied the same region with respect
to the naltrexone frame in both structures, but the conjugated fumaramate
roups were oriented orthogonal to one another. A close oxygen contact (03
from a symmetry related molecule) to the double bond carbon (C23)
observed in the crystal structure was used to model this second recognition
site and explain the failure of the -epimer to irreversibly bind to the
receptor (see figure 5).
The conformation of the C ring of naltrexone derivatives appears to be
sensitive to substitution at C6. The crystal structure of the 6 -amino
derivative of naltrexone, 6 -oxymorphamine (Lever et al. 1985) confirmed
their conclusions based on lH NMR that the C ring in the 6 -amino epimer
is in a twist-boat conformation and in the -epimer is a chair. As in the
FNA structures this places the 6 substituent in the equatorial position in both
epimers. Comparison of the C ring torsion angles in -FNA and 6 -
oxymorphamine shows they have almost identical conformations.
Acylmorphinans
Although the phenolic hydroxyl group is considered essential to activity in
morphine and structurally related analogues, its presence results in rapid
inactivation when given by oral route. Mohacsi et al. (1985) have reported
the crystal structure of a C3-acyl morphinan that retains morphine-like
analgesic activity even when administered orally. The 03 atom could be
serving as a hydrogen bond acceptor, since the phenolic oxygen in morphine
can act as both donor and acceptor of hydrogen bonds. The oxygen to
nitrogen distance in the acylmorphinan structure is 7.94 , whereas in the 30
crystal structures containing the morphine five fused-ring system in the
Cambridge Structural Database (Allen et al. 1979). the value of the distance
ranges from 6.77 to 7.16 , average 7.03(11)
Conformations of the Morphine Fused-Ring System
Brown et al. (1983) reported that the conformation of morphine in the crystal
is different from that in aqueous solution, and that the latter is the one
“available for receptor binding, ” although no evidence or explanation for this
assertion was included in the report. Their study was based on a comparison
of the high resolution 13C NMR spectra of solid morphine sulfate versus
solid morphine free base, solid morphine sulfate versus morphine sulfate
dissolved in D2O, and morphine sulfate dissolved in D2O at 22°C and 70°C.
Their data were interpreted as showing a minor component of the nitrogen
invertoisomer in solution, the nitrogen methyl went from equatorial to axial,
and the inversion was associated with a “greater freedom of motion in the
piperidine ring than previously believed.” They speculated that the
downfield chemical shifts of the spectral lines assigned to C2, C7, C11, C15,
and C16 on going from solution to solid were due to interactions in the solid
state between these atoms and the sulfate group. The authors did not
identify the crystalline polymorph they were examining. Solid state spectral
studies should always verify the identity of the crystals studied by means of
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powder or single crystal X-ray diffraction to determine cell constants and
space group. Without this information, no meaningful comparison can be
made between the spectral studies and crystallographic results. The change
in chemical shifts are difficult to explain from the crystal structure of
morphine, 0.5 SO4, 2.5 H2O (Wongweichintana et al. 1984); although C2,
Cl5, and Cl6 show close contacts to sulfate oxygens in the crystal (3.39 to
3 . 4 9 ), C7 and C11 do not, while C3 and the N-methyl carbon also show
short contacts.
The Cambridge Structural Database (Allen et al. 1979) contains 30 crystal
structure determinations of compounds that contain the morphine five fused-
ring framework. In this data base the methyl substituent on the piperidyl
nitrogen is always observed equatorial and there is little evidence for great
freedom of motion in the piperidine ring especially at C15 and C16. The
piperidyl ring is always a chair, and the torsion angle C13-C15-C16-N only
varies from -47° to -57° in the entire sample, average 51.2 (2.0)°. The main
region of flexibility is ring C, and the changes in ring C conformation can be
correlated with changes in chemical constitution, either a double bond at C6.
C7 or C7, C8. or the substitution of a nitrogen on C6, as discussed above.
There are also changes in the three carbon-nitrogen bonds of the piperidyl
nitrogen correlated with whether the structure is the free base or salt.
SUMMARY
Information on intramolecular geometry, low energy conformations,
hydrogen bonds, both intramolecular and intermolecular, and preferred
intermolecular interactions is obtained from single crystal X-ray diffraction
experiments. Structure determinations of crystals with more than one
molecule in the asymmetric unit and of different crystalline forms provide
information on conformational flexibility and stable aggregation states.
The single crystal X-ray diffraction studies of enkephalin have demonstrated
a number of minimum energy conformations of the main chain and side
chains, a type I’ turn centered on Gly2Gly3 and a number of extended
main-chain conformations. In the studies of native enkephalins, dimers and
tetramers form repeating units, and some patterns of solvation are observed
in more than one form. Certain conformations and interactions proposed on
the basis of solution spectroscopic studies have yet to be observed in the
solid state. Efforts should be made to grow different crystalline forms of the
enkephalins and to determine the solid state structure of enkephalin
analogues that exhibit high selectivity for a particular opioid receptor
subtype.
Crystallographic studies of opiate drugs with selective activity profiles at
different receptor subtypes can give infomration on the features responsible
for active site differenttation between the subtypes of opioid receptor.
Analysis of the crystallographic data base of 30 compounds containing the
five fused-ring morphine moiety indicate that: (1) the methyl group on the
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piperidyl nitrogen prefers the equatorial position, (2) the conformation of the
piperidyl ring is a relatively invariant chair conformation, (3) C-ring
conformation depends on the chemical constitution of the C-ring and
substitution at C6.
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INTRODUCTION
Extensive conformational studies of the enkephalins [H-Tyr-Gly-
Gly-Phe-Met(or Leu)-OH] by various spectroscopic techniques and
by X-ray diffraction analysis revealed that these linear
pentapeptides are highly flexible molecules capable of assuming a
number of both folded and extended conformations of comparably
low energy (Schiller 1984). In fact, it has been demonstrated
quite convincingly that in solution enkephalin exists in a
conformational equilibrium (Fischman et al. 1978). It has,
therefore, become clear that conformational studies of these
small opioid peptides and of many of their analogs are unlikely
to provide any insight into their bioactive (receptor-bound)
conformation(s). Furthermore, the conformational flexibility of
the enkephalins is most likely the reason for their lack of
specificity toward the different opioid receptor classes
because conformational adaptation to the various
receptor topographies is possible. Thus, even though the
enkephalins preferentially bind to the -receptor, they also
have quite good affinity for the µ-receptor and, therefore, are
only moderately -receptor selective.
CONFORMATIONALLY RESTRICTED ANALOGS OF OPIOID PEPTIDES
The conformational flexibility of opioid peptides can be reduced
through incorporation of conformational constraints. In recent
years conformationally restricted analogs of enkephalin have been
synthesized with two goals in mind. First, such analogs are
more amenable to a meaningful conformational analysis since
because of their relatively rigid structure they are unlikely to
undergo major conformational changes upon binding to the receptor
and, therefore, Information about the bioactive conformation at
the various opioid receptors can be obtained. Second, the
introduction of conformational constraints may result in improved
receptor selectivity, because the conformationally restricted
analog may have good affinity for one receptor type but may no
longer be able to undergo a conformational change necessary to
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bind to another receptor class. Local conformational
restrictions in enkephalins have been achieved either at
particular peptide backbone positions (e.g., through
methylation or through incorporation of small ring structures) or
in selected side chains (e.g., through substitution of a
dehydroamino acid) (for a review, see Schiller 1984). However,
the most drastic restriction of the overall conformational space
available to the peptide has been realized through the design and
synthesis of cyclic enkephalin analogs.
Three families of biologically active cyclic opioid peptide
analogs have been synthesized to date. A cyclic enkephalin
analog was first prepared through substitution of D-
diaminobutyric acid (A2bu) in position 2 of the peptide sequence
followed by cyclization between the side chain amino group of
A2bu and the C-terminal carboxyl group (DiMaio and Schiller
1980). The resulting analog, H-Tyr-cyclo[-D-A2bu-Gly-Phe-Leu-]
(figure 1, compound 2), containing a fairly rigid 14-membered
ring structure, turned out to be moderately µ-receptor selective
(Schiller and DiMaio 1982). Pharmacologic comparison of 2 with a
corresponding open-chain analog revealed that its µ-receptor
preference is a direct consequence of the conformational
restriction introduced through ring closure and, furthermore,
permitted the fundamental conclusion that µ- and -opioid
receptors differ indeed from one another in their conformational
requirements toward peptide ligands (Schiller and DiMaio 1982).
Homologs of 2 (compounds 1, 3, and 4) were obtained through
variation of the side chain length in position 2 and also were
found to display moderate preference for µ-receptors over s-
receptors (DiMaio et al. 1982). On the other hand, a
diastereomer of cyclic peptide 2, H-Tyr-cyclo[-D-A2bu-Gly-Phe-D-
Leu-], was non selective (Mierke et al. 1987). Several partial
retro-inverso analogs of 2 were found to be very potent and µ-
selective (figure 1, structures 2b and 2c), whereas both
diasteromers of 2d showed very weak activity (Berman et al. 1983;
Richman et al. 1985), presumably because the Gly3 -Phe4 peptide
bond is important for binding to the receptor.
A second class of cyclic enkephalin analogs was obtained through
side chain-to-side chain cyclization between a D-Cys and a D- or
L-cys residue substituted in positions 2 and 5 of the peptide
sequence. respectively (Schiller et al. 1981). The resulting
cystine-containing analogs (5)
were highly potent and showed either no receptor selectivity (X =
NH2) or moderate -receptor selectivity (X = OH) (Schiller et
al.  1985a). The Trp4 analog NH2 (6)
displayed an activity profile similar to that of the
corresponding Phe4 parent compound (Schiller 1983). Replacement
of the half-cystine residues in positions 2 and/or 5 with
penicillamine residues resulted in compounds (7-7c) with markedly
improved -receptor selectivity (Mosberg et al 1983).
The configurational requirements of cyclic analogs 4 and 5 at the
residues in positions 1, 2, 4, and 5 of the peptide-sequence were
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FIGURE 1
Structural Formulas of Cyclic Opioid Peptide Analogs
found to be the same as those of the corresponding residues in
linear enkephalins (Schiller and DiMaio 1983). This finding as
well as other structure-activity data obtained with these
compounds indicated that corresponding moieties in these cyclic
and linear enkephalin analogs interact with the same subsites on
the receptor. It can thus be concluded that both H-Tyr-cyclo[-D-
Lys-Gly-Phe-Leu-] and NH2 have the same
mode of binding to the receptor as the linear enkephalins.
Another family of side chain-to-side chain cyclized opioid
peptide analogs was obtained through amide bond formation between
the side chain amino and carboxyl groups of appropriately
substituted Orn (or Lys) and Asp (or Glu) residues (Schiller and
Nguyen 1984; Schiller et al. 1985b, 1987). Among the various
cyclic lactam analogs of this type prepared,
NH2 (8) turned out to be potent and highly µ-selective. The
latter analog contains a rather rigid 13-membered ring structure
and a Phe residue in the 3-position as it is the case with the
dermorphins and the -casomorphins. Among several prepared
analogs of 8,
(10) showed the same high µ-selectivity as the parent
NH2 (9) and
compound, whereas (11) was less µ-
selective due to reduced affinity for the µ-receptor. Analogs H-
(11) and (13)
showed very weak activity. Taken together, the structure-
activity data obtained with analogs of
indicated that the mode of binding of the latter peptide
identical with that of the dermorphins but different from that of
the casomorphins (Schiller et al. 1987).
CONFORMATIONAL ANALYSIS OF CYCLIC OPIOID PEPTIDE ANALOGS
Side Chain-to-End Group Cyclized Enkephalin Analogs
The conformational behavior of the cyclic prototype analog H-Tyr-
cyclo[-D-A2bu-Gly-Phe-Leu-] (2) has been investigated by various
groups, using a variety of theoretical and experimental
techniques. In a first theoretical conformational analysis, a
molecular mechanics approach was used to determine low energy
conformers of 2 (Hall and Pavitt 1984a). The lowest energy
conformer obtaized was characterized by a Gly3 -Phe4 type II'
bend, and it was suggested by the authors that the same type of
bend might also be present in the receptor-bound conformation of
linear enkephalins. Furthermore, some of the low energy
conformers found showed a transannular hydrogen bond between the
side chain NH of A2bu and the A2bu carbonyl group. Another
energy minimization study of cyclic analog 2 resulted in a number
of low energy conformers that contained either relatively planar
ring structures stabilized by intramolecular hydrogen bonds
turns or C7 structures) or twisted ring structures devoid of any
hydrogen bonds (Maigret et al. 1986). Furthermore, the authors
postulated that the tyramine portion of Tyr1 and the Gly3
carbonyl group in 2 might correspond to the tyramine portion and
the C-ring hydroxyl group contained in morphine. It was then
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attempted to impose spatial overlap of these pharmacophoric
moieties with those in the rigid morphine molecule through
conformational adaptation of each one of the low energy
conformers of cyclic peptide 2. This was possible at a
relatively low energy expenditure (6 kcal/mol) with only one of
the low energy conformers and resulted in a tilted structure
that was characterized by intramolecular hydrogen bonds from
Leu5-NH to A2bu-CO bend) and from Gly
3-NH to Tyr1-CO (C7
structure). It was suggested that the latter conformation might
represent the bioactive one at the µ-receptor, since the 6
kcal/moL increase in energy as a consequence of the imposed fit
could certainly be compensated for by favorable binding
interactions at the receptor. It must be realized, however, that
this proposed model depends entirely on the authors' somewhat
arbitrary choice of the pharmacophore.
In a third study, both computer simulations and 1HNMR
spectroscopy were employed to determine the conformation(s) of
cyclic analog 2 (Mammi et al. 1985). The performed molecular
dynamics study showed that the ring structure of 2 is not
entirely rigid but fluctuates about a few equilibrium
conformations. The most stable ring conformations were found to
be stabilized by transannular hydrogen bonds implicated in the
formation of C7 structures. The carried out energy minimization
study resulted in one lowest energy conformer characterized by
hydrogen bonds from A2bu(side chain)-NH to A2bu-CO, from Leu
5 -NH
to Gly3-CO and from Gly3-NH to Tyr1 -CO. The ring structure of
another obtained low energy conformer also showed a Leu5
Gly3 hydrogen bond, whereas the A2bu side chain NH was hydrogen-
bonded to the Phe4-CO rather than to the A2bu-CO. Determination
of the temperature dependence of the amide proton chemical shifts
in the 1HNMR study performed with cyclic analog 2 in
[2H6]DMSO revealed that both the Leu
5 NH and the side chain NH of
A2bu may be involved in hydrogen bond formation. These results
are consistent with the hydrogen bonding patterns obtained in the
energy minimization and suggest that the solution conformation of
2 may indeed be stabilized by the transannular hydrogen bonds
observed in the calculated lowest energy conformers.
It is obvious that the results of these various conformational
studies on cyclic analog 2 have not yet led to a consensus
concerning a possible unique bioactive conformation at the
receptor. Clearly, the most important finding of these
endeavors is the realization that the ring structure in 2 still
retains some flexibility and that the various intramolecular
hydrogen bonds observed are constantly formed, broken, and re-
formed again, as shown most conclusively in the molecular
dynamics study.
In a recent study, the conformational behavior of H-Tyr-cyclo[-D-
A2bu-Gly-Phe-Leu-] (2) was compared with that of its diastereomer
with Leu5 in the D-configuration (analog 2a), using again a
combination of computer simulations and 1HNMR in [2H6]DMSO
(Mierke et al. 1987). The obtained results showed that, in
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contrast to the L-Leu5 peptide, the conformation of the D-Leu5
analog is not stabilized by any intramolecular hydrogen bonds.
Furthermore, the NMR data (T1 relaxation time measurements) and
molecular dynamics study indicated that both the peptide backbone
and the side chains in 2a are considerably more flexible than in
2. In particular, the computer simulation carried out for 20
picoseconds  revealed that the important intramolecular distance
between the Tyr1 and Phe4 aromatic rings remains constant (~20
in the case of the L-Leu5 analog, whereas considerable variation
of that same distance with time (5-16 is seen in the case of
the D-Leu5 analog. It was concluded that the more rigid
conformation and the relatively large and fixed distance between
the Tyr and Phe4 aromatic rings of analog 2 may be responsible
for its µ-receptor preference, whereas the Lack of receptor
selectivity shown by 2a may be due to its comparatively higher
structural flexibility The same approach was also used to
investigate the conformational behavior of partial retro-inverso
analogs of 2, characterized by a reversed amide bond in three
different positions of the ring structure (figure 1, compounds
2b, 2c, and 2d). Various transannular hydrogen bonds, giving rise
to C7 structures or also C6 and C8 structures, were detected in
the computer simulation study and where found to be compatible  
with the results of the NMR temperature perturbation study, which
permitted the identification of hydrogen-bonded amide protons.
No -turns were observed, as the conformational restriction
introduced through ring closure renders the formation of a
hydrogen bond energetically unfavorable. In all analogs the side
chains of
flexible,
the Phe4 and Leu5 residues were found to be very
whereas the Tyr side chain appeared to exist primarily
in the trans conformation 1 ~ 180°), which was favored by more
than 3 kcal/mol over gauche conformations.
Hall and Pavitt (1985) compared the Low energy conformations of
H-Tyr-cycLo[-D-A2pr-Gly-Phe-Leu-] (1) and H-Tyr-cyclo[-D-Orn-Gly-
Phe-Leu-] (3) with those of
(2), using the
H-Tyr-cyclo[-D-A2bu-Gly-Phe-Leu-]
same molecular mechanics approach as in their
original study of 2 (Hall and Pavitt 1984a). This investigation
resulted in a number of low energy ring conformations common to
all three analogs, which differed from one another primarily in
the orientation of a particular amide bond.
conformations
Several of these
contained a type II' bend centered on Gly3 -Phe4 ,
and it was speculated that one of these might represent the
bioactive  conformation at the receptor. Kessler et al. (1985)
performed a 1H NMR study in [2H6]DMSO with H-Tyr-cyclor-D-
Orn-GLy-Phe-Leu-] (3) and H-Tyr-cyglo[-D-Lys-Gly-Phe-Leu-] (4).
The obtained NMR data indicated that cyclic analog 3 has- a
relatively rigid ring conformation, and the determination of the
temperature dependence of the amide proton chemical shifts
suggested the existence of two transannular hydrogen
bonds (Leu5-NH OC-Gly3 and Orn2 OC-Orn2). The
analogous -turn and A2bu OC-A2bu hydrogen bond had also
been observed with cyclic analog 2 in the conformational study
described above (Mammi et al. 1985). In comparison with 3, the
ring conformation in cyclic analog 4 was found to be considerably
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more flexible. The values and coupling constants
determined with 4 suggested the existence of a -turn centered
on Phe4-Leu5 and stabilized by a hydrogen bond bet een the
group of D-Lys2 and the carbonyl group of Gly3 . The ring
conformation of analog 3 defined by the two hydrogen bonds
detected in this study formed the basis for a recent computer-
modeling study aimed at determining topological similarities
between this cyclic peptide and 7- -[(1R)-1-hydroxy-1-methyl-3-
phenylpropyl]-6,14-endo-ethenotetrahydrooripavine (PEO) (DiMaio
et al. 1986).
Side Chain-to-Side Chain Cyclized Enkephalin Analogs
Using the molecular mechanics approach, Hall and Pavitt (1984b)
performed a theoretical conformational analysis of the potent,
non selective enkephalin analogs
NH2 (5). A Gly
3 -Phe4 type II' bend was indicated by the obtained
results, as it had been the case with the H-Tyr-cyclo[-D-Xxx-Gly-
Phe-Leu-] analogs analyzed in the same manner by these authors
(see above). However, comparison of the 14-membered ring
structures in these two cyclic peptides with the 14-membered ring
of H-Tyr-cyclo[-D-A2bu-Gly-Phe-Leu-] (2) indicated a higher
structural flexibility in the case of the cystine-containing
analogs, which may explain their lack of receptor preference. In
a conformational study by fluorescence techniques, the tyrosine
fluorescence quantum yield determined with
-NH2 was found to be 2.5 times lower than that of the linear
analog H-Tyr-D-Ala-Gly-Phe-Met-OH (Schiller 1983), presumably due
to the quenching effect of the adjacent disulfide group, which is
known to occur at distances of less than 6 between the Tyr
phenol ring and the -S-S moiety. This observation suggested the
existence of an energetically favorable intramolecular complex
between the phenol ring and the disulfide group, which would
result in an interaction energy of about 1 kcal/mol at an optimal
distance of 3.5 between the plane of the aromatic ring and one
of the sulfur atoms. On the basis of these findings and
arguments, a close interaction between the tyrosine side chain
and the disulfide bridge in -NH2 was
proposed.
ring of Tyr1 and the indole moiety of Trp4 was measured
Singlet-singlet energy transfer between the phenol
in the
analog -NH2 (6). Evaluation of the
determined fluorescence parameters on-the basis of Förster's
equation resulted in an average intramolecular distance of 9.7 ±
0.2 between the two aromatic rings contained in 6. This mean
distance is nearly identical with the average Tyr1-Trp4 distance
(9.5 ± 0.3 in the linear enkephalin analog H-Try-D-Ala-GLy-
Trp-Met-OH, which was determined by the same technique.
The conformations of the two non selective cystine-containing
analogs -NH2 and
Cys-NH2 (structures 5) were compared with those of the related s-
selective Pen2-containing analogs -NH2
and -NH2 (structures 7) in a 
1HNMR study
carried out in D2O (Mosberg and Schiller 1984), Similar chemical
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shifts, values, and coupling constants were observed for
corresponding penicillamine and cysteine containing analogs,
indicating similar overall conformations. However, the obtained
NMR data suggested that, in comparison with the corresponding
CYS2 analogs, the Pen2 analogs show higher structural rigidity in
the C-terminal part of the molecule, which may explain their
receptor selectivity. The determined temperature dependences of
the amide proton chemical shifts did not indicate the existence
of intramolecular hydrogen bonds in any of these four cyclic
analogs. The large chemical shift difference observed for the
two penicillamine methyl resonances in both Pen2 analogs are
indicative of a ring current effect caused by the tyrosyl
aromatic moiety and, as in the case of H-Tyr-D-
NH2, (see above), suggest a close proximity between the Tyr
1
aromatic ring and the disulfide moiety.
The same type of NMR analysis was then performed with six
penicillamine-containing cyclic enkephalin analogs (structures
7a, 7b, and 7c), all of which display -receptor selectivity
(Mosberg 1987), Some variation in various NMR parameters was
observed even between compounds that displayed similar potency
and receptor selectivity. These findings were interpreted to
indicate that these analogs must contain the crucial
pharmacophoric elements in a similar spatial disposition,
presumably as a consequence of the observed conformational
flexibility of the Gly3 residue, which allows for conformational
compensation. Measurement of the temperature dependence of the
amide proton chemical shifts indicated that most amide protons in
these analogs were fully exposed to the solvent.  The exceptions
were the D-Pen5 amide protons in [D-
2 5]enkephalin and2 5]enkephalin, which showed low values,
indicating a possible involvement in an intramolecular hydrogen
bond. Interestingly, very good agreement of all NMR parameters
was Observed between [D- 2
Pen5]enkephalin,
5]enkephalin and [D- 2
suggesting very similar conformations of these
two compounds. The latter analog is about six times more
receptor selective than the former as a consequence of its poor
affinity for the µ-receptor.
improved -receptos selectivity of [D- 2 5]enkephalin as
These results indicate that the
compared to [D- 2 5]enkephalin is not due to a different
conformational behavior but rather to the presence of the gem
dimethyl group of the Pen2 residue, which causes more severe
steric interference at the µ-receptor than at the -receptor.
Belleney et al. (1987) performed a comparative 1HNMR study with
H-Tyr-D- -OH and H-Tyr-D-Thr-Gly-Phe-Leu-Thr-OH
(DTLET)in[2H6]DMSO In contrast to the data obtained by
Mosberg (1987) with H-Tyr-D- -OH in D2O, low
values were observed for the amide proton chemical shifts of both
L-Pen3 and Gly3 in the case of the cyclic peptide. These data
were interpreted to indicate that the conformation(s) of H-Tyr-D-
-OH4in [
2H6]DMSO might contain two turns either
a -turn around Phe or a II' turn centered on Gly3-Phe4 in the
C-terminal region and a -turn centered on Pen2 in the N-terminal
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region. In the case of DTLET, the obtained values also
suggested the existence of a -turn and a -turn in the N- and C-
terminal region of the peptide, respectively, and, thus, H-Tyr-D-
conformations in DMSO. This type of backbone conformation
-OH and DTLET appear to have similar backbone
together with the similar arrangement of the Tyr1 and Phe4 side
chains in both the cyclic and the linear peptide was suggested to
be responsible for the observed preferential interaction with the
-receptor. Furthermore, the authors proposed on the basis of
these models that the two threonine methyl groups in DTLET might
play the same role in the interaction with the receptor as the
gem dimethyl groups of the two Pen residues in the cyclic
peptide.
Cyclic Lactam Analogs Containing the Phenylalanine Residue in the
3-Position
Recently, Wilkes and Schiller (1987) applied a systematic
procedure for the determination of the allowed low energy
conformations of the highly µ-receptor selective cyclic analog H-
Tyr-D- -NH2 (8), using the software package SYBYL
(Tripos Associates, St. Louis, MO). A comprehensive grid search
of the 13-membered ring structure of 8 lacking the exocyclic Tyr1
residue and the Phe3 side chain resulted in only four low energy
conformers. These four conformations showed considerable
similarity, being all fairly round and flat. The three amide
bonds within the ring were generally either perpendicular to the
plane of the ring or slightly tilted toward the ring center, but
no linear transannular hydrogen bonds were observed. The
exocylic Tyr1 residue and Phe3 side chain were then added to
these four low energy conformers and an extensive energy
minimization was carried out with each on
results indicated that the Tyr1 and Phe3 side chains en joy
of them. The obtained
considerable orientational freedom but nevertheless only a
limited number of low energy side chain configurations were
found. The lowest energy conformer obtained by this approach was
characterized by a tilted stacking arrangement of the two
aromatic rings (figure 2, structure 8). However, several other
conformers with different side chain configurations were found to
be only slightly higher in energy (1 kcal/mol or less above the
energy   minimum).
This conformational analysis has recently been extended to
several 13-membered ring cyclic analogs related to 8
which show considerable diversity in their µ-receptor affinity
and selectivity (figure 1, compounds 9-13) (Wilkes and Schiller
1988). Again, the analyses performed with the bare ring
structures resulted in no more than four low energy conformers
(within 2 kcal/mol of the lowest energy structure) in all cases.
The gross topological features of all the low energy ring
conformations observed with these analogs were similar to those
of the low energy conformers of the cyclic parent peptide 8.
Thus, in all cases no transannular hydrogen bonds were found.
Only two low energy ring conformations were obtained in the case
of compound 11, indicating that the additional conformational
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FIGURE 2
Lowest Energy Conformers of Cyclic Opioid Peptide Analogs
8, 10, 12 and 13.
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constraint introduced by N-methylation of the Phe3 residue led to
a further increase in structural rigidity. After addition of the
exocyclic Tyr1 residue and the Phe3 side chain to the low energy
ring conformations of analogs 9-13 low energy side chain
configurations were again determined by extensive energy
minimization (figure 2). The two potent and µ-selective analogs
9 and 10 showed a tilted stacking arrangement of the two aromatic
rings in their lowest energy conformations similar to that
observed in the lowest energy conformer of 8. Among the analogs
with reduced µ-receptor affinity, compound  11 showed a lowest
energy conformation characterized by a fully stacked parallel
arrangement of the two aromatic rings rather than a tilted
stacking interaction. Analysis of the weak µ-agonist 12 revealed
that chiral inversion at the 2-position precludes a low energy
stacking configuration. The lack of stacking of the aromatic
rings observed in the low energy conformers of the weakly active
analog 13 appears to be due to steric interference of the bulky
N-methyl group at the 3-position residue. Taken together, these
results suggest that a specific tilted stacking interaction of
the aromatic rings in the 1- and 3-position of cyclic opioid
peptide 8 and its analogs may represent an important structural
requirement for binding at the µ-receptor. However, it should be
kept in mind that other side chain configurations were found to
be only slightly higher in energy and that a change in side chain
conformations could occur upon binding to the receptor at an
energy expense, which could be compensated for by part of the
binding energy.
CONCLUSION
Conformational studies of three families of cyclic opioid peptide
analogs carried out to date have revealed that the ring
structures contained in these compounds are not entirely rigid
but, depending on the type and size of the ring, undergo more or
less extensive conformational fluctuations. Nevertheless, the
results of the performed molecular mechanics and molecular
dynamics studies indicate that these structural fluctuations are
relatively minor in the case of 13- or 14-membered rings and that
the various Low energy ring conformers observed for a given
cyclic analog do not differ very much in their overall shape from
one another. As expected, the results various conformationa
analyses indicate that the exocyclic Tyr1 residue and the Phe3
side chain still enjoy considerable orientational freedom. In
order to determine the distinct conformational requirements of
the µ - and the -receptor, it will be necessary to prepare and
characterize cyclic opioid peptide analogs in which the
conformational freedom of these important pharmacophoric moieties
is restricted in various ways.
FOOTNOTES
1Abbreviations: A2bu, -diaminobutyric acid; A2pr,
diaminopropionic acid; DTLET, H-Tyr-D-Thr-Gly-Phe-Leu-Thr-OH;
NMR, nuclear magnetic resonance; Pen, penicillamine; Phe(NMe),
-methylphenylalanine; Phg, phenylglycine.
70
REFERENCES
Belleney, J.; Roques, B.P.; and Fournié-Zaluski, M.-C. Comparison
of conformational properties of Linear and cyclic selective
opioid Ligands DTLET (Tyr-D-Thr-Gly-Phe-Leu-Thr) and DPLPE
(Tyr-c[D-Pen-Gly-Phe-Pen]) by 1H n.m.r. spectroscopy. Int J
Peptide Protein Res 30:356-364, 1987.
Berman, J.M.; Goodman, M.; Nguyen, T.M.-D.; and Schiller, P.W.
Cyclic and acyclic partial retro-inverso enkephalins: mu
receptor selective enzyme resistant analogs.
Res Commun 115:864-870, 1983.
Biochem Biophys
DiMaio, J., and Schiller, P.W. A cyclic enkephalin analog with
high in vitro opiate activity. Proc Natl Acad Sci USA 77:7162-
7166, 1980.
DiMaio; J.; Nguyen, T.M.-D.; Lemieux, C.; and Schiller, P.W.
Synthesis and pharmacological characterization in vitro of
cyclic enkephalin analogues: Effect of conformational
constraints on opiate receptor selectivity. J Med Chem 25:1432-
1438, 1982.
DiMaio, J.; Bayly, C.I.; Villeneuve, G.; and Michel, A.
Topological similarities between a cyclic enkephalin analogue
and a potent opiate alkaloid: A computer-modeling approach. J
Med Chem 29:1658-1663, 1986.
Fischman, A.J.; Riemen, M.W.; and Cowburn, D. Averaging of 2 and
3 in [5-leucyl]enkephalin. FEBS Lett 94:236-240, 1978.
Hall, D., and Pavitt, N. Conformation of a cyclic tetrapeptide
related to an analog of enkephalin. Biopolymers 23:1441-1455,
1984a.
Hall, D., and Pavitt, N. Conformation of cyclic analogs of
enkephalin. II. Analogs containing a cystine bridge.
Biopolymers 23:2325-2334, 1984b.
Hall. D., and Pavitt, N. Conformation of cyclic analogs of
enkephalin. III. Effect of varying ring size. Biopolymers
24:935-945. 1985.
Kessler, H.; Hölzemann, G.; and Zechel, C. Peptide
conformations. 33. Conformational analysis of cyclic
enkephalin analogs of the type Tyr-cycLo-(-Nw-Xxx-GLy-Phe-
Leu-). Int J Peptide Protein Res 25:267-279, 1985.
Maigret, B.; Fournié-Zaluski, M.-C.; Roques, B.; and Premilat, S.
Proposals for the µ-active conformation of the enkephalin
analog Tyr-cyclo( -D-A2bu-Gly-Phe-Leu-]. Mol Pharmacol
29:314-320, 1986.
Mammi, N.J.; Hassan M.; and Goodman, M.
of cyclic enkephalin analogue by 1HNMR and computer
Copformational analysis
simultions. J Am Chem Soc 107: 4008-4013, 1985.
Mierke, D.F.; Lucietto, P.; Schiller, P.W.; and Goodman, M.
Comparative conformational analysis of two diastereomeric
cyclic enkephalin analogues by 1HNMR and computer simulations.
Biopolymers 26:1573-1586, 1987.
Mosberg. H.I.  1H  n.m.r. investigation of conformational features
of cyclic, penicillamine-containing enkephalin analogs. Int J
Peptide Protein Res 29:282-288, 1987
Mosberg, H.I., and Schiller, P.W. 1H n.m.r. investigation of
conformational features of cyclic enkephalinamide analogs. Int
J Peptide Protein Res 23:462-466, 1984.
71
Mosberg, H.I.; Hurst, R.; Hruby, V.J.; Gee, K.; Yamamura, H.I.;
Galligan, J.J.; and Burke, T.F. Bis-penicilLamine enkephalins
possess highly improved specificity toward opioid receptors.
Proc Natl Acad Sci USA 80:5871-5874, 1983 (and references cited
therein)
Richman, S.J.; Goodman, M.; Nguyen, T.M.-D.; and Schiller, P.W.
Synthesis and biological activity of linear and cyclic
enkephalins modified at the Gly3-Phe4 amide bond. Int J
Peptide Protein Res 25:648-662, 1985.
Schiller, P.W. Fluorescence study on the conformation of a
cyclic enkephalin analog in aqueous solution. Biochem Biophys
Res Commun 114:268-274, 1983.
Schiller,P.W. Conformational analysis of enkephalin and
conformation-activity relationships. In: Udenfriend, S., and
Meienhofer, J., eds. The Peptides: Analysis, Synthesis,
Biology. Vol. 6. Orlando: Academic Press, 1984. pp. 219-268.
Schiller, P.W., and DiMaio, J. Opiate receptor subclasses differ
in their conformational requirements. Nature (London) 297:74-
76, 1982.
Schiller, P.W., and DiMaio, J. Aspects of conformational
restriction in biologically active peptides. In: Hruby, V.J.,
and Rich, D.H., eds. Peptides: Structure and Function.
Rockford, Ill.: Pierce Chemical Company, 1983. pp.69-278.
Schiller, P.W., and Nguyen, T.M.-D. Activity profiles of novel
side chain-to-side chain cyclized opioid peptide analogs.
Neuropeptides 5:165-168, 1984.
Schiller, P.W.; Eggimann, B.; DiMaio, J.; Lemieux, C.; and
Nguyen, T.M.-D. Cyclic enkephalin analogs containing a cystine
bridge. Biochem Biophys Res Commun 101:337-343, 1981.
Schiller, P.W.; DiMaio, J.; and Nguyen, T.M.-D. Activity
profiles of conformationally restricted opioid peptide analogs.
In: Ovchinnikov, Y.A., ed. Proc 16th FEBS Meeting. Utrecht, The
Netherlands: VNU Science Press, 1985a. pp. 457-462.
Schiller, P.W.; Nguyen, T.M.-D.; Lemieux, C.; and Maziak, L.A.
Synthesis and activity profiles of novel cyclic opioid peptide
monomers and dimers. J Med Chem 28:1766-1771, 1985b.
Schiller, P.W.; Nguyen, T.M.-D.; Maziak, L.A.; Wilkes, B.C.; and
Lemieux, C. Structure-activity relationships of cyclic opioid
peptide analogues containing a phenylalanine residue in the 3-
position. J Med Chem 30:2094-2099, 1987.
Wilkes, B.C., and Schiller, P.W. Theoretical conformational
analysis of a µ-selective cyclic opioid peptide analog.
Biopolymers 26:1431-1444, 1987.
Wilkes, B.C., and Schiller, P.W. Theoretical conformational
analysis of µ-selective cyclic opioid peptide analogs. In:
Marshall, G.R., ed. Peptides: Chemistry and Biology. Leiden,
The Netherlands: ESCOM Science Publishers, 1988. pp. 619-620.
72
ACKNOWLEDGMENTS
The authors' work described in this chapter was supported by
operating grants from the Medical Research Council of Canada (MT-
5655), the Quebec Heart Foundation, and the U.S. National
Institute on Drug Abuse (DA-04443-01).
AUTHORS
Peter W. Schiller, Ph.D., Director
Brian C. Wilkes, Ph.D.
Laboratory of Chemical Biology and Peptide Research
Clinical Research Institute of Montreal
110 Pine Avenue West
Montreal, Quebec, Canada H2W 1R7
73
Opioid Peptides: An Update: NIDA Research Monograph 87
Rao S. Rapaka, Ph.D., and Bhola N. Dhawan, M.D., eds
National Institute on Drug, Abuse, 1988
Conformational Studies of
Dermorphin
V. Renugopalakrishnan, Ph.D., and Rao S. Rapaka, Ph.D.
Dermorphin, H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, a D-Ala-
containing amidated heptapeptide, is a potent µ-receptor
agonist. It was originally isolated from the skin of a South
American frog of the genus Phyllomedusae by Broccardo et al. (1981)
(for a review, see Feuerstein 1986). and it was subsequently
synthesized (de Castiglione et al. 1981; Montecucchi et al. 1981).
Its occurrence in mammalian tissue has not been demonstrated to
date (Negri et al. 1981). Dermorphin is similar to the other
opioid peptides, especially the enkephalin and dynorphin family of
peptides, in having Tyr residue in the first position of the
sequence. The presence of D-Ala residue in the second position and
the occurrence of Phe and Tyr residues in the third and fifth
positions should be expected to confer unique conformational
preferences and thus dermorphin serves as an excellent model system
for investigating conformation-receptor site selectivity
relationships. We have investigated the conformations of
dermorphin using vibrational spectroscopic studies (which are ideal
for peptides with chromophoric residues possessing unique
electronic transitions), 1D and 2D NMR studies (both at room
temperature and at elevated temperatures), molecular
mechanics-dynamics approach, and CD studies. CD studies of
dermorphin in H20, trifluroethanol (TFE) and methanol, and the
temperature effects in the above solvents provide insight into the
conformation of dermorphin, although chromophoric residues present
in dermorphin complicate the observed CD spectra.
The studies reported here represent our continuing investigations
(Bhatnagar et al. 1985; Pattabiraman et al. 1986), and similar
studies from other laboratories are also discussed. Aqueous
solutions of dermorphin were used in all the spectroscopic studies,
whereas CD studies were performed in H20, trifluroethanol (TFE),
and methanol. While the earlier 1D and 2D NMR studies had utilized
dimethyl sulfoxide (DMSO) (Salvadori et al. 1983; Arlandini et al.
1985; Pastore et al. 1985; Toma et al. 1985) as the solvent, we
employed 90 per cent H20-10 per cent D20 in our 1D and 2D NMR
studies, as we believe aqueous solutions are more relevant than
organic solvents to deduce physiologically relevant conformation(s).
74
Modern spectroscopic techniques utilized here offer the advantage
of suppression of H20 signals, a problem that plagued especially
IR and NMR studies in the 1960s and 1970s.
EXPERIMENTAL STUDIES
CD, FT-IR, and Raman studies were performed as described earlier
(Renugopalakrishnan et al. 1985, 1986; Prescott et al. 1986; Rapaka
et al. 1987). 1D and 2D 1H NMR studies of polypeptides were
performed in 90 per cent H20-10 per cent D20 on a 500 MHz
Bruker AM-500 spectrometer (Renugopalakrishnan et al. 1987, 1988;
Huang et al. 1988). Typical concentrations were in the range of
10-12.4 mM. Proton resonances were assigned based on homonuclear
decoupling experiments and chemical shift data (Wuthrich 1986).
Chemical shifts are reported in ppm relative to the shift of HDO at
4.8 ppm as an internal reference. In 2D NOESY experiments, H20
resonance was irradiated at all times except during the data
acquisition (Huang et al. 1988).
THEORETICAL STUDIES
Molecular mechanics studies employed the program AMBER developed in
the laboratory of Peter Kollman, and the conformations were
displayed visually using the program MIDAS (Weiner and Kollman
1981). The details of the calculations have been reported
previously (Pattabiraman et al. 1986). Recently, we have begun a
reinvestigation of the conformation of dermorphin using the program
CHARMM developed in the laboratory of Martin Karplus (Karplus and
McCammon 1981). The molecular dynamics calculations have been
recently extended up to 15 picoseconds, and the results will be
reported elsewhere (Prabhakaran et al. submitted for publication).
In the molecular mechanics calculations, we considered two B-turn
conformations and an extended conformation to restrict the search
in conformational space. A distance-dependent dielectric constant,
, simulated qualitatively the effect of solvent, but we did not
explicitly include solvation shells in the computations.
GENERAL DISCUSSION OF THE CONFORMATIONAL MODEL OF DERMORPHIN
DERIVED FROM EXPERIMENTAL AND THEORETICAL STUDIES
An energetically stable conformation of dermorphin derived from
molecular mechanics calculations is shown in figure 1. Dermorphin
assumes a type III’ B-turn conformation at the N-terminal segment,
Tyr-D-Ala2-Phe3-Gly4, and a type I B-turn conformation at the
C-terminal segment, Tyr5-Pro6-Ser7-NH2. Total energies of
the ß-turn conformations, (III’-I), (II’-III), and (II’-I), and a
fully extended conformation are presented in table 1. The fully
extended conformation is less stable than the folded
conformations. The three folded conformations, however, differ by
1 kcal/mole from one another and therefore can interconvert on
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FIGURE  1
Conformation of dermorphin from molecular mechanics
calculations
conventional spectroscopic time scale, although time-resolved FT-IR
and Raman may be able to detect them. The Tyr residues, which
stack with a skew and therefore are not superimposable, probably
provide the major driving force for the stabilization of the folded
conformations. The stability of the folded conformation is,
however, not surprising, considering the presence of D-Ala2 and
Pro6 residues, which are compulsive B-turn promoting residues
(Chou and Fasman 1978). The stacking of Tyr1-Tyr5 side chains
can be observed from figure 1.
The folded conformation is consistent with the bulk of the
experimental spectroscopic data in aqueous solution. Temperature
dependence of CD spectra of dermorphin in TFE solution (not shown
here) manifests an unusual CD pattern with a broad positive band at
=226nm (band II) and somewhat less broad positive band at
=198nm (band I). As the temperature is increased to 45°C, a
dramatic shift in the CD bands occurs. A broad negative band
begins to appear at =218nm, which persists at 60°C with a
shift of the negative trough toward lower wave length region. The
above observation qualitatively indicates that the chromophore
responsible for band II is disrupted by heating. The CD spectra of
dermorphin in TFE, H20, and methanol, representing solvents of
varying polarity, suggest that dermorphin manifests discrete
conformational states in solution phase. The observed CD spectra
are difficult to interpret in terms of the secondary structure but
probably are the composite of two ß-turns (Renugopalakrishnan et
al. submitted for publication).
Raman spectrum of dermorphin in H20 shows an amide I band at 1681
cm-1 and a doublet amide III band at 1253 cm-l and 1265
cm-1. Raman amide I bands beyond the 1668-1678 cm-1 are
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TABLE  1 Conformational Energies of the seven models of dermorphine
Model -Turn-I -Turn-II Total Energy in kcal/mol
Ill’-I III’
II’-III II'
II'-I II'
III'-III II’
V'-I V’
V'-III V’
Extended Trans
I -70.7
III -69.9
I -69.6
III -57.2
I -56.9
III -46.4
Trans -46.3
believed to originate from ß-turns (Bandekar and Krimm 1979; Tu
1986). The doublet amide III band at 1253 cm-1 and 1265 cm-1
is at best representative of extended/"random"/ß-turn structures.
The alternative explanation for the amide III doublet can be
advanced from the side chain Raman vibrations of the aromatic
residues. To decide between the alternatives, deuterium exchange
studies have been carried out to observe the shift of amide III
bands resulting from exchange of labile hydrogen atoms. After the
dissolution and equilibration of the sample in D20 solution, one
of the amide III bands, the band at 1253 cm-1 is lost, whereas
the 1265 cm-l band shifts toward lower wave numbers to 1261
cm-1. Therefore the 1253 cm-l band is assigned to the peptide
backbone vibrations, and the above frequency is probably a mixed
mode originating from R-turn and probably extended structures. The
amide I' band occurs at 1661 cm-l. Although Raman results are
largely Indicative of R-turn or folded conformation, an admixture
of extended structure cannot be ruled out.
500 MHz 1D 1H NMR spectrum of dermorphin in H20 is shown in
figure 2. Ramachandran angles, , for Tyrl, D-Ala2, Phe3,
Gly4, Tyr5 and Ser7 were derived from a Karplus-like
equation, using the values of the coefficients A, B, and C derived
by Bystrov et al. (1973). From the angles derived, it is
concluded that a fully extended conformation is not compatible with
the observed spin coupling constants, J. From the calculated
Ramachandran angles, , one is led to conclude that either type
II’ or III’ ß-turn occurs at the N-terminal segment, whereas the
C-terminal ß-turn may contain any one of three types of
ß-turns--types I, II, and III. It is difficult to discriminate
between them based only on spin coupling constant data. The
variation of aromatic proton resonances as the temperature is
increased is indicative of the unfolding of the dermorphin from a
folded conformation to an unfolded state in which Tyr residues are
no longer stacked. From the combined results, one cannot but
conclude that dermorphin probably assumes a manifold of folded
conformations, which interconvert in the spectroscopic time scale.
It is possible the heptapeptide contains a partially extended
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FIGURE 2
500 MHz 1H NMR spectrum of dermorphin in H20
segment at the N-terminal end, but, in any event, such a
conformational state has a low probability of occurrence in the
aqueous solution.
Most of the previous spectroscopic studies of dermorphin were
exclusively performed in dimethyl sulfoxide (Salvadori et al. 1983;
Arlandini et al. 1985; Pastore et al. 1985; Toma et al. 1985), and
NMR studies were utilized to derive the secondary structure of
dermorphin. Toma et al. (1985) investigated the solution
conformation of a series of [Alan] substituted dermorphin analogs
by 500 MHz 1H NMR spectroscopy. Preferred conformations were
calculated using a semi-empirical method. They reached the
conclusion that none of the calculated conformations were able to
satisfy the experimental data. In contrast, both experimental and
theoretical studies could at best be reconciled with a type I
B-turn at the C-terminus. Nevertheless, no consensus could be
reached at the N-terminus, and the question of any preferred
conformation at the N-terminus could not be resolved. However,
Pastore et al. (1985) have reported 1D and 2D-NMR study of
dermorphin in DMSO and reached the conclusion that the heptapeptide
assumes an essentially extended structure. The above investigators
assumed corrections for ring current effects in dermorphin. The
question of interaction between amide protons and DMSO was thought
to be a major factor in the observed conformation in DMSO. An
extended structure of dermorphin in DMSO may be a special
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situation that is probably not valid in aqueous solutions of
dermorphin. We believe that dermorphin assumes a manifold of
folded conformations in aqueous solution, although an extended
conformation at the N-terminus should also be considered.
Nevertheless, in a llpophilic environment, it is likely that
dermorphin assumes a folded conformation, which is probably the
most relevant at the µ-receptor site (Alford et al. in
preparation). Therefore, two different perspectives of dermorphin
conformation relevant to DMSO and aqueous solution exist in the
literature currently. Due to the relatively small size of
dermorphin, which exhibits rapid molecular tumbling, it is
difficult to provide a clear-cut resolution of the existing
conformational populations.
Numerous µ- and -receptor selective opioid peptide analogs
have been synthesized, and conformational studies have been
conducted on a number of analogs. ß-turns, ß-sheets, and extended
structures have been hypothesized as some of the recognition
features for the opioid receptor types (see Rapaka 1986 for a
review). However, conformation-receptor selectivity relationships
have not yet been established. It is expected that with the
multifaceted research techniques employed, the large number of
analogs available, and a greater understanding of the biochemistry
of the opioid receptors, the critical factors for conformation-
receptor selectivity relationships will be better understood,
paving the way for design of highly receptor selective analogs and
safe and potent analogs devoid of undesirable side effects.
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INTRODUCTION
Armed with molecular biological techniques, neurobiologists interested in
biologically active peptides have begun to work on problems that they
could only dream of attacking 10 years ago. The structures of several
peptide precursors have been determined by isolating and sequencing DNAs
complementary to their respective mRNAs, and similarities among peptide
precursors have been cataloged. Based on the structures of the precursors,
inferences about their processing were generated and a number of
processing enzymes have been identified. Two of these have been
purified, and one has itself been cloned.
The availability of cDNA probes that specifically hybridize to mRNAs that
encode peptide precursors and processing enzymes allows the levels of
these mRNAs to be measured and—by means of in situ hybridization
histochemistry—to be visualized in discrete cells. In addition, cDNA
probes can be used to screen genomic libraries to isolate genes that encode
peptide mRNAs (or to determine the cause of genetic defects in peptide
production). The regulatory elements of the genes can ultimately be
identified and the transactivating molecules that mediate tissue-specific
expression of gene products and regulate mRNA levels can be identified.
Examples of the latter include the recently characterized intracellular
receptors for steroids and thyroid hormones.
To date only two neuropeptide receptors have been purified and sequenced.
Advances in expression cloning technology may soon contribute to pushing
aside our ignorance of this class of binding protein.
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CLONING PEPTlDE PRECURSORS: THE CASE OF GALANIN
Galanin, a  29 amino acid peptide, was isolated from the upper small
intestine of pigs by Tatemoto, Mutt, and their colleagues (1983). Like so
many other peptides, it has a C-terminal amide. This structural feature led
to its discovery. Afterwards, galanin was found to be present in the enteric
nervous system of the gastrointestinal tract (Melander et al. 1985; Rökaeus
et al. 1984), the urogenital tract (Bauer et al. 1986a), the pancreas (Dunning
et al. 1986), the adrenal medulla (Bauer et al. 1986b), and the brain
(Melander et al. 1986). It has several actions, including inhibition of phasic
activity of the small intestine (Fox et al. 1986), production of hypoglycemia
(McDonald et al. 1985), suppression of insulin release, and central
stimulation of growth hormone (Ottlecz et al. 1986).
With few exceptions, DNAs encoding peptide precursors have been isolated
from cDNA libraries by screening them with mixtures of synthetic
oligonucleotides, the compositions of which were based on the amino acid
sequence of the peptides. It was in this way that we isolated cDNA.
encoding the galanin precursor from a pig adrenal medullary library
(Rokaeus and Bownstein 1986). The precursor (preprogalanin,
preproGAL) is ruher typical of this class of proteins. It is 123 amino acids
long and is comprised of a leader (signal) sequence. the 29 amino acids of
galanin, and a 59 amino acid sequence (galanin message associated protein,
GMAP) (see figure 1). Unlike proopiomelanocortin, for example,
preproGAL may encode only one active peptide, galanin itself. The galanin
sequence is flanked on both sides by pairs of lysine and arginine residues.
The C-terminal lysine and arginine are separated from the final alanine in
galanin by a glycine, the donor of the amide moiety.
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1Met
Ser
Thr
L y s
T y r
His
A l a
Pro
Leu
Leu
Arg
Leu
Arg
Gly
Arg
Leu
Gly
G l y
Leu
Ser
Lys
Gly
Leu
Leu
T r p
G l y
Phe
Cys
Ala
Gly
Thr
Pro
H i s
Ala
Ser
Ser
Leu
His
Asp
Leu
Ala
Pro
Asn
A l s
Lys
Leu
Leu
Val
S e r
l l e
T y r
Leu
Ser
Lys
Ala
Asp
Gly
Ala
Ala
Glu
Gly
Asn
Leu
Arg. . . Ser
FIGURE 1. Partial sequence of preprogalanin. A very hydrophobic  N-
terminal signal sequence (beginning with residue 1, Met) precedes the
(underlined) sequence of galanin (residues 33-61). Pairs of basic amino
acids (Lys-Arg) bracket the galanin sequence. A glycine residue, the donor
of the C-terminal amide, is found in position 62. The 59-residue sequence
of as yet unknown function comprises the amino-terminal half of the
precursor.
It is clear that precursors like preproGAL are cleaved to yield their active
products by a series of enzymes. The first of these, located in the cisternum
of the rough endoplasmic reticulum, removes the signal peptide from the
prepropeptide converting it to a propeptide. Subsequent processing seems
to occur principally in the secretory granule after the propeptide has
traversed the Golgi  apparatus. First the propeptide is split by an
endopeptidase. More than one such endopeptidase may exist. A 70,000
dalton paired basic residue specific aspartyl protease (Chang and Loh 1984;
Loh et al. 1985) has been shown to be involved in the processing of
proopiomelanocortin and provasopressin. The pH optimum of this enzyme
is low (four-five) allowing it to function in the acid milieu of the secretory
vesicle. It cleaves precursors between their paired bases or C-terminal to
t h e m .
In addition to the paired basic residue specific cleavage enzyme, there are
single basic residue cleaving enzymes. Such an enzyme has been found
associated with rat brain membranes (Devi and Goldstein 1984). It cleaves
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dynorphin B1-29 between Thr13 and Arg14 to yield dynorphin B1-13. It
seems to be a neutral thiol protease.
Peptides liberated from their precursors by the action of one of the above
endopeptidases may have basic residues attached to their C- or N-termini.
These need to be trimmed off. The first trimming enzyme to be discovered
(Hook et al. 1982) and purified (Fricker and Snyder 1983) was a
carboxypeptidase. Complementary DNA encoding this enzyme has recently
been isolated. There is also an aminopeptidase that removes basic residues
from peptides’ N-termini when cleavage by the paired base specific
endopeptidase occurs between two basic residues leaving one behind
(Gainer et al. 1984). This enzyme appears to be a metalloprotease
stimulated by Co+2 and Zn+2.
The enzyme responsible for carboxyl-amidation of peptides was first
described by Bradbury et al. (1982). This copper dependent enzyme uses a
C-terminal glycine as the donor of the amide group. Other functional
groups are physically added to peptides by enzymes, notably N-
acetyltransferases, kinases, and sulfate transferases.
CLONING PEPTIDE “PRECURSORS”: THE CASE OF VALOSIN
The major structural features of a typical peptide precursor and its mode of
processing were outlined above. Comparison of the structure of a protein
containing the sequence of valosin to other precursors illustrates the power
of cDNA cloning to help in identifying peptides as strong or weak
candidates for biological functions.
Valosin is a 25 amino acid peptide purified from side fractions of an earlier
preparation of porcine peptide HI and secretin (Schmidt et al. 1984).
Following its isolation, valosin was found to release gastrin, to augment
pentagastrin-induced gastric secretion, to stimulate pancreatic protein
secretion, and to suppress migrating myoelectric complexes of the small
bowel (Schmidt et al. 1985).
On screening a porcine adrenal medullary cDNA library with an
oligonucleotide pool constructed on the basis of the amino acid sequence of
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valosin, we detected several cDNAs (Koller and Brownstein 1987). The
longest of these had a 2,466 base pair open reading frame that encoded a ~
88,660 dalton protein containing the amino acid sequence of valosin (see
figure 2). This protein is unlike other peptide precursors characterized to
date: (1) It has no obvious N-terminal or internal signal sequences and
seems, in fact, to reside in the cytoplasm of cells. (2) Its message is found
in many tissues, neuronal and nonneuronal ones alike. (3) The valosin
sequence is not bracketed by single or paired basic residues. In fact, it
appears to have been released from the valosin-containing protein by the
action of a chymotrypsin-like enzyme. It seems likely, then, that valosin is
not a physiologically active molecule but rather an artifactual product of a
(hitherto unknown) and rather ubiquitous cytoplasmic protein.
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...Gly Leu Glu Asp Val Lys Arg Glu Leu
Gln Glu Leu Val Gln Tyr Pro Val Glu
His P r o Asp Lys Phe Leu Lys Phe Gly
Met T h r Pro Ser Lys Gly Val Leu Phe
T y r Gly Pro Pro Gly Cys Gly Lys Thr
Leu Leu Ala
FIGURE 2. The portion of the valosin-containing protein (VCP) that
contains the valosin sequence (underlined). Note that valosin is not
neighbored by canonical processing signals. While VCP does have pairs of
basic residues scattered throughout it, many other proteins that are not
peptide precursors do too. Furthermore, analysis of its entire sequence
shows that VCP has no obvious N-terminal or internal signal sequences.
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PUTTING CLONING TO WORK
Cloning a cDNA and sequencing it are not ends in themselves. A cDNA
and the structural information derived from it should be used to forge tools
that can be used for biological studies (see table 1).
TABLE 1.  Examples of uses to which cloning data can be put.
A. Uses of cDNAs
1. Screening genomic libraries allows specific genes or gene families to
be isolated and sequenced. Putative regulatory elements can be fused to
marker genes for studies of gene expression. New genes can be introduced
into the cells of transgenic animals. Genes from animals with genetic
defects can be analyzed.
2. Full-length cDNAs inserted into appropriate vectors can be used to
manufacture large amounts of proteins for biochemical studies. (In the case
of peptide precursors, substrates for processing enzyme assays can be
prepared this way.)
3. cDNAs, cRNAs, or synthetic oligonucleotides can be used to
measure specific mRNAs in tissues or to visualize mRNAs in discrete cells
by means of Northern blotting and in situ hybridization histochemistry,
respectively.
4. Mutant cDNAs can be expressed in cells in order to determine the
function of the altered protein domains.
B. Uses of peptides synthesized on the basis of cDNA sequences
1. Novel candidates for roles as neuropeptide transmitters can be
synthesized and their biological activities explored.
2. Antibodies against peptides can be used for immuno-
cytochemistry or immunoptecipitation (following pulse-chase experiments,
for example).
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A WORD ABOUT RECEPTOR CHARACTERIZATION
In principle, there are three ways to clone cDNAs that encode receptors.
One might isolate the receptor, partially sequence it, and screen a cDNA
library with oligonucleotide probes based on the amino acid sequence. To
purify enough of a protein to sequence—50-100 pmoles perhaps—is
nontrivial, and receptors are frequently N-terminally blocked.
Consequently close to a nmole of material might be required, the pure
receptor has to be fragmented and the fragments themselves purified and
sequenced.
Antireceptor antibodies can be used to screen bacterial expression libraries.
Raising such antibodies and proving that they are specific for a particular
receptor is difficult. however, and if one employs an antibody that does not
recognize the receptor of interest or one that is promiscuous, one’s work
will be for naught.
Finally, it should be possible to transfect a negative mammalian cell line
with a eucaryotic expression library and to identify clones of cells that begin
to make surface receptors. This method has not yet been employed
successfully for neurotransmitter receptors, but recent advances in vector
design and transfection procedures should lead to its wider adoption.
CONCLUDING REMARKS
Numerous biologically active peptides have been discovered in the past
decade. Unfortunately, more is often known about the anatomy and
neurochemistry of peptidergic neurons than about their function. It is to be
hoped that use of molecular biological methods will contribute to
overcoming this problem.
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INTRODUCTION
A basic tenet of modern pharmacology is that the biological
activity of a drug is the result of chemical events triggered by
the drug's interaction with specific receptors on responsive
cells. Although the chemical structures of drugs have been
extensively studied, very little information has been obtained
about the molecular structures of drug receptors. The structural
analysis of receptors is fraught with difficulties, which are in
part due to limitations of the techniques used to manipulate
integral membrane proteins. Most membrane proteins are
hydrophobic, and &he removal of the lipid moiety severely limits
or abolishes the solubility of the protein in aqueous media.
Although the techniques of nonaqueous protein chemistry have
advanced over the past few years, certain experimental
constraints often make a direct attack on a protein‘s structure
difficult to manage. In addition, the removal of the membrane
lipid can disrupt the oligomeric structure of the membrane
proteins and can obscure the involvement of associated receptor
subunits. Limiting receptor abundance presents an additional
problem. Depending on the nature of the signal transduction, a
specific receptor can constitute from less than 0.01 percent to
as much as 0.5 percent of the plasma membrane protein mass.
Pharmacologically important receptors generally fall into the
lower end of the abundance spectrum. Thus, attempts to purify
receptors are compromised by the need for large amounts of
starting material. This problem is often exacerbated by the need
to use a tissue that is scarce or difficult to obtain. In
addition, receptor preparations are often very unstable. Both
native and purified receptor preparations can be sensitive to
assorted cations, oxidizing or reducing agents, and a variety of
other materials and methods commonly used for their preparation
and storage. The loss of receptor activity compromises the
ability to assess the integrity and purity of the receptor
preparation. For these reasons, it is likely that the
determination of the primary amino acid structure of many low
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abundance neuroreceptors will be inferred from the analysis of
their cloned nucleic acid sequences.
This review will discuss the strategies that can be applied to
the molecular cloning of one specific family of neuroreceptors,
the opioid receptors.
THE OPIOID RECEPTORS
The analgesic and euphoric responses to opiates are the result of
a cascade of biochemical events that are triggered by the
interaction of the opiates with specific receptors found on the
cell membranes of nervous system tissues (West and Miller 1983;
Paterson et al. 1984; Holaday 1985). These opioid receptors not
only recognize exogeneous alkaloids such as morphine, but
moreover interact with their endogeneous ligands, the opioid
peptides. The opioid receptors are clearly involved in
physiological phenomena such as pain perception, addiction, and
withdrawal, and are implicated in hormone secretion, response to
injury, and gastrointestinal motility (Holaday 1985). The
molecular basis of the participation of opioid receptors in these
phenomena is unknown.
Martin and coworkers (Martin et al. 1976; Gilbert and Martin
1976) were the first to postulate the existence of different
types of opioid receptors based on differences in the
pharmacological profiles of the different opiates. Although the
precise number of opioid receptor types is still a matter of
conjecture, -it is generally accepted that the opioid receptors
can be subdivided into three major types, (Pasternak
et al. 1983; Paterson et al. 1984). These three receptor types
are distinguished on the basis of four criteria: (1) patterns in
ligand selectivity, (2) anatomical distribution, (3)
physiologica:. and behavioral profiles, and (4) differences in the
cellular response to activation (Dole et al. 1975; Paterson et
al. 1984; Holaday 1985).
Three models can account for the heterogeneity of the opioid
receptors. First, the three opioid receptors are structurally
different and are encoded by different genes; second, the opioid
receptors are encoded by different but homologous genes; or
third, the opioid receptors are encoded by identical genes but
differ in posttranslational modifications or in their
interactions with second messengers. At the present time, there
is no definitive evidence to favor one model over the others.
Using Schwyzer's concept (Schwyzer et al. 1980), one can
formulate the existence of at least two domains in the active
site of the opioid receptor: the message domain, which recognizes
the common amino terminal sequence of the enkephalins, Tyr-Gly-
Gly-Phe, and the address domain recognizing the remainder of the
opioid peptide sequence. This model suggests that at least one
region of the opioid receptor is common to the different receptor
types and that the opioid receptors must therefore be homologous.
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Furthermore, in view of the recently discovered homology between
the -adrenergic receptor, muscarinic acetylcholine receptor, and
opsin genes (Kubo et al. 1986; Dixon et al. 1986; Bonner et al.
1987; Hall 1987), the possibility that the opioid receptors may
also be encoded by homologous if not identical genes is very
attractive.
Knowledge about the physical characteristics of the opioid
receptor has been obtained directly from receptor purification
experiments. Attempts at opioid receptor purification have been
hampered by the receptor's sensitivity to denaturation and low
abundance (Zulkin and Maneckjee 1986). These receptors constitute
less than 0.005 percent of the total rat brain membrane proteins.
In spite of the extreme difficulties in purifying opioid
receptors, several laboratory groups (Bidlack et al. 1981; Newman
and Barnard 1984; Gioannini et al. 1985; Simonds et al. 1985; Cho
et al. 1986) have succeeded in purifying opioid receptor proteins
to homogeneity. The two common characteristics established for
the ligand binding subunit of the opioid receptor are (1) an
apparent Mr range of 55,000-65,000 and (2) its glycosylated
nature. These two properties, plus ligand selectivity, represent
the important criteria for judging the authenticity of a cloned
opioid receptor.
APPROACHES TO THE MOLECULAR CLONING OF THE OPIOID RECEPTOR
Our hope in understanding the molecular structure and activation
of the opioid receptors lies with the use of recombinant DNA
technology. The cloning of the opioid receptors will allow
detailed examination of receptor structure-function relationships
and receptor gene expression. This approach will therefore help
explain the molecular mechanisms of receptor activation and its
resulting cellular responses.
The opioid receptors are macromolecular components of plasma
membranes, which specifically bind opioid ligands according to
three criteria: (1) high affinity for opioids and opiates, (2)
saturable binding, and (3) binding that is stereospecific and
naloxone reversible (Dole et al. 1975). These three criteria
constitute the accepted functional definition of the opioid
receptor. Therefore, an authentic molecular clone of the opioid
receptor must be able to code for a product that fulfills all
three criteria.
In addition, an opioid receptor clone must encode a product with
the expected characteristics of a membrane protein. Two
structural characteristics of membrane proteins are the presence
of a signal sequence that facilitates the insertion of the
receptor in the membrane, and the presence of hydrophobic
sequences that correspond to potential transmembrane domains of
the receptor, The signal peptide is not an absolute requirement,
since some membrane proteins do not have signal sequences.
Since the distribution of the opioid receptor in the central
nervous system and in peripheral organs is well documented (Pert
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and Synder 1373; Pfeiffer et al. 1982; Atweh and Kuhar 1983;
Paterson et al. 1984; Mansour et al. 1987), in situ hybridization
analysis using an opioid receptor clone as probe should correlate
sites of receptor mRNA synthesis with sites of receptor protein
localization. However, the distinction between sites of mRNA
synthesis and receptor protein localization may be difficult to
evaluate precisely because of differences in assay sensitivity.
Alternatively, an opioid receptor clone may be used to express
receptor protein in sufficient quantity to serve as an antigen in
the preparation of antibodies. These antibodies can then be used
in immunocytochemical analyses to precisely correlate the
distribution of the receptor encoded by the molecular clone to
the known distribution of the opioid receptor. Finally, based on
physical criteria obtained during receptor purification
experiments, the opioid receptor clone should encode a
glycoprotein with an apparent Mr range of 55,000-65,000.
Three different strategies can be employed in the molecular
cloning of the opioid receptor. The first approach begins with
the isolatior of the receptor in sufficient quantity to permit
amino acid sequencing. This sequence would be reverse translated
into a DNA oligonucleotide probe and this probe would then be
used in the isolation of an opioid receptor cDNA or gene clone.
The second strategy proposes to clone the opioid receptor through
gene expression without prior purification of the receptor
protein. The third strategy assumes some sequence similarity
between opioid receptors and other neuroreceptors and exploits
this feature in hybridization experiments designed to identify
potential opioid receptor clones.
CLONING THE OPIOID RECEPTOR WITH THE USE OF RECEPTOR AMINO ACID
SEQUENCE INFORMATION
The traditional cloning strategy consists of purifying and
sequencing the opioid receptor protein. The amino acid sequence
information would then be used to identify a corresponding
receptor cDNA clone.
This approach requires large-scale protein purification in order
to prepare a sufficient quantity of homogeneous opioid receptor
to permit partial amino acid sequencing. Several laboratories
have succeeded in purifying the opioid receptor to homogeneity
(Bidlack et al. 1981; Newman and Barnard 1984; Gioannini et al.
1985; Simonds et al. 1985; Cho et al. 1986). The objectives of
these laboratories were to purify the ligand binding domain of
the opioid receptor. Two approaches have been employed to purify
opioid receptors: the labeled ligand binding approach and the
affinity chromatography approach.
In the labeled ligand binding approach, radioactive opioid
ligands are bound and covalently cross-linked to opioid receptors
in the membrane; the label serves as a marker in subsequent
purification steps. Since binding of the ligand is performed
with native receptor-membrane complexes, artifacts due to
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aberrant protein interactions are minimized. One drawback,
however, is that the ligand binding site is irreversibly
occupied, making binding assays or reconstitution experiments
impossible.
The purification of solubilized opioid receptors by affinity
chromatography is dependent on the receptor's ability to
recognize immobilized opioid ligands. The receptor population
isolated by this technique can be tested for binding ability and
can be obtained in sufficient quantity to sequence. The major
drawback to this approach is the difficulty in preserving
biological activity during subsequent purification steps.
Pure receptors are subjected to partial proteolytic digestion.
Peptide fragments are separated by high-performance liquid
chromatography and analyzed using automated high-sensitivity gas
phase amino acid sequencing. Currently, automated peptide
sequencing requires as little as 10 picomoles of purified
peptide. The sequences of at least two peptide fragments are
then reverse translated into their corresponding DNA sequences
and oligonucleotides complementary to these sequences are then
chemically synthesized. The choice of oligonucleotide length and
sequence is critical for successful cloning and has been
discussed (Anderson and Young 1987). In general, oligomers of at
least 17 bases in length containing the least amount of
degeneracy are synthesized. The radiolabeled synthetic oligomers
then serve as hybridization probes to identify receptor cDNAs
(or genes) in appropriate libraries. This isolated clone is then
used as a template for determining the entire sequence of the
opioid receptor.
CLONING THE OPIOID RECEPTOR BY GENE TRANSFER IN EUKARYOTIC CELLS
Gene transfer systems have been used successfully in the
molecular cloning of eukaryotic genes, including receptor genes
(Kuhn et al. 1984; Chao et al. 1986). This approach is based on
the expression of cell surface receptors on eukaryotic cells and
does not rely on the availability of receptor amino acid sequence
information. In this approach, a large population of cDNAs (or
large fragments of genomic DNA) from tissues known to express
opioid receptors are transfected into receptor-deficient
eukaryotic cells. Transfectants that have incorporated
exogeneous DNA are selected according to traditional techniques
(Southern and Berg 1982) and are tested for their ability to
express opioid receptor by binding analyses. In transfections
using genomic DNA fragments, the fragments are purified by
conducting secondary transfections. This step consists of
repeating the transfection procedure using the DNA of the primary
transfectant as the donor. If pools of cDNAs are transfected into
cells, the opioid receptor cDNA can be isolated by gradually
decreasing the size of the analyzed pool to unity. Several
different variations of this procedure can be envisioned; in
particular, cDNA libraries enriched in opioid receptor sequences
can be constructed through mRNA subtraction (Hedrick 1984).
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There is also the possibility of expressing an opioid receptor
cDNA in prokaryotic cells. However, in view of the requirements
necessary to maintain the biological activity of the receptor, it
seems unlikely that such an expression system would be
successful.
The gene transfer and expression approach was adapted by our
laboratory as one strategy to attempt to clone the human opioid
receptor gene. This strategy is shown in figure 1. Large
fragments of human genomic DNA are cotransfected with plasmid DNA
(pRSVneo), which confers neomycin resistance to opioid
receptor-deficient mouse L cells. Drug resistant colonies are
selected by growth in neomycin analogue G418 and receptor-bearing
colonies are identified using an opioid receptor detection assay.
If receptor antibodies are available, these would be used in
fluorescent-activated cell sorting or in situ rosetting assays to
identify receptor-bearing transfectants. The unavailability of
opioid receptor antibodies that recognize extracellular antigenic
determinants has precluded the use of these conventional
detection assays and prompted the development of new techniques
that allow screening of transfectants with radioactive ligands
(see next section for details). Once receptor-bearing
transfectants have been identified, DNA from these cells is
transferred into new recipient mouse L cells. DNA from secondary
transfectants containing the opioid receptor gene is then used to
prepare a genomic library in either a lambda or cosmid cloning
vector. The genomic library is then screened by filter
hybridization using nick-translated human repetitive sequence DNA
to detect sequences contained in the original human donor, but
not recipient, mouse cell lines. Positive clones containing
human donor DNA are mapped with restriction endonucleases, and
then reintroduced by transfection into recipient L cells to assay
for opioid receptor gene expression.
Development of Tools for the Detection of Neuroreceptor
Expression in Eukaryotic Cells
Eukaryotic cells are ideal gene transfer recipients for the
expression of neurohormone and neurotransmitter receptors. The
eukaryotic cell membrane environment and posttranslational
machinery are necessary for correct neuroreceptor conformation
and are critical determinants in the successful detection of the
receptor by ligand binding. In spite of the ideal host
environment, oukaryotic expression libraries have not been widely
used for the isolation of clones expressing neuroreceptors. One
major obstacle that has hindered the use of eukaryotic expression
libraries has been the lack of rapid and reliable screening
procedures.
To facilitate the screening of large numbers of transfectant
colonies, our laboratory has recently adapted a replica copy
technique originally used for identifying somatic cell mutants
(Raetz et al. 1982). The transfer membrane is a polyester nylon
cloth that permits colony replication with high fidelity and
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Gene Transfer and Molecular Cloning of The Human Opioid Receptor Gene
FIGURE 1
Molecular cloning of the human opioid receptor by gene transfer
and expression in eukaryotic cells.
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superior resolution (see fig. 2). Following drug selection of
stable transfectants, one or more sheets of sterilized polyester
nylon are placed on top of the cell colonies and overlaid with a
monolayer of glass beads. The beads retain the filter uniformly
against the bottom of the dish and permit the exchange of growth
medium to the cells without changing the colony pattern. After
5-7 days of growth, the medium is aspirated, the beads are
discarded, and the nylon membranes are removed with sterile
tweezers. Up to five multiple copies of the transfectant
population have been made from a single dish.
The multiple copies allow simultaneous screening of transfectant
colonies with different radioiodinated neurohormone ligands in
either the presence or the absence of nonradioactive blockers
(see fig. 3). Positive signals that appear in duplicate using
the radioactive ligand alone are identified by autoradiography.
The specificity of the binding can be determined with the use of
nonradioactive blockers. If desired, cell colonies that express
neuroreceptocs can then be purified from the master plate of
transfectant;.
To test the level of sensitivity of the in situ binding assay in
detecting opioid receptors, the assay was standardized by using
the mouse neuroblastoma N4TG1, a cell line that expresses
approximately 50,000 opioid receptors per cell (Amano et al.
1972). As shown in fig. 4, 106,105, and 104 N4TG1 or opioid
receptor-negative mouse L cells were mechanically spotted on
nylon cloth; the filters were then subjected to binding with (3-
[125I]iodotyrosyl27) -endorphin (0.15 nM in 50 mM Tris-HCl pH 7.4,
1 percent BSA, 0.05 percent poly-L-lysine, 50 ug/ml bacitracin,
10 ug/ml leupeptin, and 10 ug/ml trypsin inhibitor, for 1 hr at
room temperature) in the absence or presence of opioid receptor
antagonist, naloxone (100uM). The filters were then washed with
ice cold buff‘er, dried briefly, and placed under X-ray film.
Figure 4 shows the results of an 18 hr autoradiographic exposure
of a typical experiment. Clear signals emanating from as few as
10,000 opioic receptor-positive N4TG1 cells were observed; very
little signal was observed for mouse L cells or for N4TG1 cells
whose receptor sites were blocked with naloxone. Other
experiments have shown that a signal from as few as 1,000 N4TG1
cells can be observed. This represents a detection limit of as
few as 5 X 107 opioid receptors for this assay.
Screening Expression Libraries for Opioid Receptor Expression
Eukaryotic expression libraries were constructed using high
molecular weight human genomic DNA [from the human neuroblastoma
SKN-SH cell line, which expresses 50,000 opioid receptors per
cell (Yu et al. 1986)] as the donor DNA for transfections. This
DNA was cotransfected with neomycin resistance plasmids into
opioid receptor-deficient mouse L cells and stable transfectants
isolated by selection with G418. Assuming that the human genome
contains approximately 3 X 109 bases and that each stable
transfectant incorporates 106 bp of DNA, the entire human genome
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FIGURE 2
Transfectant colonies were grown on polyester nylon filters for 7
days. Replica filters were carefully removed from the master
dish and colonies fixed with 10 percent trichloroacetic acid (10
minutes) and stained with 0.05 percent Coomassie blue in
methanol:water:acetic acid (45:45:10; 10 minutes). Excess stain
was removed by washing with methanol:water:acetic acid.
FIGURE  3
In situ replica filter binding assay for detection of
transfectants expressing neuroreceptors.
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DOT ASSAY FOR OPIOID RECEPTOR EXPRESSION
FIGURE 4
N4TG1 or L cells were spotted on nylon cloth and subjected to
binding with (3-[125I]iodotyrosyl27) -endorphin (0.15 nM, room
temperature, 1 hr.) in the absence or presence of the opioid
antagonist, naloxone (100 uM). The filters were then washed with
ice cold buffer, dried briefly, and placed under X-ray film.
Clear signals emanating from as few as 10,000 opioid receptor-
expressing N4TG1 cells are observed; very little signal is
observed for L cells or for N4TG1 cells whose receptor sites are
blocked with naloxone. The aberrant signal emanating from 10,000
N4TG1 cells in the presence of blocker is not reproducible and is
believed to be an artifact.
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can be easily represented by approximately 3,000 independent
transfectant colonies (Kuhn et al. 1984). We have prepared
several transfection libraries and screened these libraries with
(3-[125I]iodotyrosyl27) -endorphin using the detection technique
described in the previous section. Thus far, we have been
unsuccessful in detecting opioid receptor-positive clones. Our
results with the opioid receptor-rich N4TG1 cell line indicate
that an opioid receptor-bearing transfectant colony (1,000-5,000
cells per colony) can be detected if the receptor gene is
expressed at a level of at least 10,000 receptors per cell. If
the human opioid receptor promoter is weak in the heterologous
mouse cell system, our screening assay may not be sensitive
enough to detect transfectants expressing receptor at low levels.
CLONING THE OPIOID RECEPTOR BY THE HOMOLOGY APPROACH
An emerging concept in the field of molecular neurobiology is
that transmembrane signalling neuroreceptors involve three
distinct components. First, there is a specific receptor exposed
on the external surface of cell membranes that recognizes and
interacts with ligands, such as hormones or drugs, or responds to
a sensory stimulus such as light. Second, exposed, at the
cytoplasmic surface are effector enzymes such as adenylate
cyclase that either generate the second messenger CAMP or in some
other way effect an intracellular response. Third, interposed
both functionally and physically between the receptor and its
effectors are transducing or coupling proteins that bind GTP (so-
called G-proteins). The available evidence suggests that
signalling systems of this type demonstrate a high degree of
structural, functional, and regulatory homology (Dolhman et al.
1987).
To date, seven pharmacologically or functionally related G-
protein receptors have been cloned and their primary sequences
shown to be similar. These are the ß-adrenergic receptor from
human (Kobilka et al. 1987), hamster (Dixon et al. 1986), and
turkey (Yarden et al. 1986), the muscarinic acetylcholine
receptor from porcine brain and heart (Kubo et al. 1986a, b), the
human and bovine opsin protein (Nathans and Hogness 1984, 1983),
as well as the visual pigments from drosophila (Zuker et al.
1985), the human mas-oncogene (Young et al. 1986), and the yeast
mating factor receptor (Burkholder and Hartwell 1985). All these
proteins display a certain degree of sequence similarity at the
amino acid level, display similar hydropathic profiles, and have
conserved functionally important amino acids or glycosylation
sites. The opioid receptor interacts with the same regulatory G-
proteins as these other receptors. It is therefore postulated
that the opioid receptor will possess an amino acid structure
similar to the above mentioned G-protein related receptors. This
postulated relationship is the premise upon which the approach to
cloning the opioid receptor by homology is based.
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Probe Design
The most often used probes are full-length double-stranded cDNAs,
short synthetic oligonucleotides, or mRNA riboprobes that are
labeled with 32P, 35S, or biotin. The selection of the probe will
depend on the screening strategy. Full-length cDNAs for a
related receptor or short oligonucleotides for a consensus region
are the most appropriate probes for the screening of recombinant
DNA libraries. We shall focus our discussion on these methods.
If two nucleic acid sequences are related, the use of a cDNA
probe complementary to one should identify the other if the probe
is labeled by nick-translation and the regions of similarity are
a significant fraction of the nick-translated lengths.
An alternative to using double-stranded cDNAs is to use single-
stranded synthetic oligonucleotides, which are complementary to
putative consensus regions of the receptor. Oligomers, which
typically can range from 14 to 60 or more bases, are easily end-
labeled with T4 polynucleotide kinase and [ -32P]ATP. Since the
probe is labeled at either its free 5'-phosphate or hydroxyl
group, only one radiophosphate is incorporated per strand.
Therefore, this type of probe has a lower specific activity than
nick-translated cDNAs.
Screening of the Library
Screening of recombinant libraries involves the hybridization of
radioactive probes to filter bound nucleic acid targets that
constitute the elements of the library. Duplex formation in
terms of both the number of positives and the intensity of
signals is a function of both the stability of the duplex formed
and the rate of hybridization. Nucleic acid hybridization
depends on the random collision of two complementary sequences.
The time course of the reaction is thus determined by the
concentration of the reassociating species and by a second-order
rate equation. While the quantitative hybridization of two
perfectly matched sequences in solution can be rigorously
described mathematically, the hybridization of a nucleic acid
strand in solution to a filter-immobilized complementary sequence
can only be qualitatively approximated.
An important consideration when identifying new proteins by
cross-hybridization involves the discrimination of homologous
from heterologous matches. When probing with both single-strand
oligomers and denatured double-strand cDNAs, the ratio of the
extent of hybridization of homologous sequences to heterologous
sequences is not constant but varies with time. Hybridization to
similar sequences is maximal early in the reaction and decreases
with increasing time of incubation. Therefore, although the
homologous reaction is faster and will reach completion earlier,
the heterologous reaction will eventually catch up. The
discrimination of related sequences is therefore maximal early in
the reaction out deteriorates very quickly. Thus, for most
cases, maximal discrimination between homologous and heterologous
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sequences is best accomplished by keeping the incubation time
short.
Nucleic acids hybridize very slowly at low ionic strength. As
the ionic strength of the hybridization solution increases, so
does the rate of duplex formation. This effect is most dramatic
at low salt concentrations (0.15 M Na+), but remains marked up to
1.5 M Na+. High salt concentration stabilizes mismatched
duplexes; so to detect cross-hybridizing species, the salt
concentration of both the hybridization and wash solution must be
kept fairly high, generally at 2-6xSSC (1xSSC is 0.15M NaCl,
0.015 NaCitrate, pH 7.0).
The stability of a nucleic acid duplex can be described by its
melting temperature, Tm. In general, the rate of reassociation
as well as the stability of the duplex is maximal at 20-30°C
below the Tm. The optimal temperature for nucleic acid
reassociation in aqueous salt solution lies in the range from 60-
75°C. However, extended incubation at such temperatures can lead
to a considerable amount of thermal strand scission. Hence, it
is desirable to reduce the temperature while maintaining the
stringency of the nucleic acid interaction. The effective
incubation temperature can be lowered by including formamide in
the hybridization solution. Formamide acts to destabilize
hydrogen-bonding between double-strand nucleic acids (McConoughy
et al. 1969). In addition to affecting the Tm, formamide also
affects the rates of hybridization. This effect is minimal at
formamide concentrations of 30-50 percent; however at
concentrations of 20 percent formamide, the rate is decreased by
one-third, while at 80 percent the rate can drop as much as
threefold for DNA-DNA and as much as twelvefold for DNA-RNA
duplexes. Thus, in practice, the inclusion of formamide in the
hybridization solution can be used to alter the stringency of the
incubation by holding the incubation temperature constant and
varying the formamide concentration. The effective incubation
temperature can be reduced to as much as 50°C below the Tm for
perfect matches. The effects of temperature, base composition,
and formamide can be approximated by an equation that estimates
the Tm of the duplex;
Tm= 69.3 + 0.41(G+C) percent - 650/L
where (G+C) percent is the percentage of G and C residues in the
duplex and L is the average length of the probe (Marmur and Doty
1962; Wetmur and Davidson 1968). Furthermore, taking into
consideration possible mismatches, the Tm of the duplex decreases
1°C with every 1 percent increase in the number of mismatches
(Bonner et al. 1973). and the Tm at differing ionic strengths (ul
and u2) can be related by (Tm)u2 - (Tm)u1 = 18.5 log(u2/u1) (Dove
and Davidson 1962).
After hybridization, washing is carried out to remove
unhybridized probe and to dissociate unstable hybrids. The
temperature and salt concentration of the washing solution
determine which hybrids will be detected. In general, washing
should be done under stringent conditions: at 5-20°C below the
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Tm for a well-matched hybrids (65-70°C), and at 12-2OºC below the
Tm for cross-reacting species (50-60°C). No absolute rule exists
for the duration of the washing period. In general, several
short (5-10 minutes) nonstringent washes are conducted, prior to
the final stringent washes (15-30 minutes). During the washes,
filter-bound background radioactivity can be monitored with the
use of a hand-held monitor.
In principle, this strategy can lead to the molecular cloning of
any G-protein related receptor. Since the extent of the
similarity between opioid receptor sequences and other G-protein
related sequences can only be approximated, the successful use of
this strategy in the cloning of the opioid receptor will require
the careful determination of the appropriate hybridization
conditions. This determination, although based on theoretical
considerations discussed above, will be primarily empirical. The
molecular clone obtained by the homology approach will then be
expressed in eukaryotic cells to confirm the expression of
authentic opioid receptors.
CONCLUSION
Three different strategies can be employed in the molecular
cloning of the opioid receptor. The first strategy consists of
purifying and sequencing the opioid receptor and utilizing the
amino acid sequence in the isolation of a cDNA clone. This
traditional cloning approach has proven to be difficult in the
cloning of the opioid receptor because of the receptor's low
abundance and high sensitivity to denaturation. The second
strategy proposes to clone the opioid receptor through gene
expression in eukaryotic cells without prior purification of the
receptor protein. The cloning of the opioid receptor by this
approach has remained elusive. The third strategy utilizes the
possible homology between opioid receptors and other G-protein
neuroreceptors as a hybridization tool in identifying potential
opioid receptor clones. This approach, while extremely
attractive in light of the growing number of G-protein related
receptors that have found to be homologous, requires the analyses
of many full-length cDNA clones. Regardless of the approach used
in the cloning of the opioid receptor, authenticity must be
verified by careful examination of the clone's structural and
pharmacological properties.
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Effects of Opioid Peptides on
Human Neuroblastoma Cells
Wolfgang Sadee, Dr. rer. nat.; Victor C. Yu, Ph.D.; and
Günther Hochhaus, Ph.D.
The discovery of multiple opioid receptor types (e.g., ) makes it
necessary to study the molecular mechanisms of opioid action in
transformed cell lines that yield homogenous cell populations under
well-defined conditions in vitro. Much has been learned from the use of
such cell lines, which include the mouse neuroblastoma x rat glioma
hybrid NG 108-15 (Gilbert and Richelson 1983). However, this line, as
well as other neuroblastomas tested, expresses only the receptor.
Therefore, we have screened a series of human neuroblastoma cell lines
for the presence of different opioid receptor types. Of three lines with
10,000 opioid sites or more per cell, all displayed s receptor sites
(Hochhaus et al. 1986); however, one of these human neuroblastomas
also expressed abundant µ. receptor sites (SK-N-SH, ~ 50,000 sites per
cell) in a ratio of = 4.5 (Yu et al. 1986). This cell line has potential as
an excellent in vitro model for studying the effects of opiates and opioid
peptides. However, in this cell line we found only a 20 percent inhibition
of PGE1-stimulated adenylate cyclase activity following treatment with
opioid agonists (Yu et al. 1986). An additional problem is that there are
several interconverting phenotypes of SK-N-SH, which include both a
strongly substrate adherent nonneuronal form and a neuroblast form that
grows more slowly to higher saturation cell densities. Only the latter
appears to express opioid receptors.
AN IN VITRO MODEL TO STUDY OPIOID EFFECT
In order to provide more reproducible cell culture conditions, we selected
a phenotypically stable neuroblast subclone of SK-N-SH, designated
SH-SY5Y (Ross and Biedler 1985). The SH-SY5Y clone carries a
similar number of opioid receptors as the parent line, yet opioid inhibition
of adenylate cyclase remains slight.
In order to increase the opioid response, we tested the effects of
neuronal differentiation on receptor-adenylate cyclase coupling. Three
differentiating agents, retinoic acid, nerve growth factor, and dibutyryl
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FIGURE 1. Human neuroblastoma cells, clone SH-SY5Y, grown in culture in either
the absence (left) or the presence (right) of 10 uM retinoic acid.
cAMP, caused neurite extensions that are characteristic of neuronal
maturation (fig. 1). Of these three, only retinoic acid (10 µM maintained
over 5-6 days) produced differentiated cells that yield a 10- to 50-fold
increase in PGE1-stimulated adenylate cyclase activity. Moreover, the
ability of opioids to inhibit the PGE1 response was also enhanced by
retinoic acid (45 percent inhibition), while nerve growth factor was less
effective (- 35 percent inhibition). We also tested the ability of opioids to
inhibit stimulation of adenylate cyclase by forskolin (100 µM), which
directly acts on the enzyme rather than a stimulatory receptor. Opioids
were even more effective in inhibiting the forskolin response (65 percent
inhibition in retinoic acid treated cells). This opioid effect was inhibited
by naloxone and pretreatment with pertussis toxin, suggesting the
involvement of opioid receptors via an Ni coupling protein (fig. 2). Hence,
the SH-SY5Y subclone, when differentiated with retinoic acid,
represents a system for quantitative studies of u and possibly receptor
mechanisms that include tolerance and opioid dependence.
FIGURE 2. Inhibition of stimulated cAMP production in intact cells by
opioids. The morphine response was defined as maximum
inhibition (i.e., 100 percent). Both PGE1 (1 µM) and forskolin
(100 µM) were employed as the stimulating agents.
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EFFECT OF µ AND RECEPTOR SELECTIVE OPIOID PEPTIDES
In order to determine which opioid receptor type is responsible for
inhibition of the PGE1- or forskolin–cAMP response, we tested a series
of opioids for their efficacy. Both morphine and the potent general
agonist etorphine gave similar maximal responses (45 percent of the
PGE1 response and 65 percent of the forskolin response). Since these
agonists are not highly selective for either sites, we then chose
several opioid peptides of high selectivity (fig. 2). It should be noted that
the efficacy of any of these ligands at the u sites has not been previously
established. Both the µ specific agonist morphiceptin and the highly µ
selective agonist DAGO gave the same maximal inhibitory effects as
morphine and etorphine. This result strongly suggests that these
peptides are full agonists and that the inhibitory response is mediated by
the µ sites. Indeed, we confirmed earlier findings that morphiceptin is
inactive at the s sites in NG 108-15 cells. In contrast, the potent and
highly selective DPDPE gave only a small partial response at 30 nM, at
which concentration one might expect near maximal activation of sites.
Maximal response of DPDPE at 10 uM was only ~ 65 percent of that
obtained by the other agonists, and it is likely that this partial response is
largely mediated by cross-reaction with the u sites. The agonist
DADLE, on the other hand, gave full inhibitory effects at rather low
concentrations (< 1 µM). These results support the view that the opioid
receptor inhibition of adenylate cyclase in SH-SY5Y cells is largely
mediated by the µ site. Therefore, this subclone is ideally suited for
studying the efficacy, tolerance, and dependence of the narcotic
analgesics in vitro:
It should be noted that all of the above results were obtained in the
presence of the phosphodiesterase inhibitor IBMX. Therefore, the
conclusions from these studies are limited to the activity of adenylate
cyclase. However, initial experiments in the absence of IBMX suggest
that the opioid agonists may also increase the activity of
phosphodiesterase. This would indicate a second mechanism by which
cellular CAMP levels could be regulated. We are currently investigating
this possibility.
BIOTINYLATED ENDORPHIN
A better understanding of the molecular events involved in the opioid
response in neuroblastoma cells can be attained through the study of
opioid receptors on single cells. Such studies would clarify both the
distribution of opioid receptors throughout a cell population and their
location on the cell. A method for rapid isolation and quantitation of
receptors is desirable. Therefore, we intend to utilize the avidin-biotin
system for opioid receptor analysis (Korpela 1984). Typically, a suitable
ligand is labelled with biotin and allowed to bind to the receptor site.
Next, the biotinyl-tracer receptor complex is incubated with avidin.
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Avidin has an extremely high binding affinity for biotin Kd 10 
-15M).
dThe avidin molecule is then labelled with fluorescent yes, colloidal gold,
or enzymes. It is important to employ a biotinylated tracer that retains
high receptor affinity in the presence of avidin. (1-31)-endorphin
reacting with biotinyl N-hydroxysuccinamide, with or without an
intervening -aminocaproyl spacer arm, yields a series of biotinylated
products with one or more substitutions per molecule. Tyr-1 and Lys 9,
19, 24, 28, 29 represent possible reaction sites, as shown in figure 3.
Tyr-G ly -G ly -Phe-Met -Thr -Ser -G lu -Lys- S e r -
1 10
Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe- Lys-Asn -
11 20
Ala- I le - I le -Lys-Asn-A la -Ty r -Lys-Lys- G l y - G l u
21 30
FIGURE 3. Human endorphin.
These derivatives were purified by HPLC and characterized by FAB-
mass spectrometry and trypsin digestion followed by HPLC (fig. 4) and
again FAB-MS. Biotinylation of a lysine residue eliminates one tryptic
cleavage site, which allows one to determine the site of biotinylation.
The Tyr-1 terminal NH2 group was not affected in any of the products
isolated, perhaps because, in the tertiary structure, it could have an
internal location and/or it could be involved in hydrogen binding.
Monobiotinylated fractions with substitution at either Lys-9 (fig. 4), Lys-
19, or Lys-24,28,29 (Bx1 ) were analyzed for binding to the
opioid receptors in rat brain homogenates and neuroblastomas. All
derivatives retained significant opioid receptor affinity, even in the
presence of avidin. The highest affinity among the derivatives was found
with Bx1 , which was equally potent to native endorphin, even in the
presence of avidin (fig. 5). Therefore, this derivative fulfills all criteria for
application of the biotin-avidin system to the analysis of the opioid
receptor.
The biotinylated endorphin derivative Bx1  also displayed high
affinity to a endorphin specific antibody (Peninsula Labs). We
therefore developed an ELISA method for the quantitation of
endorphin, using 21Bx1 as the tracer and an avidin-alkaline phosphatase
complex as the enzyme indicator. Optimal incubation conditions yielded
a sensitivity of 0.5 femtomole ßh-endorphin per sample, equivalent to the
most sensitive 125l-RIA currently available. Current applications of the
biotin-avidin system to opioid molecular pharmacology are in progress.
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Replica Transfer of Transfectant Colonies
FIGURE 4. HPLC records (reverse phase) of tryptic digests of
endorphin and Bx1 with biotinylation predominantly at
Lys-19.
Screening Eukaryotic Expression Libraries For Neuropeptide
Receptor Genes Using Novel In Situ Replica Filter Binding Assays
FIGURE 5. Equilibrium binding competition curves between 3H-DAGO
(1 rM) and endorphin or Bx1 in rat brain homogenates
in the presence of avidin.
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Analgesia and Neuropeptides
David J. Mayer, Ph.D.
INTRODUCTION
Until quite recently, virtually nothing was known about the neurochemical
basis of pain. The past few years have seen an unprecedented explosion of
information in the neurosciences, neurochemistry the role of peptides in
behavior, and, most important here, the neurobiology of pain and pain
modulation.
As statistics about the epidemiology of pain have surfaced, the biomedical
importance of pain research has become apparent. Thus pain research in
general and research on the involvement of opioid and other eptides in pain
in particular have undergone an impressive expansion in the past decade.
This chapter will review the extensive literature on the mechanisms of pain
modulation by opioid and other neuropeptides.
Commensurate with this increase in knowledge about endogenous peptide
involvement in pain modulation has come a search for the environmental
stimuli that might normally activate these systems. Much interest has focused
on the role of painful and stressful environmental events. This chapter will
examine the mvolvement of these types of events in the activation of
endogenous peptide pain modulatory systems.
THE ROLE OF OPIATES AND OPIOID PEPTIDES IN
PAIN MODULATION
The discovery of the enkephalins (Hughes 1975) and the subsequent
discovery of related opioid peptides has led to a great interest in the role
of these substances in pain modulation. This research has elucidated an
important role for these substances in pain modulation. This section will
review both animal and human studies of the role of endogenous opioids in
pain modulation.
Historical Perspective
A number of critical discoveries about the neurobiology of opiate action
have occurred in the past few years: (1) The demonstration of stereospecific
118
and saturable binding sites for opiates in the central nervous system (Hiller
et al. 1973; Pert and Snyder 1973; Terenius 1973). (2) The associated
demonstration for multiple binding si tes [See Martin,  (Martin
1983) For an excellent review on this topic). (3) The discovery of endogen-
ous ligands for opiate receptors (Hughes 1975). (4) The concept of using
opiate antagonists to antagonize endogenous behavior repertoirses (Akil et
al. 1972). Things findings, along with the extensive utilization of the
intracerebal microinjection technique to localize site of action of
neurochemicals within the central nervous system (Tsou and Jan 1964),
have, in turn, had an important impact on theoretical and methodological
research strategies utilized for the study of the effects of opiates on behavior.
Methodological  Considerations
opiates were catalogued and seen in the light of designing drugs with more
therapeutically desirable and fewer therapeutically undesirable effects for
application to clinical pathology. Although clinical utility certainly remains
an important concern of opiate research, the discoveries described above
Before these discoveries the study of the analgesic effect of opiates (as well
as other peptides) was primarily phenomenological. The analgestic effects of
have resulted in research that is conceptually broader. The current overall
view is that opiates often act on endogenous biological substrates for beha-
viors. Hence the behavioral pharmacology of  opiates now addresses the
organization of the neurobiological substrates of behavior. Much of the
research in this area now proceeds in the following pattern: (1) Can a
behavior elicited by opiates be elicited by exogenous environmental mani-
pulations? For example, can analgesia be elicited by transcutaneous nerve
stimulation? (2) If so, can the behavior, when initiated by nonpharmacolog-
ical means, be shown to utilize endogenous opiates? This question is
generally approached by examining wheth er the behavior can be antagonized
by opiate antagonists and reduce by the induction of tolerance to opiates
(that is, does cross-tolerance occur?). Additional support for a role of
endogenous opiates is provided by the demonstration of a correlation
between release of endogenous opiates and the occurrence of the behavior
under study. (3) If the behavior is shown to involve endogenous opiates, the
precise neuroanatomical foci underlying the behavior are examined utilizing
the microinjection of opiate agonists and antagonists into restricted central
nervous system loci. (4) The opiate receptor type involved in the behavior
is examined by administering opiate agonists and antagonists at least partially
selective for particular receptor subtypes (mu, kappa, delta, etc.). (5) Ideally,
steps (3) and (4) are combined to determme the anatomical locus of specific
receptor types mvolved in the behavior being studied. (6) An attempt is
made to determine the precise endogenous ligand (beta-endorphin,
Met-enkephalin, dynorphin, etc.) involved in a particular behavior. Again
an attempt is made to determine the anatomical locus of action of the parti-
cular ligand.
This is, of course, an idealized outline of the path followed to investigate
opioid involvement in a behavior. More often than not the actual course
of research is less direct than this, and the final conclusions are not usually
simple. Nevertheless, keeping in mind the general  approach described above
will aid the reader to see the overall progression of the field.
Until the early 1970s, in spite of evidence to the contrary (Tsou and Jang
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1964; Dewey et al. 1969), the generally accepted theory of opiate analgesic
action (Lim 1966) considered opiates to produce analgesia by a central ner-
vous system mechanism analogous to the action of local anesthetics on a
peripheral nerve. That is, it was thought that opiates acted by directly
inactivating the afferent transmission of pain in the central nervous system.
Since then, a major advance in our conception of the neural processing of
pain has occured. It has become clear that information about tissue damage
is not passively recieved by the nervous system. Rather, it is filtered, even
at the first synopse, by complex modulatory systems. The discovery of these
central nervous system contains endogenous substances, endorphins, that
possess analgesic properties virtually identical to opiates of plant and syn-
thetic origin. In this section, the development of these concepts is examined.
The existence of opiate and nonopiate central nervous system pain modula-
tory mechanisms activated by environmental stimuli such as stress is then dis-
cussed.
Development of the Concept of Endogenous Pain Control
It has long been recognized that a simple invariant relationship between
stimulus intensity and the magnitude of pain perception is often not present.
Two general classes of observations support the complexity of this relation-
ship. The first is the clinical observation that pain is often present without
any apparent precipitating pathology. This situation represents the clinical
problem of pain treatment. More important for the topic of this section is
the common observation that pain may not be experienced in the presence
of factors that should produce it; that is, under a variety of circumstances,
total or partial analgesia is seen. These observations were explicitly
recognized in earlier models of pain perception in spite of the lack of direct
evidence supporting the theoretical models (Noordenbos 1959; Melzack and
Wall 1965). Thus, the concept that the nervous system possesses intrinsic
pain inhibitory mechanisms was recognized when only indirect evidence was
available.
The earliest work indicating opiates produces analgesia, at least in part,
by activation of endogenous pain inhibitory systems was done by Irwin et al.
(1951). They demonstrated that morphine was not effective in inhibiting the
spinally mediated tail flick response in spinalized rats. They reasoned based
on this result that morphine must activate supraspinal neural circuitry which
has an output to the spinal cord and modulates the processing of nociceptive
information at spinal level. This work was largely ignored until the early
1970's even though it was replicated in the mouse (Dewey et al. 1969).
The first impetus for the detailed study of pain-modulatory circuitry resulted
from the observation that electrical stimulation of the brain could powerfully
suppress the perception of pain (Reynolds 1969; Mayer et al. 1971 Further
investigation of stimulation-produced anal esia provided considerable detail
about the neural circuitry Involved [see ayer and Watkins (1984) for a
detailed review of this topic].
Significantly, at that time, several similarities were recognized between these
observations and information emerging from a concomitant resurgence of
interest in the mechanisms of opiate analgesia (Mayer et al. 1971 The most
important parallel facts revealed by these studies were the fo lowing: (1)
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Effective loci for both opiate microinjection analgesia (Tsou and Jang 1964)
and stimulation-produced analgesia (Mayer et al. 1971) lie within the
periaqueductal and periventricular gray matter of the brain stem. (2) Opiate
analgesia and stimulation-produce analgesia are both mediated in part by
the activation of a centrifugal control system that exits from the brain and
modulates pain transmission at the level of the spinal cord (Dewey et al.
1969; Irwin et al. 1951). (3) The ultimate inhibition of the transmission of
nociceptive information occurs, at least in part, at the initial processing stages
in the spinal cord dorsal horn and homologous trigeminal nucleus caudalis
by selective inhibition of nociceptive neurons (Satoh and Takagi 1971).
In addition to these correlative observations, studies of stimulation-produced
analgesia provided direct evidence indicating that there were mechanisms
in the central nervous system that depend upon endogenous opiates: (1)
Subanalgesic doses of morphine were shown to synergize with subanalgesic
levels of brain stimulation to produce behavioral analgesia (Samanin and
Valzelli 1971). (2) Tolerance, a phenomenon invariably associated with
repeated administration of opiates, was observed to the analgesic effects of
brain stimulation (Mayer and Hayes 1975). (3) Cross-tolerance between the
analgesic effects of brain stimulation and opiates was demonstrated (Mayer
and Hayes 1975). (4) Stimulation-produce (analgesia could be antagonized
by naloxone, a specific narcotic antagonist (Akil et al. 1972, 1976a). This last
observation, in particular, could be most parsimoniously explained if
electrical stimulation resulted in the release of an endogenous opiate-like
factor. Indeed, naloxone antagonism of stimulation-produced analgesia was
a critical impetus leading to the eventual discovery of such a factor (Hughes
1975).
Coincidental with work on stimulation-produced analgesia, another discovery
of critical importance for our current concepts of en ogenous analgesia sys-
tems was made. Several laboratories, almost simultaneously, reported the
existence of stereospecific binding sites for opiates in the central nervous
system (Hiller et al. 1973; Pert and Snyder 973; Terenius 1973. These
“receptor” sites were subsequently shown to be localized to neuronal synaptic
regions (Pert et al. 1974) and to overlap anatomically with loci involved in
the neural processing of pain (Pert et al. 1975). The existence of an opiate
receptor  again suggested the likelihood of an endogenous compound with
opiate properties to occupy it.
In 1974, Hughes (1975) and Kosterlitz reported the isolation from neural
tissue of a factor enkephalin) with such properties. An immense amount
of subsequent work has characterized this an other neural and extraneural
compounds with opiate properties. As with the opiate receptor, the
anatomical distribution of endogenous opiate ligands shows overlap with
sites involved in pain processing [see
of these studies].
Akil et al. (1984) for a recent review
To summarize these important historical developments, the existence of an
endogenous opiate analgesia system is suggested by several lines of
evidence. Electrical stimulation of the brain produces analgesia The
anatomical structures and neural mechanisms involved in stimulation-pro-
duced analgesia parallel those involved in opiate analgesia. The central
nervous system contains opiate binding sites and endogenous ligands capa-
ble of interacting with those sites. These binding sites and ligands are found
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at anatomical loci consistent with sites at which stimulation-produced
analgesia and opiate microinjection analgesia are elicited.
Neural Circuitry Involved in Analgesia Resulting from the Administration
of Exogenous opiates
This section will review the current data available on the sites and mechan-
isms involved in the modulation of pain by the administration of exogenous
opiates. Primarily, two lines of experimentation will be examined: (1) The
locations in the central nervous system of sites at which administration of
opiates results in analgesia and the administration of opiate antagonists
blocks analgesia. (2) The locations in the nervous system where lesions block
the action of exogenously administered opiates.
Following the work of Tsou and Jang (1964), it wasn’t until the early 1970’s,
with one exception (Lotti et al. 1965), that opiate microin’ection mapping
studies began. Initially these studies concentrated on the periaueduc-
tal- eriventricular regions of the mesencephalon and diencephalon (Jacquet
d Laitha 1973; Pert and Yaksh 1974; Yaksh et al. 1976). Overall, thesean
and other studies confirmed the importance of the periaqueductal-peri-
ventricular region in opiate analgesia and provided an impetus for the
examination of other brain areas.
A second brain area that has proved to be of considerable importance for
opiate action is the anatormcally complex re ion of the ventromedial
medulla. This region consists of at least three distinct nuclei: the medially
located nucleus raphe magmus (NRM), more laterally situated nucleus
reticularis paragigantocelluaris (NRP), and the dorsolaterall located nucleus
reticularis gigantocellularis (NRG). Based on retrograde labeling criteria,
Watkins et al. (1980) have proposed the term nucleus raphe alatus (NRA) for
the combined cell groups in NRM and NRP. Takagi et al. 1976) were the
first group to map this region for analgesia resulting
microinjection. Overall (Ta agik
from morphine
1980), this group found the NRP to be
approximately 20 times more sensitive to mo
found microinjection of morphine into the NRM to be ineffective in the
hine than the NRG. They
production of analgesia. This point is controversial, since other groups
Azami et al. 1982; Zorman et al. 1982) have reported
microinjection into NRM. Axami et al. (1982) did f!ind, however, that the
analgesia from
NRM was less sensitive than the NRPG.
A number of other brain areas including the amygdala (Rodgers 1977, 1978),
the medial lemniscus (VanRee 1977, nucleus medialis dorsalis of the
thalamus (VanRee 1977), the mesence
Mittleman 1978; Pert and Yaksh 1974), and the nucleus of the solitary tract
halic reticular formation (Haigler and
(Oley et al. 1982) have been reported to produce analgesia when injected
with opiates. However, the work on these areas is scant compared with those
discussed above, and the relative potency of injections into these areas has
not been explored.
A final but crucial point to be made in this section concerns the analgesic
effects of microinjections of opiates directly into the intrathecal space of the
spinal cord. Although Tsou and Jang (1964) reported no analgesia from
Direct spinal application of morphine subsequent work has consistently 
demonstrated relatively potent effects of intrathecal morphine microinjection
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(Yaksh and Rudy 1976, 1977).
From this line of evidence it appears, then, that at least three general areas
of the central nervous system are involved in opiate analgesia: the peria-
queductal-periventricularray matter, the ventromedial medulla, and the
spinal cord. This observation indicates that the analgesic effects of a systemi-
tally administered opiate may produce analgesia by acting at any, all, or
some combination of these distinct regions.
The utilization of the microinjection of narcotic antagonists has provided at
least a partial answer to this question. A number of early studies concluded
that supraspinal sites of opiate action are the effective ones, since analgesia
from systemically administered opiates was antagonized by either in-
tracranioventricular or intracerebral microinjection of narcotic antagonists
Albus et al 1970; Jacquet and Lajtha 1974; Tsou, 1963; Vigouret et al
1973). Later work, however, demonstrated that naloxone administered
intrathecally could antagonize the analgesia resulting from even relatively
high doses of systemically administered opiates (Yaksh and Rudy 1977).
Thus, these stud ies lead to the paradoxical conclusion that both supraspinal
sites and spinal sites of opiate action are the critical ones involved in
analgesia.
This seeming paradox was resolved in a series of complex but unusually
important studies by Yeung and Rudy (1980a,b). They demonstrated that by
simultaneously administering various doses of morphine intrathecally (into
the spinal cord) and intraventricularly (into the brain) a multiplicative dose
response function was observed. That is, simultaneous spinal and supraspinal
morphine resulted in greater analgesia than the same total dose administered
at either location alone. The effect is quite large, with the multiplicative
factor being as much as 45 under certain circumstances (Yeung and Rudy
1980a). This type of multiplicative interaction, as will be seen below, may
turn out to be a confounding factor in many pharmacological and physio-
logical analyses of the involvement of opiates in various behaviors. Thus, the
reader should keep in mind, when evaluating the literature on this and other
topics, the potential for complex interactions between the same or various
neurotransmitters and/or neuromodulators.
Although the experiments just described elucidate the contribution of spinal
vs. supraspinal sites to opiate analgesia, the relative contribution of the
various supraspinal sites at which opiates act to produce analgesia is Iess
clear. The only work to examine this issue utilizing microinjection of nar-
cotic antagonists was done by Azami et al. (1982). They found, as did the
work of Takagi’s group, that the NRP was more sensitive to morphine than
the NRM for the elicitation of analgesia. Surprisingly, however, they found,
when analgesia was produced by systemically administered morphine,
naloxone injection into the NRM antagonized anal esia more effectively
than injection into more lateral medullary regions including the NRP. They
concluded that NRP does not make a significant contribution to the analge-
sia resulting from systemic administration of morphine. The relative
contribution of medullary vs. more rostral mesencephalic sites has not been
examined.
An approach similar to the one just described for dissectin the neural
circuitry participating in opiate analgesia utilizes the selective destruction of
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nuclei and pathways suspected of being involved in opiate analgesia. Opiates
are administered systemically or at discrete sites in the nervous system and
the effects of particular lessons are examined. An overview of this work
supports the conclusion reached above utilizing injection of antagonists. It
appears that several brain areas including the periaqueductal gray matter,
NRM, and NRP need to be intact for the full expression of opiate analgesia.
Environmental Activation of Endogenous Analgesia Systems
The demonstration that opiates activate well-defined neural systems capable
of potently blocking pain transmission suggests, but by no means proves, that
the function of this stem is to dynamically modulate the perceived intensity
of noxious stimuli. If, in fact, this system as such a physiological role, then
one might expect that the level of activity within the system would be
influenced by impinging environmental stimuli. If environmental situations
that produce analgesia could be identified, it would give credibility to the
idea that invasive procedures, such as bram stimulation or narcotic drugs,
inhibit pain by mimicking the natural activity within these pathways.
TABLE  1
REFERENCES FOR TABLE 1
1. Akil and Liebeskind 1975 2. Akil et al. 1976b
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3. Akil et al. 1972
4. Akil et al. 1978b
5. Augstinsson et al 1977
6. Belenky et al. 1983
7. Bodnar et al. 1978
8. Bodnar et al. 1978
9. Cannon et al. 1982
10. Cannon et al. 1984
11. Chance et al. 1978
12. Chapman et al. 1980
13. Chapman et al. 1976
14. Chesher and Chan 1977
15. Cobelli et al. 1980
16. Coderre and Rollman 1984
17. Das et al. 1984
18. Drugan et al. 1981
19. Fanselow 1979
20. Faris et al. 1983
21. Freeman et al. 1983
22. Frenk and Yitzhaky 1981
23. Galligan et al. 1983
24. Geller 1970
25. Gintzler 1980
26. Girardot and Holloway 1984
27. Girardot and Holloway 1984
28. Grau et al. 1981
29. Grevert et al. 1983
30. Griffiths et al. 1983
31. Hall and Stewart 1983b
32. Hall and Stewart 1983a
33. Han and Xie 1984
34. Han et al .1984
35. Han et al. 1983
36. Hart et al. 1983
37. Hayes et al. 1978
38. Hill and Ayliffe 1981
39. Holaday et al. 1986
40. Hosobuchi et al. 1977
41. Hosobuchi et al. 1979
42. Hyson et al. 1982
43. Janal et al. 1984
44. Jorgensen et al. 1984
45. Juma 1980
46.
47.
Kajander et al. 1984
Kayser and Guilbaud 1981
48. Kraus et al. 1981
49. Kulkami SK 1980
50. Lewis et al. 1981
51. Madden et al. 1977
52. Mah et al. 1980
53. Maier et al. 1980
54.
55.
Mayer and Hayes 1975
Mayer and Murfin 1976
56.
57.
Mayer et al. 1976
Mcgivem et al. 1979
58.
59.
Meyerson et al. 1978
Miczek and Thomson 1984
60. Miczek et al. 1982
61. O’Conner and Chipkin 1984
62. Panerai et al. 1984
63. Pertovaara et al. 1982b
64. Richardson and Akil 1977
65. Ross and Randich 1984
66. Rossier et al. 1977
67. Rossier et al. 1978
68. Saavedra 1981
69. Schlen and Bentley 1980
70. Sessle et al. 1981
71. Shimizu et al. 1981
72.
73.
Shyu et al. 1982
Snow and Dewey 1983
74. Szechtman et al. 1981
75. Terman et al. 1983
76. Teskey and Kavaliers 1984
77. Teskey et al. 1984
78. Urca et al. 1982
79. Urca et al. 1981
80. Watkins et al. 1982d
81. Watkins Cobelli et al. 1982
82. Watkins Young et al. 1983
83. Willer et al. 1982b
84. Willer and Albe-Fessard 1980
85. Willer et al. 1981
86. Willer et al. 1982b
87. Woolf and Wall 1983
88. Zamir et al. 1980
89. Zorman et al. 1982
TABLE 1 - Summary of representative studies on endogenous opiate analgesia
systems. Each number in each cell of the matrix indicates a study utilizing a
particular opiate manipulation to implicate endogenous Opiates in various forms
of environmentaliy produced analgesia. Citation numbers are matched with
authors at the bottom of the table. The various opiate manipulations studied are
indicated in the vertical columns and the environmental manipulations in the
horizontal rows. Abbreviations: CCA = classically conditioned analgesia;
COND = conditioned; CNS = central nervous system; DEP = deprivation;
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DNIC = diffuse noxious inhibitory controls; ECS = electroconvulsivehock;
FREQ = frequency; FPFS = front paw footshock; INT = intensity; INTER =
intermittent; IT = intrathecal; LO = low; MIN = minutes; NRM = region of
the nucleus raphe magnus; PAG = periaqueductal  gray matter; SPA = stimula-
tion produced analgesia,- SPON = spontaneous; TNS = transcutaneous nerve
stimulation; TS = tail shock; 4PFS = four paw footshock
A systematic search for environmental stimuli that activate pain inhibitory
systems was begun by Hayes et al. (1978ab). They observed that potent
analgesia could be produced by such diverse stimuli as brief footshock,
centrifugal rotation, and injection of intraperitoneal saline. These effects
appeared to be specific to pain perception insofar as normal motor behavior,
righting and corneal reflexes, vocalization, startle responses, and response to
touch remain unimpaired (Hayes et al. 1978b). Two important additional
concepts emerged from this work. First was the conclusion that exposure to
“stress” was not sufficient to produce analgesia. Although almost all envi-
ronmental stimuli studied to date that produce analgesia are stressors (cf.
table 1), the failure of classical stressors, such as ether vapors and horizontal
oscillation, to produce pain inhibition indicated that “stress” was not the
critical variable responsible. Second was the rather unexpected finding that
the opiate antagonist, naloxone, did not block all environmentally induced
analgesias (Hayes et al. 1978b). Therefore, it appeared that non-opiate
systems must exist in addition to the system activated by opiates described
earlier.
Although the stimuli studied by Hayes et al. (1978a,b) did not appear to
activate an opiate system, subsequent investigations found clues that
endogenous opioids might be involved in at least some types of environmen-
tally induced analgesias. Akil et al. (1976b) studied the analgesic effects of
prolonged footshock. In contrast to the results of Hayes et al. (1978a,b),
naloxone did partially antagonize the analgesia. This initial indication of
opiate involvement led Akil and coworkers to look for biochemical evidence
that footshock caused brain opiates to be released. They found that changes
in brain opiate levels did indeed parallel the development of footshock-
induced analgesia (Akil et al., 1976b). When tolerance developed to the
analgesic effects of footshock, brain opiate levels returned to control values.
The controversy over the involvement of opiates in footshock induced
analgesia was resolved, in art, by Lewis et al. (1980). They noted that the
duration of footshock used by Hayes et al. (1978b; 1978a) and Akil et al.
(1976b differed greatly and exammed whether this variable might explain
the difference in their results. By comparing the effects of naloxone on
analgesia produced by brief (3 min) vs. prolonged (30 min)  footshock, Lewis
et al. (1980) showed that only the latter could be blocked by naloxone. This
suggested that different analgesia systems become active as the duration of
footshock increases.
Concurrent with this work of Lewis et al. (1980), Watkins et al.( 1982d) made
the observation that brief shock restricted to the front paws produced
analgesia that was antagonized by low doses (0.1 mg/kg) of naloxone. In
contrast, even high doses (20 mg/kg) of naloxone failed to reduce analgesia
produced by hind paw shock. In addition, they showed that animals made
tolerant to morphine showed cross-tolerance to front paw but not hind paw
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footshock analgesia.
endogenous opiate anal gesia system while hind paw shock activates an inde-
Thus it appears that front paw shock activates an
pendent nonopiate analgesia system. In addition, this work showed again
that stress is not a sufficient factor to activate opiate analgesia systems, since
identical shock parameters were used for hind paw and front paw shock
(Watkins et al. 1982d).
Additional work has revealed the following important facts about front paw
and hind paw footshock-induced analgesias  (FSIA): (1) Front aw FSIA is
mediated by central  nervous system opioids, since elimination of extraneural
opiates by hypophysectomy, adrenalectomy, or sympathetic blockade does not
block the effects (Watkins et al. 1982c). (2) Front paw FSIA involves a
neural circuit that ascends to the brain and then descends by way of the
dorsolateral funiculus (DLF) to block pain transmission at the spinal level
(Watkins et al. 1982a). This descending DLF athway originates in the
nucleus raphe alatus (NRA)(Watkins et al. 1983a). (3) The complete
circuitry for the effect is caudal to the mesencephalon since decerebration
does not affect the analgesia (Watkins et al. 1983b) (4) The critical opiate
synapse for the system is situated in the spinal cord (see figure 1) at the
segment of nociceptive input, since intrathecal injection of naloxone in the
lumbosacral but not thoracic spinal cord blocks the effect (Watkins and
Mayer 1982). (5) Once the system is activated, continued opiate release is
not needed, since naloxone only blocks the effect when given before
footshock but not after (Watkins and Mayer 1982). (6) The integri of
spinal cord serotonin is critical for the expression of front paw FSIA
(Watkins et al. 1984a). (7) Front paw FSIA is blocked by small systemic or
intrathecal doses of the peptide CCK-8 (Faris et al. 1983) and potentiated by
the putative CCK antagonists proglumide and benzotript (Watkins et al.
1984b) (see section below on CCK for a more detail discussion of this
point).
Hind paw FSIA is also a CNS-mediated phenomenon (Watkins et al. 1982c).
However, this manipulation activates both intraspinal and suraspinal pain
inhibitory systems (Watkins et al. 1982a). The brain centers or hind paw
FSIA differ from those for front paw FSIA since NRA lesions do not
eliminate the analgesia Watkins et al 1983a
hind paw FSIA also differ from front paw FSIA: (1) CCK, serotonin, and
. The neurochemical bases of
norepinephrine do not appear to be involved in hind paw FSIA (Watkins et
al. 1984a). (2) Brain, but not spinal cord, acetylcholine is necessary for the
expression of hind paw FSIA but does not appear to be involved in ront paw
FS IA (Watkins et al. 1984c).
involved in front paw FSIA is activated, since conditioned analgesia is
eliminated by (1) systemic and intrathecal naloxone, (2) morphine tolerance,
(3) DLF lesions, and (4) NRA lesions and is unaffected by hypophysectomy,
a enalectomy, and sympathetic blockade (Watkins et al. 1982c) . In addition,
as would be expected, higher structures are involved in the conditioned
analgesia since it is eliminated by decerebration and reduced by periaqueduc-
tal gray (PAG) lesions (Watkins et al. 1983b).
Of considerable interest is that both hind paw and front paw FSIA can be
classically conditioned by repeated pairings of a CS with footshock (Watkins
et al. 1982b). Regardless of whether hind paw or front paw shock is used as
127
Figure 1. Neural circuitry of opiate and nonopiate analgesia induced by front
paw and hind paw shock Front paw shock activates the nucleus raphe alatus
(NRA) within the ventral medulla This nucleus sends descending projection
through the DLF to the dorsal horn of the spinal cord A serotonergic pathway
lying outside of the DLF (non-DLF) is recruited as well In turn, endogenous
opioids are released, inhibiting pain transmission neurons (PTN). Activation of
endogenous opiates stimulates a negative feedback loop, which utilizes CCK to
reduce activity of endogenous opioid systems. Hind paw shock inhibits PTN via
two nonopioid pathways: an intraspinal pathway and a descending DLF
pathway. The latter originates from the NRA and from some other yet
unidentified medullary area(s). Classical conditioned (opioid) analgesia seems
to result from activation of the same DLF output path way as from paw (opioid)
FSIA. After conditioning trials in which the conditioned stimulus is paired with
either front paw or hind paw shock (the unconditioned stimulus), the condi-
tioned stimulus becomes capable of activating rostral centers in the brain which,
in turn, activate the periaqueductal gray (PAG) and subsequently the nucleus
raphe alatus. This results, via a descending DLF pathway, in the release of
endogenous opiods within the dorsal horn, producing analgesia.
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A circuit diagram of these systems is shown in figure 1. A point that should
be emphasized is that the involvement of other neurotransmitters or
neuromodulators at the spinal cord level may be quite complex. For ex-
am le, as shown in figure 1 and discussed in detail below, cholecystokinin
(CCK) appears to modulate endogenous opioid systems. Intrathecal
application of CCK antagonizes anagesia from application of exogenous
opiates as well as analgesia elicited by activation of endogenous opiates
(Faris et al. 1983). Also, CCK antagonists applied intrathecally potentiate
these analgesias as well as reversing opiate tolerance Watkins et al. 1984b).
These findings suggest that other transmitters and/or modulators may
interact with opiates to form complex circuits.
In addition to the work done by Liebeskind’s group [see Terman et al. (1984)
for a review and our own, a number of other laboratories have now
demonstrated that numerous environmental variables can be critical in
determining the particular pain modulatory circuitry activated. Table 1
summarizes the environmental events now known to influence the transmis-
sion of pain utilizing endogenous opioid peptides. It is clear that numerous
environmental manipulations result in modulation of pain transmission. The
involvement of endogenous opioids in pain modulation is now beyond
question. On the other hand, man questions remain unanswered. For
example, it is generally not known where a particular endogenous opioid is
released by a particular environmental manipulation nor is the endogenous
ligand or the receptor type involved usually known. Nevertheless, the
techniques and general strategies for answering these questions are available,
and progress in this area should be forthcommg. It should also be pointed
out that, in addition to systems that modulated nociceptive information
utilizing endogenous opioids, there are nonopiate systems as well. For
example, Maier’s group has shown that inescapable tail shock results in
opiate analgesia, but analgesia resulting from tail shocks with identical
temporal and intensity characteristics is nonopiate if the shocks are escapable
(Maier et al. 1982). In sum, a review of the animal data provides strong
evidence for the existence of multiple pain modulatory systems. Our
knowledge of endogenous opiate analgesia systems probably represents the
most detailed description of any opioid behavioral system available. It is,
however, less clear what the critical characteristics of the environmental
stimuli activating these systems are. Although many of the events activating
the systems are clearly stressful, not all are. Also, a number of known
stressors are ineffective.
Evidence for Endogenous Opiate Analgesia in Man
At this point, some parallels will be made between the work described above
and experimental and clinical studies in humans. This will be done in order
to high ight the potential relevance of this work to the very difficult problem
of treating pain syndromes in man. Throughout this discussion, it will be
important to bear in mind that a number of distinct modulatory systems have
been identified under controlled laboratory conditions. In the more
naturalistic circumstances of clinical research, it is likely that more than one
of these systems may be active at any given time, which may account for the
variability and controversy in the clinical literature.
Research on the involvement of endogenous opioids in pain modulation in
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man has examined a number of environmental manipulations known to have
some degree of efficacy for the reduction of clinical and experimental pain.
Most of these procedures were developed before the recent explosion of
information about endogenous pain control systems. Indeed, many of them
evolved from theoretical approaches that are now outdated or incorrect.
Nevertheless, the procedures are efficacious and have inspired a considerable
body of research aimed at determining the involvement of endogenous
opioids in pain modulation.
There are at least two situations available for study in which endogenous
pain modulatory systems may be active in man. The first involves the basal,
tonic activity within these systems and allows the experimenter to assess
whether pain inhibition occurs continuously, at least to some degree. The
second involve:; clinical manipulations that attempt to activate pain inhibitory
systems.
Attempts have been made to determine whether pain modulatory systems
are tonically active. The assumption made by these studies has been that
administration of opiate antagonists should alter the perception of pain if
opiate systems are tonically active. This change in pain perception would
be recorded either as a decreased pain threshold or an increased level of
ongoing pain. In general, naloxone has failed to affect pain thresholds of
normal human volunteers (Grevert et al. 1978; El-Sobky et al. 1976). On the
other hand, Buchsbaum et al. (1977) found that naloxone lowered the
thresholds of subjects with naturally high pain thresholds, yet had no effect
in subjects with low pain thresholds. This observation is consistent with
reports that the high pain thresholds seen in some cases of congenital
insensitivity to pain can lowered by naloxone (Cesselin et al. 1984; Dehan
et al. 1977; Dehen et al. 1978. It should be pointed out that demonstrating
analgesic or hyperalgesic effects of drugs in human subjects is diffcult.
These studies, taken together, suggest that endogenous opiate pain modula-
tory circuits may not always be tonically active in people. Such a
conclusion is supported by the report that naloxone decreases the higher pain
thresholds seen in man in the morning as compared with those in the
afternoon (Davis et al. 1978).
Naloxone a pears to be more consistently effective when delivered to
experimental subjects who are experiencing some level of clinical pain. In
this regard, these results are consistent with the animal studies described
above in which pain was observed to be a powerful activator of endogenous
analgesia systems. Thus, Lasagna (1965), Levine et al. (1979), and Gracely
et al. (1983) report that naloxone can increase the reported intensity of
posto erative pain. It is important to note that two of these studies reported
cmplex dose-response interactions between naloxone and pain. Levine et
al. found that while naloxone produced hyperalgesia at high doses, low doses
produced analgesia. The Lasagna study is somewhat more difficult to
interpret because no placebo control group was included, but the results are
consistent with a conclusion that naloxone has both analgesic and hyperal-
gesic effects. These reports, in turn, are consistent with reports in the animal
literature (Girardot and Holloway 1984a; Grau 1984; Mcgivem et al. 1983)
indicating that certain environmental manipulations produce hyperalgesia as
well as analgesia, and some of these “hyperalgesia systems” may be opiate in
nature since the hyperalgesia can sometimes be antagonized by naloxone.
This is a complex but important observation because it indicates that studies
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of the effects of naloxone on pain levels must be interpreted with extreme
caution. In conclusion, it appears that, under normal circumstances, endo-
genous opiate pain inhibitory systems have little spontaneous activity.
However, when some level of pain is present, these systems seem to be
activated.
A second line of research on the involvement of endogenous opioids in pain
modulation in man has examined a number of environmental manipulations
known to have some degree of efficacy for the reduction of clinical and
experimental pain. This research has utilized two primary experimental strat-
egies. The first reasons that if a particular environmental manipulation
induces anal
antagonized by a narcotic antagonist (usually naloxone). The second strate
esia by utilizing endogenous opioids, that analgesia should be
reasons that if endogenous opioids are mvolved in an environmentally
elicited analgesia, then changes should be observed in the levels of these
compounds in plasma or the central nervous system.
Stimulation-produced analgesia in man
Perhaps the most dramatic outcome of the basic science research on
endogenous opioids has been the rapid and effective clinical application to
the treatment of chronic pain syndromes in man. As early as 1973,
Richardson and Akil (1977) reported the use of periventrtcular gray
stimulation to treat pain syndromes. Since then there have been more than
20 reports in the literature describing various studies of this technique. In
a recent review of this literature Young et al. (1984) conclude that “the
method is reasonably effective in properly selected patients and, importantly,
safe.”
Several lines of evidence indicate a likely but not unequivocal role for
endogenous opiates in stimulation produce analgesia (SPA) in man. Table
2 summarizes the evidence for the involvement of endogenous opioids in
SPA in man. Opiate antagonists are reported to reduce SPA, tolerance
develops to SPA, and dependence upon SPA has been reported. A more
controversial literature exists with regard to the release of endogenous opi-
oids, primarily Beta-endorphin, by electrical stimulation of the periaqueduc-
tal gray matter in man. It can be seen from table 2 that generally increased
levels of endogenous opioids have been found to result from this stimula-
tion. However, the possibility that these results are due to an artifact of
using a contrast medium for electrode placement has been raised Dionne
et al. 1984; Fessler et al. 1984). This criticism has been convincingly disputed
for at least for some circumstances (Akil and Richardson 1985). At this
point, it seems likely that endogenous opioids mediate, at least in part, the
analgesia elicited by periaqueductal gray stimulation in man. The particular
endogenous opioid and its site an mechanism of action have not been
established.
Counter-irritation analgesia in man
The belief that an acute painful stimulus can be used to alleviate ongoing
pain has been held since antiquity and is known as counter- irritation. This
procedure has a great deal in common with acupuncture and TNS. All use
the application of somatic stimuli, either noxious or innocuous, to obtain
relief from pain. The site of treatment in relation to the painful area is
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highly variable, ranging from the painful dermatome itself to a theoretically
unpredictable constellation of points in classical Chinese acupuncture. Lastly,
the duration of treatment varies from less than a minute to hours. All of
these factors, as we have seen, are important determinants of the effects
produced by footshock in animals. Thus, the highly variable effects observed
in the clinic would be predicted from animal research. Nevertheless, human
data suggest the involvement of the same systems described above.
TABLE 2
EVIDENCE FOR THE INVOLMENT OF OPIOID PEFTIDES
IN STIMULATION-PRODUCED ANALGESIA IN MAN
NALOXONE TOL/DEP ENDORPHIN LEVELS
B-ENDORPHIN ENKEPHALIN
PLASMA CSF PLASMA CSF
4< 15 2> 5> 4>
10< 14 6= 3>
l3< 8 7= ll>
l< 12 9> 15<
REFERENCES FOR TABLE 2
1. Adams 1976 9. Hosobwhi 1981
2 Akil and Richardson 1985 10. Hosobuchi et al.  1977
3. Akil et al. 1978a 11. Hosobuchi et al. 1979
4. Akil et al. 1978b 12. Hosobuchi and Wemmer 1977
5. Amano et al. 1980 13. Richardson and Akill 1977
6. Dianne et al. 1984 14. Schmidt et al. 1981
7. Fessler et al. 1984 15. Tsubokawa et al. 1984
8. Hosobuchi 1978
TABLE 2 - The effect of various opiate manipulations on analgesia and
endorphin levels resulting from electrical stimulation of the brain Symbols “< ”
= attenuates analgesia; “= ” = no effect on endorphin level; “>” = increases
endorphin levels. Numbers in the table refer to numbered citations listed
alphabetically below the table. Abbreviation: CSF = cerebrospinal fluid;
TOL/DEP = tolerance or dependence
Twelve studies have measured the effect of naloxone on clinical or ex-
perimental analgesia produced by acupuncture. Of these, eight reported
that naloxone reduce the analgesia while four found no effect. In two of
the studies failing to find analoxone effect (Chapman et al. 1980, 1983) the
negative interetation of the results has been called into uestion (Miglen
and Szekely 985; Mayer and Price 1981). The third of the four negative
studies examined lon -term
(Lenhard and Waite 1983) and thus does not fit into the general paradigm
effects of acupuncture on migraine headache
of the other studies addressed here. The final ne
1983) utilized a dose of naloxone (0.4 mg.), which is on the low end of the
ative study (Kenyon et al
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TABLE 3
(11)==
(8)=2 <
(29)<
(21)=
EVIDENCE FOR THE INVOLVMENT OF OPIOID PEPTIDES
IN COUNTERRITATION ANALGESIA IN MAN
A
ACUPUNCTURE ANALGESIA
NALOXONE ENDORPHIN LEVELS
B-ENDORPHIN ENKEPHALIN
PLASMA CSF PLASMA CSF
( 9 ) <  ( 2 7 ) < ( 6 ) >
(14)= (1)<
(24)= (13)> ( 9 ) >
(28)= (23)> (6)=
(12)= (22)<
( 4 ) =  ( 3 ) <
(25)=
(29)< (18)<
(13)=
(26)=
( 5 ) =  ( 1 7 ) < (16)>
B
TRANSCUTANEOUS NERVE STIMULATION
NALOXONE B-ENDORPHIN LEVELS
HI FREQ LOW FREQ HIGH FREQ LOW FREQ
PLASMA CSF PLASMA
( 1 5 ) =
( 1 9 ) =
( 8 ) =
( 2 ) =
( 2 9 ) =
( 2 0 ) =
( 2 2 ) =
(15)<
(19)=
(2)<
(29)<
(21)=
(22)<
(19)=
(7)>
(10)>
(11)= (19)=
(10)>
REFERENCES FOR TABLE 3
1. Boureau et al. 1979
2. Casale et al. 1983
3. Chapman 1978
4. Chapman et al. 1983
5. Chapman et al. 1980
6. Clement-Jones et al. 1980
7. Facchinetti et al. 1984
8. Freeman et al. 1983
9. He and Do 1983
10. Hughes et al. 1984
11. Johanson et al. 1980
12. Kenyon et al. 1983
13. Kisher et al. 1983
14. Lenhard and Waite 1983
15. Lundberg et al.  1985
16. Masala et al. 1983
17. Mayer et al. 1977
18. Mayer et al. 1976
19. O’Brien et al. 1984
20. Pertovaara and Kermppainen 1981
21. Pertovaara et al. 1982b
22. Sjolund and Eriksson 1979
23. Sjolund et al. 1977
24. Szczudlik and Kwasucki 1984
25. Szczudlik and Lypka 1983
26. Szczudlik and Lypka 1983
27.  Tsunoda  et al. 1980
28. Umimo et al. 1984
29. Willer et al. 1982b
TABLE 3 - The effect of various opiate manipulations on analgesia and 
endorphin levels resulting from transcutaneous nerve stimulation and acupunc-
ture. Symbols:"<"= attenuates endorphin or analgesia level; "=" = no effect
on analgesia or endorphin level; ">" = increase in endorphin levels. Numbers in
the table refer to numbered refrences. Abbreations CSF= cerebrospinal fluid
range of effective doses. Thus, it seems clear that naloxone, at least under
most circumstances, appears to antagonize acupuncture analgesia.
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Table 3-A summarizes the studies that have examined the effect of naloxone
on “acupuncture” analgesia as well as those studies which have measured
“acupuncture’‘-induced changes in plasma or CSF Beta-endorphin or
enkephalin levels. It is important to note that “acupuncture” is not a
well-defined procedure. The only criterion for including a study
was that the authors call the procedure “acupuncture.” Many of the
in this table
procedures discussed below under transcutaneous electrical nerve stimula-
tion (TNS) are similar or identical to those defined as “acupuncture” here.
The effects of acupuncture on CSF and plasma endorphin levels resent a
somewhat less consistent picture, but this is not surprising considering the
complexities of these types of data Considering that one could question
the entire concept of plasma endorphin levels, since they are indicative of
CNS level in only very indirect ways, a nevertheless somewhat consistent
picture emerges. As can be seen in table 3-A, five studies have reported
endorphin increases while six have reported no effects. Such results should
be interpreted with extreme caution since (1) the meaning of increases in
plasma endorphin levels are entirely unclear, and
levels are likely to be ambiguous since the site of endorphin release probably
2) even CSF endorphin
varies with the particular type of acupuncture stimulation. Nevertheless, an
overview of these data is consistent with an involvement of endogenous
opioids in at least some forms of acupuncture analgesia.
are apparent in the literature. While only 4 of 13 studies of TNS analgesia
have reported naloxone antagonism, all 4 studies utilized low-frequency
TNS. On the other hand none of 6 studies utilizing high-frequen TNS
found a naloxone antagonism (see table 3-B for references). The effects of
TNS on endorphin levels have been less well studied. As seen in table 3-B,
3 of the 6 reported studies have found an increase in endorphin levels, while
the remainder have found no effects. Such results should be interpreted with
the caveats discussed above in mind. Overall, these results are strikingly
consistent with reports in the animal literature (e.g., Han et al. 1984) and
suggest the posseibility that certain types of sensory stimulation either
inactivate opiate systems or activate opiate hyperalgesia systems as discussed
above. Nevertheless, these results are consistent with an emerging picture
Eriksson 1979) invokes endogenous opioid mechanisms. Such studies, taken
together, probaably provide the most convincing evidence available that
endogenous opioids can function to modulate pain transmission in man.
The literature concerning the involvement of endogenous opioids in TNS
analgesia is considerably more complex than that associated with acupunc-
ture analgesia This is likely to result from a greater variability in the
intensity, frerquency, duration, location, and ot er parameters of TNS.
Despite this diversity in experimental paradigm, some general consistencies
that low-freguency, high-intensity acupuncture-like TNS (cf. Sjolund and
In conclusion, acupuncture and transcutaneous nerve stimulation appear to
be forms of counterirritation that activate both opiate and nonopiate
systems. The variable clinical outcomes observed following these treatments
probably result from differential recruitment of segmental, extrasegmental,
opiate, and nonopiate pain inhibitory systems, all of which are now known
to be activated by these types of stimulation in animals.
Stress analgesia in man
A manipulation related to, but not identical with, counterirritation analgesia
is a phenomenon most generally referred to as “stress analgesia.” This issue
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was discussed above in relation to animal studies, and similar caveats should
be taken under consideration in human studies. These studies have utilized
environmental manipulations tht are either severe physical or psychological
stressors. The stressors catalogued in this section include surgery, labor, and
childbirth, application of overtly painful stimuli such as cold pressor am or
ischemic pain, chronic pain anticipation of pain, and chronic stressfu states
such as life threatening disease.
TABLE 4
EVIDENCE FOR THE INVOLVEMENT OF OPIOID PEPTIDES
IN STRESS ANALGESIA IN MAN
NALOXONE ENDORPHIN LEVELS
B-ENDORPHIN ENKEPHALIN
PLASMA CSF PLASMA CSF
(6)   < (8)   > (7)  >  (11)  = (12)   <
(9)   < (3)   > (10)   <
(15)   <
(5)     <
(11)   >
(1)   >
(14)   <
(13)   <
(2)   >
(4)   <
REFERENCES FOR TABLE 4
1. Atkinson et al. 1983 9. Pertovaara et al. 1982a
2. Cohen et al. 1982
3. Delke et al. 1985
10. Puig et al. 1982
11. Smith et al. 1985
4. Frid and Sin er
5. Frid et al. 1981
1979
6. Jungkinz et al. 1983
7. Katz et al. 1982
8. Pancheri et al. 1985
12. Szczudlik and Lypka 1983
13. Willer and Albe-Fessard 1980
14. Willer et al. 1981
15. Willer et al. 1982a
TABLE 4 - The effect of various opiate manipulations on analgesia and
endorphin levels resulting from stress. Symbols: "<" = attenuates analgesia or
endorphin level; "=" = no effect on analgesia or endorphin level; ">" =
increases endorphin levels. Numbers in the table refer to numbered citations
listed alphabetically below the table. Abbreviation: CSF = cerebrospinal fluid.
Examination of table 4 reveals a strikingly consistent outcome for studies of
this sort. It can be seen that in eight of eight studies in which a “stressful”
manipulation increased nociceptive thresholds, naloxone at least partially
reversed this increase. Another study (Janal et al. 1984
exercise, at least a possible stressor, to increase pain threshold and also
utilized vigorous
showed naloxone reversibility. In addition, and not surprisingly, since
beta-endorphin is coreleased with ACTH, stress resulted in an increase in
plasma beta-endorphin levels in five of five studies. Although such a result
is not convincing alone, it is certainly consistent with the notion that
endogenous opioids may underlie changes in pain threshold produced by
stress. In addition, such results are consistent with the results of counterir-
ritation studies discussed above with respect to the observation that naloxone
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reversibility is more likely to occur with hi intensity peripheral stimulation
(see table 3)  In conclusion, considering the diversirty of procedures used in
counterirration studies and stress studies, a generally convincing picture of
opioid involvement in pain modulation in man emerges. Many important
questions about the nature of this involvement remain unanswered. The
most important of these are the particular endogenous opiate involved and
its site of action. Answers to such questions are unlikely to come from
human studies, since invasive procedures are probably necessary to acquire
such information. The consistency of the animal and human studies,
however, indicates the likelihood that such questions may be studied with
animal models and verified in man.
Placebo analgesia in man
A placebo manipulation may well be considered a form of stress, at least
under some circumstances. Naloxone has also been used to examine whether
endogenous opiates are involved in placebo analgesia. Levine and coworkers
(1978) reported that naloxone antagonized placebo analgesia in postsurgical
patients. Although this conclusion as been questioned on technical rounds
(Goldstein and Grevert 1978; Korczyn 1978; Skrabanek 1978), little
conflicting data have been published. Gracely et al. (1983) have reported
that naloxone results in an increase in pain levels experienced by post
surgical patients that is independent of placebo effects.On the other hand,
Levine and Gordon (1984). in a study at rectified the technical problems
of their earlier one Levine et al. 1978), found convincing evidence for at
least a partial reversal of placebo analgesia by naloxone. A difficulty with all
of these studies is that surgical stress itself is a powerful activator of
endogenous opioid systems (see above and may influence the experimental
results. A carefully controlled study utilizing experimentally induced ischemic
pain (Grevert et al. 1983) indicates that a artial antagonism of placebo
analgesia can occur in the absence of any effects of naloxone  on baseline
pain responsivity. At this point, it seems most likely that endogenous opioids
mediate at least some components of placebo analgesia. It should be kept
in mind, however, that placebos, like other analgesic manipulations discussed
above, are multidimensional manipulations likely to ativate multiple pain
inhibitory and possibly pain facilitatory systems. Thus, hypnosis, a manipula-
tion that has at least a superficial resemblance to placebo procedures,
consistently has failed to be antagonized by naloxone (Barber and Mayer
1977; Goldstein and Hilgard 1975; Mayer et al. 1976; Spiegel and Albert
1983). The possibility that opiates are involved in some aspect of placebo
analgesia appears articularly reasonable considering the fact that footshock
analgesia can be classically conditioned in rats. Placebo analgesia can easily
be conceived of as a classical conditioning paradigm wherein the placebo
manipulation (e.g., injections, pills) serves as the conditioned stimulus and
prior medication or treatment serves as the unconditioned stimulus. The
observation by Grevert et al. (1983) that placebo effects tend to extinguish
with repeated trials supports such a conceptualization.
Although explanations of this sort are clearly speculative, they are indicative
of the wealth of concepts from experimental pain research now available for
clinical evaluation. Our increasing knowledge of pain modulatory systems
has the potential not only of providing explanations of current therapies but
of suggesting new approaches for the control of pain. The preponderance of
current pain therapies involve either the surgical destruction of neural tissue
or the use of addictive drug. Such procedures offer great difficulties for the
prolonged treatment of chronic pain. If multiple pain inhibitory systems
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could be activated pharmacologically or otherwise in an alternating sequence,
the problems of tissue destruction and addiction could be circumvented.
OTHER PEPTIDES
In addition to the endogenous opioids. other peptides have been reported to
be involved in endogenous analgesia-producing mechanisms in various ways.
Thus, neurotensin and substance P produce analgesia upon central ad-
ministration by themselves; CCK, on the other hand, has been demonstrated
to modulate analgesia produced by other manipulations.
Substance P
In addition to the numerous papers that have proposed substance P (SP) as
a transmitter of primary afferent neurons in the spinal cord and medulla, it
has been demonstrated that SP possesses analgesic properties, as well.
Systemic and intracerebroventricular (ICV) admmistration of SP produce
analgesia in mice (Stewart et al. 1976; Starr et al. 1978; Hall and Stewart
1983a; Meszaros et al 1981; Oehme et al. 1980) and in rats following both
systemic (Mohrland and Gebhart 1979) and ICV (Malick and Goldstein 1978;
Meszaros et al. 1981) injections. It should be noted that this analgesic effect
when compared with that produced by opiates is very small (Frederickson et
at all, particularly following systemic administration, by others Goldstein and
al. 1978; Frederickson and Gesellchen 1980) and has failed to be observed
Malick 1979; Growcott and Shaw 1979; Hayes and yers 1979; Inoki et al.
1977).
The analgesic action of SP is antagonized by naloxone
1978; Frederickson and Gesellchen 1980; Malick and Goldstein 1978; Stewart
Frederickson et al
et al 1976). Since SP does not bind to opiate receptors (Teremus 1975;
Szreniawsky et al. 1980) SP a arently releases opioid peptides. Both the
periaqueductal central gray (PAG) and the spinal cord are likely substrates
for this SP effect because (1) SP has been demonstrated to produce analgesia
both after administration into the PAG (Mohrland and Gebhart 1979 and
following intrathecal administration (Doi and Juma 1981, 1982b , (2) SP
causes a release of opioid peptides in both the PAG (del Rio et al 1983) and
the spinal cord (Tang et al. 1983), and 3) tolerance to and opiate cross-toler-
ance with the analgesic action of SP has been demonstrated following
intraventricular injections (Naranjo et al. 1984).
The apparent paradox that intrahecal injection of SP may induce both
analgesia and "hyperalgesia" (Akerman et al. 1982; Lembeck et al. 1981;
Matsumra et al. 1985; Yashpal and Henry 1983; Yasphal et al. 1982) [but
see Piercey et al. (1981) for absence of any change in nociceptive threshold]
has been partially resolved by Yashpal and coworkers. They showed that the 
SP-induced analgesia occurs after 10-15 min, when "hyperalgesia" disappears.
Although these findings are consistent with results of others, they are in
conflict with those obtained by Han et al. (1984). The latter administered SP
antibodies into the PAG and intrahecally prior to inducing electroacupunc-
ture analgesia. Whereas the SP antibodies reduced electroacupuncture
analgesia following intracerebral administration, confirming the importance
of the analgesic effects of SP at this site in this behavior, they potentiated
electroacupuncture analgesia upon intrahecal administration. In view of the
fact that the hyperalgesic effects of SP have been shown to be generally
short-lived [up to 10 minutes (Yasphal and Henry 1983; Yasphal et al. 1982)]
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while the analgesic effect has lasted in some studies for over 30 minutes
(e.g. Doi and Juma 1981, 1982b; Yashpal and Henry, 1983), the predominant
hyperalgesic action of spinal SP on electroacupuncture is surprising.
Although the analgesic effect of SP has been reliably observed and its
mechanism understood, the very existence of SP-induced analgesia remains
enigmatic. First, it seems to negate a role for SP as a transmitter of pain, as
the analgesic effects clearly abolish its presumably algesic ones. Second,
since it has been proposed that the presumed hyperalgesia results from spinal
convulsive-like excitation (Bossut et al. 1986), the physiological relevance of
the analgesic action is to be doubted.
Neurotensin
NT has been administered to mouse and rat via three different routes:
intracerebroventricularly (ICV), intracistemally (IC), and intrathecally (IT).
As NT affected the pain threshold in a different way depending on the route
of administration, the literature is reviewed accordingly.
IC administration. The analgesic effect of NT has been observed in mice
Whereas NT analgesia in mice was dose-related and could be observed on
(Clineschmidt and McGuffin 1977) and rats Clineschmidt et al. 1979).
the hot plate test, writhing test Clineschmidt and McGuffin 1977; Davis et
al. 1983; Osbahr et al. 1981), and tail immersion test (Nemeroff et al. 1979,
it could be demonstrated only on the hot plate test and not on the tail-flick
test in rats (Clineschmidt et al. 1979). Naloxone (1-5 mg/kg failed to
antagonize NT-induced analgesia in both species (Clineschmidt and
McGuffin 1977; Clineschmidt et al. 1979. Osbahr et al 1981). however the
observation that repeated pretreatment with morphine reduced the analgesic
effect of NT (Luttmger et al. 1983) could be viewed as cross-tolerance, thus
suggesting some involvement of opiate mechanisms.
NT analgesia is reduced by thyrotropin releasing hormone (Osbahr et al.
1981) and its structural analogs Hemandez et al. 1984). The mechanism of
this antagonism is, as yet, not fully understood.
IT administration. The behavioral effects of a drug injected IC may be
caused at both spinal and supraspinal sites of action. One way to test
whether spinal sites are involved in NT-induced analgesia is administering
the drug IT.
The results of IT administration of NT are somewhat confusing. In rats NT
in doses up to 90 micrograms [3,000 times the dose producmg hot plate
anal esia in this species following IC administration Clineschmidt et al.
1979)], failed to produce hot plate analgesia when administered IT
(Clineschmidt et al. 1982; Martin and Naruse 1982
indicate that the site of action for NT-induced analgesia is supraspinal.
. These results seem to
However, Yaksh et al. (1982) reported that doses of 1-100 micrograms of
neurotensin injected IT produce analgesia on the hot plate, and even some
analgesia on the tail flick test. Moreover, this grou reported that this
analgesia was fully reversible by naloxone (10 or 15 mg/kg). Consistent with.
this report are the finding that IT-administered NT produced naloxone (2
mg/kg) reversible analgesia in the mouse Hylden and Wilcox 1983).
However, this analgesia was not observed on the tail flick reflex but rather
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ICV administration When NT is administered ICV to mice, it readily
produces analgesia on the writhing test, and this analgesia is not reversible
by naloxone (5 mg/kg) (Nicolaides et al. 1985). However, results obtained
in the rat are more equivocal. Thus, while 20 micrograms of NT ICV in the
latter species induced analgesia in one stud (Martin et al. 1981), 5 micro-
grams did not in others (Kalivas et al. 1982; Parolaro et al. 1983). Although
these observations seem consistent with the view that these negative findings
result from an insufficient dose of NT, hot plate analgesia from the cisterna
magna was reported following 25 ng of NT (Clineschmidt and McGuffin
1977). It seems, therefore, hardly likely that the anatomical substrate for NT
analgesia is located in the immediate vicinity of the lateral ventricles;
structures in the brainstem in the immediate proximity of the cisterna seem
better candidates. This conclusion was not confirmed by a mapping study,
in which both periventricular structures (medial preoptic area, amygdala),
mesencephalic (rostral periventricular gray), and rhombencephalic (medial
pars of the reticular formation were equally effective injection sites for
inducing hot plate analgesia with NT in rats (Kalivas et al. 1982).
Conclusion NT undoubtedly has analgesic properties, but neither its
mechanism nor its site of action are understood. Thus, it is possible that NT
induces analgesia upon IT administration by releasing endogenous opioids.
This would explain some of the results using this paradigm (Hylden and
Wilcox 1983; Yaksh et al. 1982) but not the lack of analgesia obtained by
others (Clineschmidt et al. 1982; Martin and Naruse 1982).
The increase in latency to response reported from discrete injection of NT
into supraspinal areas (Kalivas et al. 1982) may well reflect true analgesia in
some cases, but not all. Thus, although it is not known whether NT excites
neurons in amygdala or PAG upon iontophoretic application, in view of its
effects in spinal cord and cortex this is a likely possibility. If NT causes
general neuronal excitation, it could well cause analgesia in the PAG, as do
electrical stimulation (Mayer et al. 1971) and injection of glutamate
1977 in forebrain produce analgesia. Further work is needed in order to
Behbehani and Fields 1978; Urca et al. 1980). Also, electrical stimulation
Abbott and Melzack 1978) and morphine (Rodgers 1977, 1978; VanRee
decide these issues.
CCK
The earliest experiments with CCK in systemic doses of over 50 micro-
grams/kg in the mouse (Zetler 1980, 1983) and intracerebral or intrathecal
doses of 10-40 ng in the rat (Juma and Zetler 1981) demonstrated the
analgesic potential of this peptide. The observation that this anal esia was
reversible by naloxone made these authors suggest that it was mediated by
endogenous opioids. However, at these and higher doses it failed, unlike
morphine, to depress ascending A-delta and C fiber activation (Doi and
Jurna 1982a), suggesting a different mode or site of action.
(Itoh et al. 1985; Han et al. 1985). The antagonistic effect of CCK fo lows an
inverted “U” dose response curve with doses lower and higher than the
aforementioned producing less effect.
More recent experiments indicate that lower doses of CCK, although playing
a role in opiate analgesia, have effects opposite to the one imtially de-
scribed. Thus, 3 micrograms/kg of systemic and 3.6 ng of intrathecal CCK
antagonize the analgesia produced by morphine and opiate mediated foot
shock analgesia (Faris et al. 1983). Similar effects were observed by others
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has similar effects. Also, morphine analgesia in rats immunized a ainst CCK
is potentiated (Faris 1985). Proglumide (Suberg et al. 198 or CCK
aantibodies (Suberg et al. 1985) potentiate the morphine induce
reversible suppression of nociceptive spinal cord dorsal horn neurons
, naloxone
Cindicating that the interaction between
same site.
CK and morphine occurs at the
Subsequent work with proglumide, a CCK antagonist, showed that this
compound, after both systemic and intrathecal administration, significantly
otentiated analgesia induced by morphine, endogenous opioids, and various
behavioral manipulations that release endogenous opioids in rats (Watkins
et al. 1984b, 1985; Tang et al. 1984) Anothe CCK antagonist, benzotript,
The antagonist action of CCK on opiate action and roglumide’s potentia-
tion seems not to be limited to analgesia. Itoh and Katsuura (1981) found
that CCK significantly
traventricularly injected beta-endorphin in rats, whereas proglumide poten-
reduced the duration of catalepsy following in-
tiated it Itoh et al. 1985; Katsuura and Itoh 1985). Similarly, proglumide
was found to potentiate morphine’s effect on open field motility in the rat
(Ben-Horin et al. 1984).
The interaction between CCK and opiate action has some very interesting
clinical implications. Thus, it has been demonstrated in rats that proglum-
ide prevents or reduces tolerance induced by repeated morphine administra-
tion (Watkins et al. 1984b; Tang et al. 1984). Together with the recent
demonstration that
well (Price et al. 1985),. these findings promise new perspectives both for the
proglumide potentiates morphine analgesia in humans as
use of opiates in treating pain and for treating opiate addicts.
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Mechanism of Development of
Tolerance and Dependence to
Opioids in Neuroblastoma x Glioma
Hybrid Cells and Mice
Shail K. Sharma, Ph.D.; Madhav Bhatia, M.Sc.; and
Ranju Ralhan, Ph.D.
Neuroblastoma x glioma (NG108-15) hybrid cells are
enriched with opioid receptors (Klee and Nirenberg
1974; Chang and Cuatrecasas 1979). In these cells
opiates and opioid peptides regulate the synthesis of
cyclic AMP at two different levels. A rapid receptor-
mediated inhibition of adenylate Cyclase is followed
by a delayed and long-lived compensatory increase in
its activity. It has been suggested that the latter
effect may be responsible for narcotic dependence and
tolerance (Sharma et al. 1975a,b 1977; Traber et al.
1975; Lampert et al. 1976). Ascorbic acid suppresses
the etorphine-induced compensatory increase in the
levels of cAMP with little or no effect on the short-
term response of NG108-15 hybrid cells to the
effector agents (Sharma and Khanna 1982). These
studies suggest that ascorbic acid may play a role in
the Prevention of the development of tolerance in
therapeutic applications of narcotics as analgesics.
The mechanism by which ascorbic acid prevents the
development of tolerance to opiates is still obscure.
Effect of Ascorbate on Etorphine-Induced Alterations
in Cyclic AMP Levels
Results reported earlier from this laboratory show
that ascorbic acid suppresses the etorphine-induced
compensatory increase in the levels of CAMP in NG108-
15 hybrid cells (Sharma and Khanna 1982) It was of
interest to study the effect of variation of
ascorbate concentration on etorphine-induced
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compensatory increase in basal and PGE1-stimulated
cAMP levels. Results in tl show that in the absence
of ascorbate, etorphine led to a compensatory
increase of 80 percent in the basal and 65 percent in
the PGE1-stimulated CAMP levels. A progressive
decrease in the compensatory response is seen as the
concentration of ascorbate is raised to 10mM.
Initially, at lower concentrations of ascorbate the
decrease is more pronounced for PGE1-stimulated CAMP
levels.
Preexposure of NG108-15 hybrid cells toascorbate did
not abolish stimulatory or inhibitory effects of
drugs on cAMP levels (Sharma and Khanna 1982).
indicating that receptors for opiates and PGE1 were
functionally coupled to adenylate cyclase. The effect
of preincubation of NG108-15 hybrid cells with
ascorbate on etorphine-induced compensatory increase
in the levels of CAMP was studied. In this experiment
cells were preexposed to ascorbate for 4 hours. After
washing, the second incubation was with and without
etorphine for an additional 4 hours. The monolayer
cultures were washed free of ascorbate and used to
determine basal and PGE1-stimulated CAMP levels as in
t1. Results in t2 show that etorphine-induced basal
and PGE1-stimulated compensatory increase in CAMP
levels observed is of the same order of magnitude in
the cells preincubated with or without ascorbate. The
data from tl and t2 clearly show that simultaneous
presence of ascorbate and etorphine is necessary to
suppress the etorphine-induced compensatory increase
in basal and PGE1-stimulated CAMP levels. These
studies have been carried out in a cultured cell line
of neuronal origin. Therefore, we studied the effect
of ascorbic acid on development of tolerance and
dependence in vivo in mice.
The in vivo effects of ascorbate on morphine-induced
analgesia, physical dependence, and tolerance were
studied. In mice ascorbate, when administered along
with morphine, suppresses the development of
tolerance and physical dependence on the drug,
without significantly affecting its analgesic
properties. Mice receiving morphine along with
ascorbate became less tolerant to and dependent on
the drug. The duration of morphine-induced analgesia,
however, is progressively reduced with an increase in
the amount of ascorbate. However, ascorbate does not
alter the intensity of morphine-induced analgesia
(Khanna and Sharma 1983). Ascorbate at lg/kg body
weight did not alter the pH of blood and did not have
an effect on the levels of lipid-peroxides in blood
and brain. These results suggest that action of
ascorbate is not mediated by its oxidation and lipid
peroxide formation.
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TABLE 1
Suppression of opiate-induced compensatory increase
in c-AMP levels by ascorbate
NG108-15 hybrid cells (1.2 x 106, passage 20) were
plated in (Medium A) OMEM (Flow Labs U.K.)
supplemented with 0.1 mM-hypoxanthine, 1µM-
aminopterin, 16 µM-thymidine, and 10 percent of fetal
bovine serum (Flow Labs) in 60 mm Falcon petri-
dishes. When 60-80 percent confluent, the culture
plates were divided in five groups: (i) control with
no effector agents; (ii) etorphine (1.6 µM); (iii)
etorphine 1.6 µM and sodium ascorbate (1 mM); (iv)
etorphine 1.6 µM and sodium ascorbate (5 mM); (v)
etorphine 1.6 µM and sodium ascorbate (10 mM). The
cells were incubated for 4 hours at 37°C, washed with
medium B [DMEM with 25 mM Hepes (4-(2-hydroxyethyl)-
1-piperazine-ethanesulfonic acid)]. Incubations were
carried out in 3 ml of medium B with 0.5 mM Ro20-1724
[4-(3-butoxy-4-methoxybenzyl) imidazolidine-2-one].
Amounts of intracellular levels of c-AMP were
determined over a period of 15 minutes with and
without PGE1 (10 µM) by the method of Gilman (1970).
Protein in each petri dish was estimated by the
method of Lowry et al. (1951). Values are the
average of three individual experiments (each
experiment had four plates in a group).
Additions during cell cAMP (Pmole/mg protein)
growth for 4 h Basal PGE1
328 3800
Etorphine 584 6263
Etorphine + ascorbate 1 mM 535 3954
Etorphine + ascorbate 5 mM 308 4400
Etorphine + ascorbate 1OmM 192 3542
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TABLE 2
Compensatory increase in CAMP levels after
preincubation of cells with ascorbate
NG108-15 hybrid cells (1.4x106, passage 20) were
plated in medium A in 60 mm petri dishes. When 60-80
percent confluent the culture plates were divided in
two groups (eight plates in each group): (i) control
with no effector agents; (ii) sodium-ascorbate
(5mM). The cells were incubated for 4 hours at 37°C,
washed with 4 x 3 ml medium A, and each set of
culture plates was divided into two groups: (ia)
control with no effector agents; (ib) etorphine 1.6
µM; (iia) control with no effector agents; (iib)
etorphine 1.6 µM. Incubations were carried out in 4
ml medium A for 4 hours at 37°C and washed with
medium B. 3ml medium B with 0.5 mM Ro20-1724 was
added, and the plates were incubated in presence of
naloxone with and without PGE1 (10 µM) for 15 min.
Intracellular CAMP levels were determined as in tl.
Each value is the average of three individual
experiments (each experiment had four plates in a
group).
Additions during cell growth CAMP (pmole/mg protein
Preincubation 1 Preincubation 2
(4 h) (4 h) Basal PGE1
Ascorbate
Ascorbate
Etorphine
Etorphine
433±49 5821±254
782±36 8063±422
371±19 5216±397
679±42 7976±510
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Mechanism of Ascorbate Action
Ascorbic acid may exert its effect at the level
either of binding of opiates to the receptor or of
coupling of the receptor to other components of the
adenylate cyclase system, i.e., inhibitory guanine
nucleotide regulatory protein (Ni) and catalytic unit
of adenylate cyclase.
Effect of Ascorbate on (3H) Etorphine and (3H) DADLE
Binding
Effect of ascorbate on binding of (15,16-3H)
etorphine to intact NG108-15 hybrid cells was studied
as a function of ascorbate concentration. Ascorbate
at 1 and 5 mM concentration inhibited the specific
binding of etorphine by 28 percent and 56 percent
(t3). Similar effect of sodium ascorbate on D-Ala2-
(tyrosyl-3,5-3 H) enkephalin (5-D-leucine) binding was
observed. Specific binding was inhibited by 24
percent, 56 percent, and 68 percent, respectively, in
the presence of 1 mM, 5 mM, and 10 mM ascorbate (t4).
These studies are compatible with those of Dunlap et
al. (1979).
In order to ascertain that ascorbate does not destroy
opiate receptors, NG108-15 hybrid cells in monolayer
were preincubated with 1 and 5 mM ascorbate, washed
and assayed for (3H) etorphine binding. There was no
significant change in specific (3H) etorphine binding
in the cells preincubated with ascorbate as compared
to that in controls (t5). These results show that
ascorbic acid does not destroy opiate receptors.
Effect of Ascot-bate on GTPase Activity
Klee et al. (1984) proposed that opiate inhibition of
adenylate cyclase in NG108-15 hybrid cells is the
direct result of stimulation of a low Km GTPase
component associated with Ni protein of the adenylate
cyclase complex. Adenylate cyclase shuttles between
two states, an active one with bound GTP and an
inactive one with bound GDP. Stimulatory receptors
facilitate exchange of GTP for bound GDP, whereas
inhibitory receptors (including opiate receptors)
stimulate low Km GTPase activity, which converts GTP
bound to the Ni complex to GDP (Ross and Gilman 1980;
Katada and Ui 1979, 1982a,b; Koski et al. 1982).
We have studied the short- and long-term effects of
sodium ascorbate and etorphine on low Km GTPase
activity and thus Ni in NG108-15 hybrid cells.
Etorphine stimulates low Km GTPase activity of NG108-
15 hybrid cells by 54 percent. This acute stimulatory
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effect of etorphine is reversed by opiate antagonist
naloxone (t6).
TABLE 3
Effect of sodium ascorbate on binding of (3H)
etorphine to monolayer cultures of NG1O8-15
hybrid cells
NG108-15 hybrid cells (2x104, passage 20) were plated
in medium P in 24 well Falcon culture plates. When 80
percent confluent, the wells were washed with medium
Incubations were carried out in 2 ml of medium B
containing 2 nM (15,16-3H) etorphine at 37°C in a
water bath. Specific binding was determined by
subtracting the nonspecific binding measured in the
presence of 2.5 µM naloxone from total binding at
each concentration of sodium ascorbate. Each value is
the average of four individual determinations and is
expressed as Mean ± S.D.
Addition (3H) etorphine binding
CPM/mg protein
None 750 ± 101
Sodium ascorbate 0.1 mM 770 ± 58
Sodium ascorbate 0.5 mM 697 ± 47
Sodium ascorbate 1.0 mM 537 ± 56
Sodium ascorbate 5.0 mM 327 ± 20
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TABLE 4
Effect of sodium ascorbate on binding of (3H) DADLE
to monolayer cultures of NG108-15 hybrid cells
Conditions of the experiment were the same as in t3.
Specific binding of 5nM D-Ala2-(tyrosyl-3,5-3H)
enkephalin (5-D-leucine) was measured.
Addition (3H) DADLE binding
CPM/mg protein
None 295 ± 14
Sodium ascorbate 1 mM 225 ± 18
Sodium ascorbate 5 mM 131 ± 11
Sodium ascorbate 10 mM 92 ± 5
TABLE 5
Binding of (3H) etorphine to NG108-15 hybrid
cells, preincubated with ascorbate
NG108-15 hybrid cells were plated in 60 mm Falcon
petri dishes as described in tl. When 60-80 percent
confluent, the monolayer of cells was washed with 5 x
3 ml of medium B, and plates were divided in three
sets: (i) control with no effector agents; (ii)
sodium ascorbate (1 mM); (iii) sodium ascorbate 5mM.
Incubations were carried out in 3 mlof medium B, for
60 min at 37°C. washed with 5 x 3 ml of medium B, and
incubated in 3 ml of medium B containing 2 nM (15,16-
H) etorphine at 37°C in a water bath. Specific
binding was determined as described in t3.
Preincubation (3H) etorphine binding
60 min CPM/mg protein
None 1085 ± 134
Sodium ascorbate 1 mM 1243 ± 78
Sodium ascorbate 5 mM 1153 ± 133
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TABLE 6
Effect of etorphine and sodium ascorbate on
GTPase activity in membranes prepared from
NG108-15 hybrid cells
Membranes were prepared and used for GTPase assay as
described by Koski and Klee (1981). All experimental
conditions were the same except that membranes were
collected by centrifugation at 48,000 g for 50 min.
Concentration of effector agents were naloxone, 2.5
mM; etorphine, 1 µM; sodium ascorbate, 5 mM; PGE1, 10
µM.
Each value is the difference of GTPase activity
obtained in the absence and presence of 50 µM GTP
determined in triplicates and is expressed as Mean ±
S.D.
Additions GTPase activity (+ PGE1)
pmole of Pi formed/min/mg protein
35.3 ± 1.3
Naloxone 35.5 ± 3.8
Etorphine 54.6 ± 0.89
Etorphine + naloxone 33.5 ± 1.11
These results are consistent with the earlier
observations of Koski and Klee (1981) on opiate
stimulation of low Km GTPase activity. Recently we
have shown that NG108-15 hybrid cells grown with
etorphine or ascorbic acid for 4 hours had decreased
low Km GTPase activity. Inhibition of the low Km
GTPase by ascorbic acid may be the mechanism by which
ascorbic acid inhibits the etorphine-induced
compensatory increase in CAMP formation (manuscript
under preparation).
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Development of Spinal Substrate
for Nociception in Man
Veena Bijlani, Ph.D.; Tilat A. Rizvi, M.Sc.; and
S. Wadhwa, MS.
The dorsal horn of the spinal cord is the first site
of interaction between primary afferents and intrinsic
neurons. There is considerable evidence in literature
about the existence of a variety of descending fibers
taking part in the spinal neuronal circuitry. The
small diameter nociceptive fibers have been shown to
establish synaptic contacts with the neurons of lamina
I, II, and III(Kerr 1975; Bishop 1980; Christensen
and Perl 1970; Willis and Coggeshall 1978). Spino-
thalamic tract neurons are dispersed in lamina I, IV,
V, and VI (Trevino et al. 1978; Kerr 1975; Carsten
and Trevino 1978). The small neurons of lamina II and
III do not appear to project for long distances
(Trevino and Carsten 1975). Kerr (1975) has suggested
these to be inhibitory neurons. The precise under-
standing of function of neuronal circuitry requires
that the afferent and efferent synaptic connections
and the transmitters of its constituent be identified.
Studies were done on the dorsal gray of human fetal
spinal cord ranging-in age from 8 to 37 weeks of
intrauterine life with a view to identify neuronal
circuits that modify/modulate the afferent inputs.
MATERIAL AND METHODS
Present study was conducted on 30 human embryos and
fetuses ranging in age from 8 to 37 weeks of intra-
uterine life obtained by hysterotomy and still birth
autopsies. The fetal age was calculated on the basis
of last menstrual period, crown rump length, biparietal
diameter, and external features of the fetuses, while
that of premature infant was assessed on the basis of
crown heel and biparietal length. Lower cervical
segments of spinal cord were processed for various
techniques.
The neurons and afferent fibers were identified in the
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Golgi preparation (100 µ thick celloidin sections),
and circuitry was reconstructed using camera lucida.
One Golgi impregnated neuron was processed for electron
microscopy using the method of Fairen et al. (1977).
1 µrn semitnin sections were cut to identify different
zones for ultrastructural studies, and electron
microscopy was done to study synaptogenesis.
Immunohistochemical localization of substance P,
enkephalin, and serotonin at different age periods
was carried out with the help of avidin biotin
peroxidase complex technique using monoclonal anti-
body (Sera Lab). GABA was localized using polyclonal
antibody (Sera Lab) with PAP technique of Sternberger
(1974).
RESULTS
Morphologically, on the basis of axonal projections
and dendritic arborization, different types of neurons
could be identified in different zones of dorsal horn.
Interneurons (encased of Lima and Coimbra 1983) and
projection neurons in marginal zone (Bijlani et al.
1986), islet, stalked, bipolar and multipolar neurons
in substantia gelatinosa, and multipolar and antenna
neurons in deeper zone were typed in Golgi preparation
at all age periods (unpublished observation).
One interneuron at 13 weeks (encased) after Golgi
impregnation was processed for electron microscopy.
Different types of axodendritic and axosomatic
synapses with clear spherical, dense core and
pleomorphic vesicles were found on the dendrite and
soma of this neuron (figs. 1c, 1d).
Mild substance P immunoreactivity was localized at the
age of 8 weeks in the tangential plexus of fibers in
superficial dorsal horn and in laterally curving
fibers. Immunostained ventrally curving fibers could
also be seen in the region of substantia gelatinosa
(figs. 2a, 2d). Intensity of immunoreactivity increased
with the age (fig. 3).
Serotonin inmunoreactivity was also found to be of the
same pattern as that of substance P at 12 weeks in the
superficial dorsal horn. Eoth medially and laterally
curving fibers picked up intense reaction. Inter-
mediate horn was found to have network of immunostained
fibers (fig. 2b). Immunoreactivity again intensifies
with the increasing age.
Enkephalin was localized at the age of 12 weeks of
gestation in the laterally curving fibers and in
intermediate gray. At 14 weeks onward mild immuno-
reactive positive cells were found in marginal zone
and substantia gelatinosa. At the same age superficial
dorsal gray: i.e., the region capping the dorsal horn,
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FIGURE 1
Electron micrographs showing (la) an axodendritic asymmetrical
synapse (arrow) with clear spherical and dense core vesicles
at 18 weeks of intrauterine life in marginal zone. X 35640.
(1b) serial types of synapses from deeper zone at 25 weeks of
age. X 35640.
(1c) Golgi impregnated neuron from marginal zone after gold
toning at 13 weeks of age. X 6385.
(1d) asymnetric synapse (arrow) on the soma of gold toned
neuron(c) with clear spherical vesicles. X 46827.
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FIGURE 2
Photomicrographs showing immunoreactivity in the dorsal horn
of spinal cord at the age of 16 weeks of gestation.
2a - Substance P X 75.
2b - Serotonin X 75.
2c - Enkephalin X 75.
2d - Substance P immunoreactive fibres under high power X 750.
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FIGURE   3
Comprehensive chart illustrates the appearance of various neurotransmitters in
the dorsal gray at different age periods.
and laterally curving fibers were also immunopositive
(fig. 2c).
GABA was first localized in terminals on dorsal side
of superficial dorsal gray at 8 weeks, while at 10
and 12 weeks immunostained cells were seen in the
marginal zone, substantia gelatinosa, and intermediate
gray (unpublished observation).
At ultrastructural level dense core vesicles were
seen in axonal terminals at 8 weeks. From 12 weeks
onward axosomatic synapses with plemorphic vesicles
were identified (Rizvi et al. 1986). These vesicles
could contain either GABA or serotonin or even
enkephalin. Asymmetric synapses were seen at 18 weeks
(fig. la), while axoaxonic synapse was visible at 20
weeks (Rizvi et al. 1986). Serial types of synapses
could be visualized at 25 weeks (fig. 1b).
DISCUSSION
Gobel (1978a) stated that all neurons in the marginal
zone are projection neurons. Our studies are not in
agreement with Gobel, as we have identified both
projection (Waldeyer 1888) and interneurons at 13
weeks in that marginal zone on the basis of cell size,
location, and dendritic morphology (Bijlani et al.
1986). We could also identify "encased neuron",
specifically described by Lima and Coimbra (1983) in
rat spinal cord as having a prominent dorsally
directed dendrite situated dorsolaterally. Encased
neuron picked up from Golgi section reembedded in
araldite, was sectioned for electron microscopy (fig.
1c) and was found to have axosomatic (fig.1d) as well
as axodendritic synapses. This neuron appears to be
contacted by descending supraspinal fibers and could
thus be involved in modulation mechanisms (Lima and
Coimbra 1983). We also found this neuron situated in
close proximity of GABAergic terminals at 8 weeks.
No GABA positive cells were seen in dorsal horn at
this age period (unpublished observations). The
punctate appearance of GABA positive terminals in the
region of Lissauer tract suggests the presence of GABA
in the bulbcspinal fibers.
Cajal (1909) and Gobel (1978b) have reported central
and limiting cells, islet, arboreal, and lamina II-III
border cells in substantia gelatinosa, respectively.
In our Golgi studies at 13 to 14 weeks we could find
primitive stalk cell with axon projecting to lamina I.
According to Gobel (1978b), these neurons are
equivalent to the limiting cells of Cajal (1909) and
may be excitatory interneurons, but according to
Bennett et al. (1982) they contain enkephalin, an
inhibitory neurotransmitter.
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We could also find islet cell with axon in its
vicinity in the same lamina (Bijlani et al. 1985).
According to Gobel (1978b), these neurons may be
inhibitory interneuron of Golgi type II class and
central cells of Cajal (1909).
In deeper zone we could find antenna neurons with
dendrites directed toward substantia gelatinosa.
According to Willis et al. (1979), some spinothalamic
tract cells in monkey do send dorsally directed
dendrites through lamina II to lamina I so it may
correspond to spinothalamic tract cell.
Substance P is putative neurotransmitter for dorsal
sensory neurons (Otsuka and Konishi 1977; Nicoll
et al. 1980). Recently Bossut et al. (1986) stated
that substance P does not appear to be a primary
afferent transmitter for pain in the spinal cord.
Present investigations have suggested that substance
P appears very early in ontogeny, as it was visible
at 8 weeks embryonic spinal cord in our study (Mehra
and Bijlani 1986). The neuropeptide has earlier been
reported in the dorsal horn of human spinal cord at
12 weeks (Charnay et al. 1983) with immunofluorescent
technique. Our immunohistochemical studies corroborate
with Charnay et al. (1983) but with earlier ontogenic
appearance (figs. 2a,2d).
The role of descending fibers in the modulation of
sensory pathways at spinal level is well illustrated
(Fields and Basbaum 1978; Mayer and Price 1976).
Activation of serotoninergic pathways has been
described to inhibit nociceptive responses of
spinothalamic neurons (Messing and Lytle 1977). In
dorsal horn serotoninergic axons have been described
by Dahlstrom and Fuxe (1965) that originate from brain
stem cells containing 5 HT. In our study serotonin
positive immunoreactivity was localized at the age of
12 weeks using monoclonal antibodies. Serotonin
positive neurons could not be identified in the spinal
cord, thus supporting supraspinal origin of these
fibers. Serotoninergic terminals gave an appearance
of honey comb network around unstained neurons in
substantia gelatinosa, supporting close proximity of
gelatinosa neurons to supraspinal serotoninergic
terminals.
At ultrastructural level visualization of axosomatic
and axodendritic synapses with pleomorphic vesicles
may correspond to serotoninergic terminals (Rizvi et
al. 1986). Ruda and Gobel (1980) have described in
detail the mode of action of descending serotoninergic
fibers on islet, stalked, and projection neurons and
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have stressed the modulatory role in nociception.
Our observations indicate the existence of a
morphological substrate corroborating Ruda and Gobel's
(1980) findings.
Neuromodulatory role of enkephalin in the pain sensory
system was supported by physiological (Basbaum and
Fields 1978; Mountcastle 1980) and anatomical
(Hokfelt et al. 1977; Glazer and Basbaum 1981)
findings. Enkephalin has been localized immuno-
histochemically in the spinal cord of man (DeLanerolle
and LaMotte 1983) and monkey (Aronin et al. 1981) and
in human fetuses and infants (Charnay et al. 1984) by
immunofluorescent technique. Enkephalin immunoreactive
fibers in these studies were predominant in the
marginal layer and substantia gelatinosa (Elde et al.
1976; Sar et al. 1978), while enkephalin containing
cell bodies were located in the substantia gelatinosa
(Ditirro and Ho 1980). Opiate receptors have been
described to be located in the superficial dorsal horn
on primary afferent fibers (Atweh and Kuhar 1977),
thereby indicating the formation of axoaxonic synapses
(Jessel et al. 1979) and causing presynaptic inhibition
by enkephalinergic neurons of substantia gelatinosa
(Mudge et al. 1979).
In contrast, physiological studies have shown that
enkephalin acts at postsynaptic sites in dorsal horn
(Henry et al. 1980). At electron microscopic levels
in rat dorsal horn enkephalin has been localized in
axon terminals (Pelletier and Leclere 1979) and found
to form synapses with aendrites and soma (Hunt et al..
(1980). For the first time, enkephalin positive
neurons were found in lamina I, II, III, and V at ultra-
structural level (Aronin et al. 1981). According to
these authors, enkephalin binds mostly to opioid
receptors contained on dendrites and soma within the
spinal cord, while direct synapses by enkephalinergic
axons with primary afferent fibers form a secondary
and not so common site of interaction. Therefore,
earlier concept that opiate receptors are on primary
afferent terminals and form axoaxonic synapses for
presynaptic inhibition appears to be contradicted.
In present investigation on developing dorsal gray,
enkephalin immunoreactivity was localized in the
dorsal gray at the age of 12 weeks in fibers entering
to intermediate dorsal horn through lateral funiculus.
From 14 weeks, immunoreactive fibers were found in
superficial dorsal gray, i.e., marginal zone and
substantia gelatinosa (fig. 2c). Laterally curving
fibers also were found to show immunoreactivity. Our
immunohistochemical findings corroborate with the
immunofluorescent finding of Charnay et al. (1984).
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At 17 weeks, in addition to immunoreactive fibers,
some cells positive for enkephalin could also be
visualized, suggesting the presence of enkephalin in
substantia gelatinosa neurons. The intensity of
reaction in fibers and cells increased from 12 weeks
to 25 weeks (the specimen used for immunohistochemical
localization).
Curtis and Johnston (1974) and Levy (1977) have
described GABA as a major neurotransmitter involved
in mediation of presynaptic and postsynaptic
inhibition and presynaptic felicitation. Wolf (1981)
has described relationship between GABA positive
neurons and development of excitatory synapses in
developing visual cortex and has specified that in
prenatal phase GABA has extra synaptic function.
Light et al. (1979) and Kumazawa and Perl (1978) have
stressed the roles of GABAergic synapses in the
integration of afferent information.
In the present investigations on human fetal material,
GABA was localized using polyclonal antibodies. At 8
weeks of intrauterine life, immunopositive terminals
were identified in dorsal most-regions of the spinal
cord. These appear to be in the region of Lissauer
tract and could be the terminals of bulbospinal
pathways. At 12 weeks of intrauterine life, GABA
positive cells were found in the marginal zone,
substantia gelatinosa, as well as in the deeper zones.
These findings support the results of Barber et al.
(1982) in the rat spinal cord. These authors,
however, identified GAD positive cell bodies.
At ultrastructural level presence of various types
of synapses with morphologically different types of
vesicles, namely, clear spherical (fig. 1b), dense
core (fig. 1a), and pleomorphic vesicles (Rizvi et
al. 1986), suggest the presence of different
transmitter, e.g., substance P, serotonin, GABA, and
enkephalin.
CONCLUSIONS
In conclusion, present investigations suggest
that among various neurotransmitters that have been
described in the literature to play a role of
mechanism of nociception, substance P of dorsal root
origin appears at 8 weeks and at the same age GABA
in the bulbospinal fibers is present. Serotonin and
enkephalin neurotransmitters are present at 12 weeks
in the fibers while enkephalinergic cell bodies are
visualized at 14 weeks onward. The presence of these
transmitters indicates the possibility of the
existence of various components of morphological
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substrate for nociception in spinal cord at very early
stages of human ontogeny. All the same, possibility
of neurotrophic role of these various transmitters
cannot be ruled out.
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INTRODUCTION
In recent years the knowledge on the wide distributions of the opioid
neurons, fibre terminals, and their receptors has been growing (Atweh
and Kuhar 1983; Akil et al. 1984; Snyder 1984, 1986). The opioid
peptide neuronal and receptor mechanisms are considered to participate
in a range of homeostatic integrations in the different subsystems of
the brain, including the stress response and coping, pain control, anal-
gesia, neuro-endocrine, cardiovascular, and other visceral regulations,
and the mechanisms of reward, mood, and psyche. The present state
of knowledge generally indicates that the beta-endorphin neurons
and the epsilon, mu, and delta receptor mechanisms might be pre-
dominantly involved in the visceral and neuro-endocrine regulations, the
enkephalins and the delta receptors involved primarily in the psychic
and other limbic neuronal mechanisms, the dynorphins and the kappa
receptors primarily involved in the analgesic and sedative neuronal
mechanisms, and with several overlapping roles also in the functioning
of these neurons and receptors in different subsystems.
The enkephalins were shown to have the reward properties in intra-
ventricular self-administration experiments (Stein and Belluzzi 1979),
the leu-enkephalin was more self-administered than the met-enkephalin
or the morphine. The self-administration of morphine and of D-ala2-
mets-enkephalinamide (and its blockade by naloxone) into the self-
stimulation sites of lateral hypothalamus was also reported (Olds
1979; Olds and Williams 1980), but these results were argued to be
artifacts by Bozarth (1983), who stated that the morphine self-
administration property was not present in lateral hypothalamus, but
present only in the ventral tegmental area (Bozarth and Wise 1981).
Shaw et al. (1984) reported that while the intra-ventricularly injected
morphine caused a reduction of spontaneous motor activity, the elec-
trical self-stimulation (SS) of medial prefrontal cortex (MPC) was
facilitated. Similar results were also observed by them with the intra-
ventricular injection of the enkephalin analogue BW 180 (tyr-D-ala-
gly-phe-D-leu), but these effects were indirect according to them
as direct injections of morphine or naloxone into MPC caused no change
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in the SS of MPC. Naloxone (intraperitoneal) has also been shown
to cause a small but significant reduction in the SS of lateral hypo-
thalamus (Ichitani et al. 1985). Broekkamp et al. (1976) reported that
the SS of LH was inhibited by injecting morphine into central grey.
In contrast, microinjections of morphine or of D-ala2-met5-enkephalin-
amide administered into ventral tegmental area facilitated the SS
of lateral hypothalamus and the effect of morphine was antagonized
by systemic naloxone (Phillips et al. 1983). They also reported rewarding
effects in the conditioned place preference paradigm and that such
a facilitatory effect was attenuated by haloperidol or by lesions
of dopamine pathways (Phillips et al. 1983).
The above studies indicate the need for investigations of the role of
the opioid peptides administered into the different regions of SS to
understand the intrinsic and interlinked components in the mechanisms
of the brain reward neuronal systems. The present study was designed
to investigate the effects of enkephalins and dynorphins administered
directly into the loci of self-stimulation of ventral tegmental area-
substantia nigra (SN-VTA) and of lateral hypothalamus (MFB-LH)
on the self-stimulation operant rates of the same loci. Such studies
have not appeared in the literature so far.
METHODS
Wistar rats weighing 260-320 g were implanted with bipolar SS elec-
trodes made up of 28 g stainless steel wire, and bipolar cannula-cum-
wire electrode made up of the same type of wire joining to 22 g cannula
needle. The cannula-wire electrode (both insulated except for tips)
served either as bipolar SS electrode or for microinjections of chemicals
through the cannula into the SS site. In each rat one bipolar wire
electrode and one bipolar cannula electrode were implanted, one in
MFB-LH and the second in ipsilateral SN-VTA . In different rats
the placement of the two types of electrodes was interchanged between
the regions. After a few days of post-operative recovery, the self-
stimulation rates of each of these sites were shaped and stabilized
reproduceably in a few sessions. The stimuli used were sine waves
of 50 Hz, 0.25 sec train duration for each pedal press, and current
intensities ranging between 75 µA and 200 µA as required to get the
maximum possible SS without apparent side effects. The duration
of a control or a test session was 15 min. At least three test sessions
(with drug) and three control sessions (with vehicle) were made for
each dose, and all repeated in at least three rats. 33 rats were used
in the present study. All intra-cerebral injections (drug or vehicle
solutions) were made through the cannula slowly in about 60 seconds
in a constant volume of I µl. At the end of the experiment, the place-
ments of the electrodes were noted from frozen sections cut at 60 µ
stained with cresyl violet, and marked on the charts of atlas of Paxinos
and Watson (1982). Data were processed by using the F test (Anova)
to test the homogeneity of variance and by Student’s ‘t’ test to know
the levels of significance of the effects.
The chemicals used were: leu5-enkephalin; met5-enkephalin; leu5-
enkephalinamide; dynorphin-A[1-13] (all these of Sigma, USA); D-ala2-
D-leu5-enkephalin (BW 180C of Wellcome Research Laboratories,
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UK); naloxone-HCI (Endo Laboratories, USA).
RESULTS
The leu5-enkephalin (leu-enk) was administered (500 ng) into SN-VTA
and one hour and two hours later, the SS operants were recorded.
It was observed that the SS of the site was reduced by 48% at 1 hr
and by 70% at 2 hrs from the level of the control value obtained
under the vehicle injection (Fig. 1), the SS of the other site (MFB-LH)
was not changed. In the reverse experiment, administration of the
leu-enk in MFB-LH has not changed the SS of the same site but has
caused a facilitation of the SS of the SN-VTA (Fig. 1). A similar pattern
of response was obtained with the leu5-enkephalinamide also (Fig. 2).
The D-ala2-D-leu5-enkephalin (ala-leu-enk or BW 180c) caused, contrary
to the above opioids, a facilitatory effect on the SS of SN-VTA when
it was admiristered either in the SN-VTA or in the MFB-LH (Fig. 3).
This opioid also has not influenced the SS of the MFB-LH. Naloxone
hydrochloride (30 mg/kg ip) has brought down the facilitated effect
of SN-VTA back to about the normal level (Fig. 3).
The met5-enkephalin (met-enk) administered in doses of 500 ng or
2 µg either into SN-VTA or into the MFB-LH has not been found to
influence the SS of either region (Fig. 4).
Dynorphin-A[1-13](dyn) administered in doses of 500 ng or 1 µg into
SN-VTA has caused facilitation of its SS. Administration of the same
into the MFB-LH has not influenced either its SS or that of the
SN-VTA (Fig. 5).
In summary, the leu-enk or its amide have caused reduction in the
SS of SN-VTA when administered into the same site. When these opioids
were administered into the MFB-LH its own SS was not influenced,
but caused indirect facilitatory effects on the SS of SN-VTA. Met-enk
caused no changes of SS in both these regions. Contrary to leu-enk,
dynorphin-A[1-13] caused facilitatory effect in the SN-VTA, and also
no effect through MFB-LH. Ala-leu-enk caused both types of faci-
litatory effects on the SS of SN-VTA, when it was administered into
it and also into the MFB-LH, without changing the SS of the
MFB-LH.
DISCUSSION
There seems to be no study made previously to find the effects of
the above cited opioid peptides on the SS of SN-VTA and of MFB-LH,
after administering them into the same SS sites.
It was previously reported (Shaw et al. 1984) that only the intra-
ventricular administrations of BW 180 (ala-leu-enk) up to 40 µg doses,
or morphine up to 20 µg, caused facilitation of the SS of the medial
prefrontal cortex (MPC), but no effects were observed when morphine
or naloxone was administered into the MPC. As the ventricular drug
could act at many sites in the brain, the authors interpreted the effects
as indirect ones on the MPC. These authors have also reported that
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FIGURE 1
Effects of slow microinjection (1 µ1 in 60 sec) of leuenkephalin either
into SN-VTA (A) or into MFB-LH (B) on the electrical self-stimulation
of the injected site and of the other site. Cannula site is open circle,
filled circle is wire. Typical placement sites of histology indicated
in the atlas drawings of hypothalamus and midbrain. A’, one hour
or two hours (A”) after the drug is administered in other site; B,
before the drug is administered in the other site; D’, one hour or
two hours (D”) after the drug is administered in the same site; V,
after the vehicle (saline) is administered in the same site. ‘n’ indicates
the data of number of rats and the number of sessions conducted
on each of them. * = P < 0.005; ** = P < 0.001.
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FIGURE 2
Effects of leu-enkephalinamide in two doses represented by the two
sets of bars (1,2). Self-stimulation sessions were conducted one hour
after the drug (D) or the vehicle (V) administration. After testing
the injected site, the other site was tested. Other symbols as in Figure 1.
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FIGURE 3
Effects of D-ala2-D-leu5-enkephalin, and of intraperitoneal (ip) naloxone
hydrochloride administered during the enkephalin effect. Naloxone
effect studied from 15 min after its administration. Symbols as in
Figure 2.
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FIGURE 4
Effects of met-enkephalin in two doses represented by the two sets
of bars (1,2). Symbols as in Figure 2.
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FIGURE 5
Effects of dynorphin-A[1-13] in two doses represented by the two
sets of bars (1,2). Symbols as in Figure 2.
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the intraventricular BW 180 caused a reduction of the spontaneous
motility, particularly in the dose range of 20-40µg. In our local study
on SN-VTA and MFB-LH, only a dose of 2 µg of the ala-leu-enk has
been used and the effects on their self-stimulation have been very
significant. Further, we have also observed that the facilitatory effect
was relieved by administration of naloxone hydrochloride intraperito-
neally. Naloxone has not significantly affected the normal SS of SN-VTA
or of MFB-LH in our study, in contrast to the report of Ichitani et
al. (1985) who observed a small but significant reduction of the SS
of lateral hypothalamus under naloxone (5mg/kg ip). The effects of
naloxone hydrochloride on the SS could depend on the regional differen-
ces and on the conditions of reinforcement, the FR-30 schedules being
most affected and the CR schedules least affected. Schaefer and
Michael (1985) observed the SS (FR-30) of the periventricular grey
to decrease in a dose-dependent manner, by about 70% at a naloxorie
dose of 30 mg/kg given sub-cutaneously. At this dose, they have also
observed slight reduction (about 15%) in the ambulatory activity.
Phillips et al. (1983) reviewed the observations to show that morphine
or ala-met-enk administration into SN-VTA caused facilitation of
the SS of lateral hypothalamus, whereas our results with the ala-leu-enk
administration into the SN-VTA have not caused any change in the
SS of MFB-LH. Probably the difference in the opioids used and the
receptors upon which they act could be the reason for the opposite
patterns of the results. Our present study with the leu-enk, met-enk,
ala-leu-enk, and dyn has also disclosed such differences in the pat-
terns of the effects on SS of the SN-VTA and the MFB-LH. In the
studies of Phillips et al. (1983) the effect of morphine or of ala-met-
enk on the _SS of the injected site (SN-VTA) was not studied, whereas
we have found that with the ala-leu-enk the SS of the injected site
(SN-VTA) was facilitated. We have also observed the converse, i.e.,
administration of the ala-leu-enk into the MFB-LH has not changed
the SS of the injected site and yet led to a change of the SS of the
SN-VTA. This could imply that at the MFB-LH the ala-leu-enk could
have acted on an additional interlinked substrate besides on the SS
substrate (intrinsic) of MFB-LH and that the additional substrate
could have been linked to the SN-VTA intrinsic substrate of SS. In
other words, the opioid effects probably differentiated in the MFB-LH
the intrinsic SS substrate from a separate substrate present there
and interlinked to the SN-VTA mechanism of SS.
The mode of synaptic transmission actions of opioids and the details
about differerces in the proportions of the opioid receptor types present
on the neurons of the MFB-LH and the SN-VTA are not adequately
available to enable to infer the possible mechanisms underlying the
effects seen in the present study. A review of the previous studies
(North and Williams 1983) indicates that morphine would enhance K+
conductance and cause inhibition of noradrenergic neuronal firing.
These effects could widely differ according to the types of the neurons
and the sites in the brain. There was also an opposite type of observa-
tion that morphine when administered iontophoretically led probably
indirectly to an increase in the firing of dopaminergic neurons at
SN-VTA and that iontophoressed naloxone had not reversed this effect,
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whereas the non-DA neurons in the vicinity were suppressed, which
could be reversed by naloxone (Gysling and Wang 1983). It has been
reported that the leu-enk has primarily the delta receptor activity
(Akil et al. 1984). Dynorphin-A [1-13] is known to be very potent
at both mu and kappa receptors, and its fibre terminals are present
only in SN and not in LH, which has the cell bodies (Akil et al. 1984).
Ala-leu-enk also labels preferentially the delta sites. Hence, the
opioid peptides used in the present study would be primarily acting
upon the delta, mu, and kappa receptors of the non-opioid and the
opioid neurons and axon terminals in the MFB-LH and SN-VTA. However,
the differences in the proportions of these receptor types present
in the two regions, and the organization of the types of neurons and
terminals in the linkages of circuits in which these receptors are
located in the two regions, are unknown. The mu receptors are pro-
bably more predominant in the MFB-LH (Akil et al. 1984), whereas
the delta and kappa may be relatively more in the SN-VTA substrates
of SS. It is hypothesized from the present results that the leu-enk
in the MFB-LH could be inhibiting a projection mechanism inhibitory
to the SS system of SN-VTA, thereby releasing the facilitation of
the SN-VTA. The opposite type of effects of the leu-enk and the
ala-leu-enk on the SS of SN-VTA, when these are administered in the
SN-VTA, is probably due to their differences in actions on the recep-
tor types present in the SN-VTA. The dynorphin-A actions suggest
that the kappa receptors seem to be involved in the SS mechanism
of SN-VTA and not in that of MFB-LH.
The differential effects of the above opioids on the SS of the SN-VTA
and the MFB-LH emphasize the differences in the neural mechanisms
of the SS of the two regions. Our previous study (Singh and Desiraju
1986) of the SS of the two regions with local administrations of halo-
peridol and apomorphine also disclosed that the two regions have
separate synaptic types of intrinsic mechanisms of SS, besides having
an inter-linkage mechanism. As the opioids have shown either inhibitory
or facilitatory effects on the SN-VTA, and little such effects on the
MFB-LH, the possibility arises whether this striking difference could
be due to the dopaminergic neurons and receptors present in the SN-VTA.
This difference in effects could also as well be due to the opiate
receptors present on non-dopaminergic neurons and terminals located
in the SN-VTA.
SUMMARY
Leu-enkephalin, leu-enkephalinamide, ala-leu-enkephalin, met-enkephalin
and dynorphin-A[1-13] were administered in microinjection into one
of the self-stimulation sites of SN-VTA or MFB-LH and the electrical
self-stimulation (SS) of the injected site and of the second site was
recorded. The study revealed that the leu-enkephalin and the leu-
enkephalinamide inhibited the SS of SN-VTA and produced no effect
on the SS of MFB-LH, when administered into these sites. The MFB-LH
injection, however, facilitated the SS of SN-VTA. The effect of ala-
leu-enkephalin injection in MFB-LH was similar to the above, but
the effect of the injection in SN-VTA was different in that it caused
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the facilitation of its SS and not the depression as seen with leu-
enkephalin. Met-enkephalin injections in the two regions caused no
direct or indirect changes of the SS of the regions. Dynorphin injection
in SN-VTA facilitated its SS, like the injection of ala-leu-enk, but
dynorphin injections in MFB-LH produced no effects. The results essen-
tially demonstrate the differences in the effects of the different
opioids in the reward system of the SN-VTA, and it is discussed that
these differences are probably due to the preferences in the types
of the receptors upon which these opioids act in the SN-VTA neuronal
organisation. The results also demonstrate the major difference in
the organisation of the reward substrate of the MFB-LH from that
of the SN-VTA, as the effects of the opioids in the MFB-LH are mar-
kedly differert or none compared to the effects in the SN-VTA.
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Peptides and Thermoregulation
Rakesh Shukla, Ph.D., and Bhola N. Dhawan, M.D.
Many neurotransmitters are involved in the central regulation of
body temperature under normal conditions, in fever, and during
exercise and heat and cold stress. Emphasis on amines and
prostaglandins has declined to some extent, and a major focus in
recent years has been on the peptides that might participate in
central nervous system (CNS) mediation of temperature control.
Interest in -the neurobiology of peptides has developed coincident
with their identification and chemical characterization in mammalian
brain. Several of these peptides were originally isolated from
pituitary tissue or the alimentary canal, but they also occur in
various regions of the CNS. Although the central roles of most of
the peptides are still not adequately understood, many neuropeptides
are known to have profound effects on regulation of body
temperature, and the available data on the neuropeptides will be
briefly reviewed.
1. OPIOIDS
The endogenous opioids are unique in that their ability to alter
thermoregulatory mechanisms is shared by nonpeptide opioids. While
evidence is accumulating that opioid ligands and opioid receptors
play a functional role in thermoregulation, an exhaustive study in
different species has not yet been undertaken for opioid peptides.
Much less information is available on the opioid peptides than on
morphine.
A. Morphine
Most studies have been conducted with morphine, although some
investigations have also been carried out with other opioids.
Several reviews have appeared on the effects of morphine on body
temperature, the most comprehensive being those by Clark (1979).
Clark and Lipton (1983, 1985), and a recent review by Adler et al.
(1988). The effects of morphine are species-dependent. A
hypothermic response is predominant in the dog, rabbit, and pigeon;
a hyperthermic response in cat, cattle, goat, and horse; and a dual
response (low--dose hyperthermia and high-dose hypothermia) in rat,
mouse, and primates (Clark and Lipton 1985). A biphasic response,
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hypothermia followed by hyperthermia, in rat and mouse is also
reported (Rosow et al. 1980). All these responses to morphine are
blocked and antagonized by naloxone. There is also some interaction
with calcium channel antagonists (Pillai and Ross 1986b). Morphine
responses are dependent on ambient temperature: a hypothermic
response is predominant at ambient temperature below
thermoneutrality; biphasic responses appear as the ambient
temperature increases, and ultimately hyperthermia predominates at
the highest ambient temperatures (Adler et al. 1988). Recent
studies have demonstrated that morphine responses are also dependent
on the route of administration (Adler et al. 1984; Geller et al.
1986), and route is a critical determinant not only of quantitative
effects but of qualitative effects as well. The exact mechanisms
involved in the body temperature changes produced by morphine are
still not known with certainty. The effects may result primarily
from the actions on oxygen consumption, however. Morphine-induced
hypothermia is associated with decrease in oxygen consumption and
metabolic heat production in a variety of species (Lotti et al.
1966; Lin et al. 1980). Recent studies by Adler and his colleagues
(1986, 1988) suggest that body temperature responses to morphine are
due to the change in thermal set point in hypothalamus. In dog, an
increased heat loss after morphine administration has been
demonstrated (see Clark and Lipton 1985 for a review and
references). Some interaction of morphine with dopaminergic and
cholinergic systems in thermoregulation has been shown by Cox et al.
(1975) and Adler et al. (1986).
B. Naloxone
Naloxone has been used by several investigators to establish
evidence for involvement of opioid receptors. Naloxone, per se,
however, does not have an effect on thermoregulation in rat (Pillai
and Ross 1986a) or man (Fuenmayor and Cubeddu 1986) though in
morphine-dependent rats naloxone and related compounds reduced
rectal temperature by a central action since quarternary derivatives
were inactive (Katovich et al. 1986). The drug interactions are not
always well defined. Thus naloxone only partially blocked ethanol
hypothermia, which was completely blocked by kappa antagonist MR
2266 (Pillai and Ross 1986a), whereas it completely antagonized
microwave blockade of amphetamine hyperthermia (Lai et al. 1986).
The blphasic temperature changes with phencyclidlne are antagonized
by naloxone, by the E and K antagonist SKF 10,007 as well as by
the pure k antagonist MR2266 (Hiramatsu et al. 1986).
C. Endogenous Opioids
Identification of endogenous peptides and their precursor molecules
in the brain encouraged intense research efforts to determine both
the in vivo and the in vitro effects of these substances and the
possible functional roles played by the opiold
receptors. Recent data utilizing more selective ligands in rat
suggest that µ opioid receptors play a role in hyperthermic
response. Morphine, a prototypic µ ligand, and DAGO, a µ
selective receptor agonist, produce hyperthermla in several species
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of animals (Adler et al. 1988) and prompt rats to seek warmer
temperatures. On the other hand, receptors seem to be involved
in hypothermia, as U50488H, a receptor agonist, produces
dose-related hypothermia. A role for receptors in
thermoregulation cannot be ruled out completely.
a. ß-Endorphin. If nonpeptide opioids act at receptors that are
stimulated by oploid peptides, the thermoregulatory effects of
endogenous opioids and of morphine and related agonists ought to be
alike. When ß-endorphin is injected centrally to a variety of
species, it induces patterns of temperature change that closely
resemble those associated with central or peripheral administration
of morphine (Clark and Lipton 1985). Relatively low doses of
morphine and ß-endorphin raise the level at which temperature is
regulated in the cat, rat, mouse, and rabbit (Rezvani et al. 1982),
primate (Murphy and Lipton 1983), and fish (Kavaliers 1982).
Evidence from studies on rabbits indicates that this change in
regulation may be due to impaired input from peripheral warmth
sensors (Rezvaini and Heath 1984). Such an effect would be of
greater significance in a warmer environment and could account for
the greater increase in body temperature at usual ambient
temperatures than in a cold environment after injection of a given
dose of ß-endorphin to cats, rabbits, etc. In contrast to the above
species, which have been used most often for the study of
opioid-induced temperature changes, ß-endorphin lowers the
temperature of chickens and hamsters (Clark and Lipton 1983).
In those species in which small doses of ß-endorphin induce
hyperthermia. naloxone and similar antagonists ought to lower
temperature if' ß-endorphin contributes to maintenance or elevation
of body temperature. Both naloxone and naltrenone prevented a rise
in the temperature of rats secondary to restraint or handling, or
lowered temperature when stress was minimized by habituation of the
animals to the experimental procedures (Clark and Lipton 1983; Pae
et al. 1985). Except for such reports, evidence is not available to
indicate that reasonable doses of opioid antagonists appreciably
affect temperature. So it is unlikely that ß-endorphin, which has
been readily antagonized in most studies, plays a major role in
normal thermoregulation, even in hot or cold environments (Clark et
al. 1983). Likewise, naloxone has not altered responses to pyrogen
in the cat, rat (Clark and Lipton 1983), guinea pig (Kandasamy and
Williams 1983), and sheep (Duranton and Bueno 1984). So a role for
ß-endorphin in fever is unlikely. This view is also supported by
the fact that antipyretics failed to antagonize the hyperthermic
action of opioid peptides in the cat, mouse (Clark and Lipton 1983),
guinea pig (Kaidasamy and Williams 1983), and rabbit (Kandasamy and
Williams 1983; Rezvani and Heath 1984). It is likely that the
endorphin effects are mediated via a mechanism independent of the
arachidonic acid cascade.
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b. Enkephalins. Very little information is available on the
potential thermoregulatory actions of enkephalins. Met-enkephalin
is a relatively weak agonist in altering body temperature (Clark and
Lipton 1985), probably because of its rapid inactivation (Miller
1981). To obtain measurable temperature changes, larger doses
(0.1 mg to 10 mg centrally) of the enkephalins (as compared to
ß-endorphin) have been required. The usual response at room
temperature has been hyperthermia (Clark and Lipton 1985), although
there have been exceptions (Sakurada et al. 1983). Shukla et al.
(1982) have demonstrated that Met-enkephalin induced hyperthermia
varied inversely with ambient temperature over a temperature range
of 10° to 33°C In the desert rat Mastomys natalensis.
A major difference between Met-enkephalin and ß-endorphin is that
the hyperthermic response to the former is less readily antagonized
by naloxone (Clark and Lipton 1983). Hence the lack of appreciable
effect of naloxone on temperature does not rule out the mediation of
thermoregulatlon by enkephalins. Assessment of this possibility has
been hampered by the lack of a selective enkephalln antagonist. A
number of relatively stable and more potent enkephalin analogs have
been tested (see 1985 review by Clark and Lipton). Unfortunately,
these have generally been more readily antagonized by naloxone, and
act more like ß-endorphin than like the parent enkephallns, probably
because the structural modifications that increase stability tend to
shift sensitivity away from naloxone-insensitive types of receptors.
Recently Shukla et al. (1988) suggested an enkephalinergic and
serotonergic interaction in the thermoregulation of the desert rat.
c. Other Opioid Peptides. Dermorphin produces a naloxone-reversible
hypothermia which is unaffected by antagonists of other putative
neurotransmitters such as serotonin, catecholamines, GABA,
acetylchollne, etc. (Tatara et al. 1986).
Currently available data do not permit a definitive statement
regarding the role of opioid peptides in thermoregulatlon. It is,
however, abundantly clear from data reviewed above that multiple
oploid receptors are involved. It appears likely that several types
of transmitters/modulators are involved in regulation of body
temperature in health and disease and that their relative importance
varies in various situations. It is necessary to study the effect
of specific agonists and antagonists at various opioid receptors in
several species, not only at different ambient temperatures but also
during pyrexia induced by different agents to assess their roles.
It is also necessary to study their interaction with other putative
neurotransmitters and to analyze in depth their effect on heat
production and heat loss mechanisms. There is evidence to indicate
that some of the peptides may be acting at sites such as the septum
(see below). Such sites have not been investigated for the effect
of oploid peptides.
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II. ANTIPYRETIC PEPTIDES
A. ACTH/MSH
ACTH and MSH, which were first isolated from pituitary tissue, are
widely distributed within the brain (Krieger and Martin 1981). They
were first shown to reduce temperature when given centrally to
rabbits (Lipton et al. 1984). Subsequently, ACTH and MSH were found
to be antipyretic when administered centrally or peripherally in
doses that had no effect on normal temperature (Murphy et al.
1983). The parent molecule ACTH (1-39) was actually the first
peptide with documented antipyretic activity. Most of the recent
research, however, has been focused on MSH. This peptide is about
25,000 times more potent than acetaminophen as an antipyretic
(Murphy et al. 1983). MSH reduces fever whether administered
i.c.v., i.v., or into the stomach of rabbits (Murphy and Lipton
1982). Its central site of action may be the septum, as injections
of MSH into the septum are also antipyretic. ICV administration of
ACTH reduces endotoxin-induced fever in squirrel monkeys, and MSH is
likewise antipyretic when given i.v. to these primates (Lipton and
Shih 1985). Corticotropin-releasing factor (CRF), which releases
ACTH/MSH from the pituitary, also reduces fever in a dose-related
fashion when given i.c.v. to rabbits.
The precise mechanism of action of MSH in reducing fever has not
been determined. However, it is unlikely that antipyretic doses
directly inhibit central heat production and conservation pathways,
since MSH has no effect on the temperature of a febrile rabbit
exposed to cold (Richards and Lipton 1984). The doses required to
induce the antipyretic and hypothermic effects of peptides differ.
These effects appear to represent distinct actions within the CNS.
Studies on hyperthermic responses to arachidonates suggest that
central release of MSH could mediate the antipyretic effect of
acetaminophen
B. Arginine Vasopressin (AVP)
The role in thermoregulation of arginine vasopressin, the
antidiuretic hormone in man, has been studied in the past. Most of
the supportive data have been obtained recently, however. Studies
of temperature-induced changes in plasma vasopressin levels or
diuresis have produced conflicting data. Concentration of AVP did
not change in the pig during exposure to warm, neutral, or cold
environments (Forsling et al. 1976). Cooling of the rostral
hypothalamus in cold and thermoneutral environments, or heating in
thermoneutral and warm environments, likewise did not affect
vasopressin levels. However, increasing core temperature to 42°C
caused a rise in plasma vasopressln that could be completely
suppressed by reducing preoptic/anterior hypothalamic temperature.
Brisk water diuresis was observed with preoptic/anterior
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hypothalamic cooling in rhesus macaques, presumably due to
inhibition of vasopressin release (Hayward and Baker 1968). These
findings suggest a relation between vasopressin and central
temperature control mechanisms. They give no indication, however,
that this relationship is important under normal circumstances. The
evidence for arginine vasopressin as an endogenous antipyretic is
strong but not yet conclusive. It includes direct suppression of
fever by the application of AVP in a sensitive, dose-dependent
manner by push pull perfusion into the region of the septum in
animals given intravenous pyrogens, and the appearance of AVP in the
perfusate after perfusion of the septal region with an artificial
interstitial fluid during fever. The vasopressin concentration is
inversely related to the magnitude of fever.
Hemorrhage, a well-known stimulus for the release of vasopressin
into the circulation, was found to be without effect on normal body
temperature but to suppress the fever elicited from intravenous
pyrogen. The application of an antibody to AVP in the septal region
led to a markedly greater rise in body temperature than would
normally occur from a fixed dose of endotoxin given intravenously
(Cooper 1987). AVP itself is without effect on normal body
temperature in the sheep when perfused through the ventral septal
area. Zeisberger et al. (1980) and Merker et al. (1983) have
demonstrated that the pregnant guinea pig close to term and several
hours post partum is refractory to endotoxin. In the nonpregnant
guinea pig during fever, AVP reactivity was increased in fibers
projecting from the hypothalamus to the septum and amygdala
(Zeisberger et al. 1983).
Arginine vasopressin suppressed pyrexia caused by intraventricular
injection of PGE when the AVP was perfused through the rostral
diencephallc loci at which PGs caused fever (Ruwe et al. 1985).
Evidence of the endogenous antipyretic action of AVP has been found
in rats (Kovacs and De Wied 1983). Banet and Wleland (1985) found
that AVP infused into the lateral septum of the rat suppressed the
heat production caused by hypothalamic cooling but did not affect
vasomotor tone in the skin. The reduction in thermoregulatory
increase in heat production that led to a fall of body temperature
during cold exposure might explain the antipyretic action of AVP.
Wilkinson and Kasting (1986) psesented evidence to indicate that
vasopressin reduces the set point for body temperature in febrile
rats.
Only one study (Lee et al. 1985) has evaluated the role of AVP in a
subhuman primate, macaque monkeys, where intraventricular AVP had no
effect on the normal body temperature or fever, except at a dose of
65 ng, where the mean fall of body temperature of 0.5°C appeared
to be due to a larger response in one animal. AVP has also been
shown to cause hyperthermia in rabbit (Lipton and Glyn-Ballinger
1980) but is without effect in cats and causes hypothermia or
hyperthermia when microinjected into the preoptic area in the rat
(Naylor et al. 1986).
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Arginine vasopressin might be a mediator of fever within the
anterior hypothalamus/preoptic anterior hypothalamus and an
antipyretlc within the ventral septal area. Such a dual function
would be consistent with a negative feedback system to modulate the
magnitude of' fever, a useful function if fever is a beneficial
accompanimert of disease. A role for AVP as a fever mediator as
well as an endogenous antipyretic is, however, far from conclusive.
III. OTHER PEPTIDES
A. Thyrotropin-Releasing Hormone (TRH)
TRH is the most extensively studied peptide, and it usually induces
a brief increase in temperature (Clark 1979). Cats respond with
hypothermia (Metcalf 1974; Myers et al. 1977), however, as do rats
(Lin et al. 1980) and nonhibernating ground squirrels (Stanton et
al. 1981). TRH-induced temperature changes are independent of its
action on the thyroid. Effects of TRH on body temperature were
determined over a range of ambient temperatures, but the pattern of
body temperature change in the majority of reports is consistent
with increase in the level of regulation. TRH has frequently been
observed to have a general excitatory action that would tend to
raise temperature by increasing heat production. It can enhance
locomotor and other behavioral activities alone and can reverse
behavioral depression, hypnosis, and anesthesia induced by other
agents (Clark and Lipton 1983).
The hyperthermic effect of TRH administered into the
preoptic/anterior hypothalamus of rats was unaffected by
pretreatment with aspirin, but was reduced by adrenergic antagonists
(Chi and Lin 1983). However, based on resistance to inhibition by
adrenergic antagonists, other investigators have concluded that the
noradrenerglc system is not essential for this response in mice
given TRH by intraperitoneal injection (Pawlowski and Kwiatek
1983). In another study, TRH given intraperitoneally to mice caused
hyperthermia that was associated with increased plasma
noreplnephrlne and eplnephrine concentration (Boschi et al. 1983).
Simultaneous injection of these catecholamlnes increased
hyperthermia. Adrenal demedullation suppressed both the increase in
plasma catecholamines and TRH-induced hyperthermia, but not the
hyperthermic response to TRH plus catecholamines. Hypophysectomy
also reduced --RH hyperthermia, in contrast to earlier reports, but
not the increase of plasma catecholamines or the effect of
combinations with exogenous catecholamines. These authors concluded
that both the adrenal and pituitary have essential roles in
TRH-induced hyperthermia. When injected into the hypothalamus of
pigeons, TRH induced hyperthermia, shivering, and vasodilation that
was probably compensatory (Lathi et al. 1983). Evidence that TRH
might be involved in the maintenance of body temperature has been
presented by Prasad et al. (1978, 1980). In this study, a
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dose-related decrease in temperature occurred when rabbit TRH
antiserum was injected into the lateral ventricle of rats. and this
response was prevented if the antiserum was neutralized with TRH.
B. Neurotensin (NT)
Neurotensin was initially isolated from bovine hypothalamus
(Carraway and Leeman 1973). The primary temperature response to
central administration of NT in a variety of species is hypothermia,
which is enhanced in cold environments. Neurotensin has been
reported to have less than one-thousandth the potency of bombesin in
rats exposed to cold (Brown et al. 1977), whereas under similar
conditions in mice both of these peptides were equipotent (Mason et
al. 1980). Injections of NT into 223 brain sites in rat (Kalivas et
al. 1982) indicated that regions responsive to its hypothermic
action are distinct from sites at which it inhibits nociception.
Administration of NT into the periaqueductal gray had no clear
effect on normal body temperature (Kalivas et al. 1982). The
N-terminal fragments of NT were inactive, but a C-terminal fragment
(8-13) did lower temperature (Widdowson et al. 1983). Neurotensin
also lowered the temperature of guinea pigs and hamsters only in a
cold environment and did not change the temperature of fish, frogs,
lizards, pigeons, ground squirrels, woodchucks, and rabbits (Prange
et al. 1979).
The research on the mechanism of action of NT has been limited to
studies on interactions with other substances. Intracisternally
administered NT potentiated the hypothermic response of ethanol
(Luttinger et al. 1981) and of dopamine agonists (Jolicoeur et al.
1983), but inconsistent effects were obtained with pentobarbital-
induced hypothermia (Nemeroff et al. 1977). The hypothermic
response to NT in rat was antagonized by i.c.v. administration of
prostaglandin E2 and by calcium chelator EGTA (Lee et al. 1983) but
not by TRH. somatostatin, or naloxone. The hypothermic response was
also antagonized by amine and cholinergic antagonists (Morley et al.
1982) and was enhanced by thyroidectomy (Nemeroff et al. 1980).
Since central administration of EGTA and PGE2 alone causes
hyperthermia, a nonspecific antagonism may be responsible for
preventing the hypothermic effect of NT at thermoneutral
environment. Mason et al. (1982) suggested that release of central
prostaglandlns may oppose the hypothermic response of NT in cold
environment. Lee and Myers (1983) concluded that NT renders the
animals poikilothermic, because NT caused hypothermia in rats in
thermoneutral and cold environments but not in hot (34°-4O°C)
environment.
C. Bombesin
Bornbesin was originally isolated from frog skin (Anastasi et al.
1972, 19751. The central administration of bombesin caused
hypothermia in rat and mouse at normal laboratory temperatures. The
magnitude of the fall in the temperature has generally been dose
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related. However, systemically given bombesin did not affect the
temperature of rats in the cold (Brown et al. 1977; Brown and Vale
1980). It was subsequently found that injections of bombesin into
the PO/AH of rats increased locomotor activity and enhanced both
heat reinforcement and heat escape behavior (Hawkins and Avery
1983). It was concluded that the effects on behavior are secondary
to the change in activity and do not demonstrate that bombesin
lowers the regulated temperature. Avery and Calisher (1982) showed
that in a thermoneutral environment i.c.v. bombesin caused
dose-related decrease in body temperature and food intake of
food-deprived rats.
D. Somatostatin
Nemeroff et al. (1979) found that intracisternal administration of
somatostatin in mice caused hyperthermia at normal laboratory
temperature. Brown et al. (1981) did not find any change in body
temperature of rat after intracisternal administration of
somatostatin in cold environment. Lateral ventricular
administration of somatostatin also did not alter the temperature of
rabbits (Lipton and Glyn 1980). In only one study somatostatin
caused hyperthermia at high ambient temperature and hypothermia at
low ambient temperature (Chandra et al. 1981). The pattern of
associated effector changes was unusual in that the hyperthermic
response at ambient temperature was associated with vasoconstriction
and an increase in metabolic rate, whereas the hypothermic response
at lower ambient temperature was associated with vasodilation and
decreased metabolism. Morley et al. (1982) elicited a small
decrease in temperature of rats with i.c.v. injection of
somatostatin (10 µg). which was even less if given with TRH.
Somatostatin did not appreciably affect changes in temperature
induced by bombesin or neurotensin. Intracisternal administration
of somatostatln 10 min after pentobarbital did not alter the
hypothermic response to the barbiturate (Breese et al. 1975).
However, a slight enhancement by i.p. somatostatin of
pentobarbital-induced hypothermia has been reported in the mouse
(Prange et al. 1975).
E. Angiotensin II
The major response to central administration of angiotensin in most
of the species has been a fall in temperature; the monkey, when
experiments were conducted in a hot environment, was an exception
(Clark 1979). Later, Lin and coworkers (1980) reported that central
injection of angiotensin to rats did not alter body temperature when
the ambient tenperature was 30°C but caused comparable
dose-related hypothermia at lower ambient temperatures. The
hypothermic response was inhibited by pretreatment with propranolol
or by depletion of whole brain catecholamines with
6-hydroxydopamine. Depletion of brain serotonin by
5,6-dihydroxytyptamine did not inhibit the response to angiotensin,
nor did prior administration of atropine or phentolamine. They
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concluded that the hypothermic action of angiotensin II is due to
its effects on the mechanisms that promote reduced metabolism and
increased heat loss. The heat loss effecters vary in different
species.
IV. KININS
Small hyperthermic responses, which were associated with increased
muscle tone, ear vessel vasodilation, and piloerection were
inhibited by pretreatment with indomethacin and acetaminophen.
These responses were recorded after lateral ventricular
administration of bradykinin to rabbit (Almeida et al. 1978).
However, i.c.v. administration of bradykinln to rat (Francesconi
and Mager 1981) and to mouse (Nemeroff et al. 1979) did not alter
body temperature. Similarly, substance P caused a small rise in
temperature of rabbit when given in the third ventricle. This
hyperthermic response was reduced by pretreatment with indomethacin,
phenobarbital, or phentolamine but not by acetazolamide, atropine,
capsaicin, or propranolol (Krupin et al. 1982). In the rat,
substance P was consistently ineffective in altering temperature
whether given i.c.v., i.v., or intracisternally at any ambient
temperature.
V. CONCLUDING REMARKS
Attention has been focused on the role of neuropeptldes in
thermoregulation, because many of them are found within
neuroanatomical sites important to temperature control and exert
profound effects on body temperature. As with several other classes
of putative neurotransmitters, the effect seen is dependent on
species, ambient temperature, degree of restraint imposed on the
subject, route of drug administration, and several other factors.
For neuropeptides also the effect observed is dependent on several
factors. A limiting factor has been the unavailability of selective
pharmacological antagonists in many classes. Specific antisera to
many peptides have, however, become available in recent years. The
physiological relevance of a peptide to temperature control could be
studied by inactivation of the endogenous peptide through local
treatment with specific antibodies. There is evidence that certain
peptldes such as bombesin, which disrupt thermoregulation, have no
physiological significance in temperature control (Clark and Lipton
1983). For many of the peptides, the data available are not yet
adequate to determine their roles as mediators in central
thermoregulatlon. As noted above, however, convincing data exist to
support an antipyretic role for certain peptides, such as ACTH/MSH.
To understand the physiological role of central peptldes in
thermoregulation. several methodological factors should be
considered in future studies. The effect of peptides should be
tested in animals exposed to cold, hot, and thermoneutral
environments. This will make it possible to assess the functional
nature of the peptide effect. Past research clearly reveals that
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species differences do exist for the temperature responses obtained
by the central administration of peptides. These may reflect either
real differences in the utilization of specific peptides in
temperature control or artifactual differences due to physical
factors such as variation in spread of peptide to active sites after
intracerebral injections. Many systems of the brain are involved in
thermoregulation, and multiple contributions of a given neuropeptide
to thermoregulatory control may lead to conflicting results when the
peptide is injected into different brain regions. It is already
known that endogenous peptide levels are affected by stress, and it
has been shown that opiate-induced temperature responses are
reversed by restraint stress. Stress may be reduced by avoiding
restraint; all all studies, of course, appropriate use of control
animals is essential to minimize misinterpretation of data, since
stress can naver be eliminated from the experiments with conscious
animals. The route of administration also plays an important role.
Thus it has been shown that intracerebroventricular administration
of most agonists, including agonists, produced
hyperthermia. possibly because mostly in receptors are reached by
that route (Geller et al. 1986).
It is also important to recall that the thermoregulatory apparatus
utilizes other major body systems (respiratory, cardiovascular, and
others). Thus, for example, a centrally acting peptide that
primarily affects the distribution of peripheral blood flow could
secondarily alter body temperature and be thought erroneously to act
directly on thermoregulatory controls. Direct actions on
thermoeffectcr pathways can generally be discovered in experiments
carried out in disparate thermal environments. These considerations
underline one obvious conclusion: only through triangulation of
information from experiments using different methods can the
importance of a neuropeptide to thermoregulation be established.
Techniques that are relatively new in this field, such as assay of
peptides in brain samples taken from febrile, hypothermic, and
hyperthermic animals, and immunoneutralization coupled with pyrogen
administration or direct thermal challenge, can provide convincing
evidence about the role of specific peptides in physiological
control of body temperature. There are technical difficulties and
other problems with these approaches, but there is little doubt
about the advantages they provide.
A second major question in research on neuropeptides is whether they
may eventually have some clinical application. In the case of
thermoregulation, as with several other functions, it is too early
to predict. There is considerable hope, however, that applications
will be found once the roles of central neuropeptides are
understood. We speculate that the mechanism of action of
temperature-altering agents such as pyrogens may be explainable in
terms of alterations in central peptides. Naturally occurring
changes in these peptides with aging, metabolic diseases, etc., may
contribute to the increased incidence of dysthermia in certain
populations. Further, the discovery of the temperature-altering
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effects of peptides may lead to new therapeutic compounds for
antipyresis. for induction of surgical hypothermia, and for
treatment of dysthermias such as heatstroke and accidental
hypothermia.
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ABSTRACT
Possible involvementofendogenousopioids inhumoral immune responses
has been explored in the experimental animals. Opioid agonists like
morphine and leu-enkephalin significantly enhanced antigen-induced
histamine release from the peritoneal mast cells of sensitised rats in
vitro; this was effectively antagonised by naloxone. Naloxone itself
inhibited antigen-induced histamine release. Animals were effectively
protected against anaphylactic shock by naloxone which also antagonised
morphine-induced increase in anaphylactic mortality. Naloxone reduced
haemagglutination titre to sheep red blood cells and IgE antibody titre
as measured by passive cutaneous anaphylaxis. Thus, endogenous opioids
appear to be involved in the mediation of humoral immune responses.
They seem to act at various steps in the immune mechanism viz (i)
antibody production and (ii) release of mediators of hypersensitivity
reactions.
INTRODUCTION
In the cities we live in, we are surrounded all over by a polluted
atmosphere containing billions of heterogenous substances which are
foreign to our system. Although most of us can withstand an onslaught by
these agents, a considerable number of individuals respond violently
and develop various types of immunological disorders. It is, however,
not known why only some and not all persons respond violently to these
offending substances. It has been reported that many psychosocial
situations and stressful conditions can modify host resistance to a
variety of illnesses including allergic and infectious disorders and
influence the immune processes of an individual (Solomon and Amkraut
1981). Hypothalamus is known to be a centre for correlation and co-
ordination of the autonomic and endocrinal activities with the
emotions of an individual. Stein et al. (1976) observed that in
sensitised animals lesion of the anterior hypothalamus produced
significant protection against anaphylaxis, lowered the titre of
the circulating antibodies, and also depressed the delayed type of
209
hypersensitivity reactions. Hypothalamus is rich in neurohormones
and neurotransmitters, which may affect immune functions. Opioid
peptides are one such group of hypothalamic neuropeptides. A num-
ber of reports indicate that administration of opioids or opioid
antagonists can modulate the immune competence (Lancet 1984).
Hence, it was considered worthwhile to explore the possible role
of endogenous opioids in immune responses.
MATERIALS AND METHODS
The experiments were carried out mainly on Wistar rats (100-150 gms)
and Swiss mice (20-30 gms) of either sex. They were obtained from the
local source and fed on Hind Lever Laboratory animal feed with water
available ad lib. Animals were sensitised using egg albumin (EA) or
sheep red blood cells (SRBC) as antigens. Freund's complete adjuvant
and B. pertussis were used as adjuvants. The results were statistically
analysed by Chi2 test or t test as appropriate.
Acute Systemic Anaphylaxis In Mice
Four groups of mice (15-25 in each group) were sensitised by injecting
subcutaneously 0.2ml EA(25mg/ml) along with 0.5ml of triple antigen
(containing 20,000x 10°B. pertussis organisms) and 0.2ml of Freund's
complete adjuvant. On the 12th day following sensitisation, control
group received 0.2 ml of normal saline; one group was given naloxone
10mg/kgi.p., second group receivedmorphine in a dose of 10mg/kg i.p
and third group was administered naloxone (10mg/kg) along with
morphine (10mg/kg). Thirty minutes after the drug pretreatments all
the groups were challenged with 0.2 ml EA i.v., and mortality was
recorded after two hours.
Histamine Release From The Peritoneal Mast Cells Of Sensitised Rats In
Vitro
Histamine release from the peritoneal mast cells was studied by the
method of Chakravarty et al. (1973). Rats were sensitised by injecting
subcutaneously 0.5 ml (25 mg/ml) along with 0.5 ml triple antigen
(containing 20,000 x 10°B. pertussis organisms) and 0.5 ml Freund's
complete adjuvant. Rats were sacrificed by exsanguination on the 14th
day; peritoneal cell suspensions were prepared and divided into 10-12
samples. Cells were usually pooled from two sensitised rats. Samples
were treated with various drugs under investigation (opioid agonists
and antagonist) and incubated at 37°C under gentle shaking for 10
minutes. The antigen (0.5 mg/ml EA) was added to the cell suspension
and the incubation, thereafter, continued for another ten minutes. The
reaction was terminated by placing the samples in ice cold water.
Adequate controls using agonists or antagonist alone were included.
Histamine content of different samples was estimated by biological
assay using isolated guinea pig ileum. Control histamine release as
well as spontaneous release values were detected from the results.
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Haemagglutination Titre To Sheep Red Blood Cells (SRBC)
Twogroups of 6 mice were immunized by injecting 1 x 109SRBC i.p. One
group was given naloxone 5 mg/kg twice daily from day 1 to 5 and the
control group received normal saline in the same schedule. Animalswere
bled on the 8th day and sera separated. Two fold dilutins (0.025ml) of
the seraweremade inthemicrotitre plates with normal saline. To each
well 0.025 ml of 1% (V/V) SRBC was added. The plates were incubatedat
37°C for one hour and then observed for haemagglutination.
Passive Cutaneous Anaphylaxis
This was studied in two groups of 6 rats sensitised with 0.5 ml EA
(25mg/ml) with 0.5 ml triple antigen (containing 20,000 x 106B.
pertussis organisms) and 0.5 ml of Freund's complete adjuvant
subcutaneously. The test group received naloxone 5 mg/kg twice daily
from day 1 to 5 while the control group received normal saline. Animals
were bled on the 6th day and sera collected. Serial dilutions of the
sera were made,and O.1ml of different dilutions was injected into the
shaven dorsal skin of normal rats. 72 hours later i.v. challenge was
given with EA (0.5ml) and Evan's blue (1%,0.2ml) and blueing reaction
at test site was observed after one hour.
RESULTS
Effect On Acute Systemic Anaphylaxis
Pretreatment with naloxone (1Omg/kg) significantly protected animals
against anaphylactic shock; mortality was reduced from 56% in the
control group to 32% in the naloxone pretreated group (p<0.01).
Morphine pretreatment (10mg/kg) enhanced anaphylactic mortality which
was effectively antagonised by naloxone (p<O.001; Table 1).
Effect On Antigen Induced Histamine Release
Opioid agonists like morphine (100 µM) and leu-enkephalin (10 µM)
significantly enhanced antigen induced histamine release from the
peritoneal mast cells of sensitised rats in vitro; this enhancement was
effectively antagonised by naloxone (Table 2(i) and 2(ii)). Naloxone
(1 µM) pretreatment itself significantly inhibited antigen induced
histamine release (p<0.01, Table 3).
Effect On Haemagglutination Titre To SRBC
In the control group in all the 6 i.e., 100% animals the detectable
level of haemagglutination titre was between 1/128 and 1/2048.
Pretreatment with naloxone reduced the detectable level of
haemagglutination titre to 1/2 - 1/16 in all the 6(100%) animals (Table
4).
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TABLE 1. Effect of Naloxone and Morphine on Acute Systemic
Anaphylactic Mortality in Mice
Group No. of Senitization (Day 12) %
Animals (Day 0) Drug Pre- Chal- Mortality P
treatment lenge
1 25 EA+DPT+FA Normal Saline EA 56.00
2 25 EA+DPT+FA Naloxone EA 32.00 <0.01
10mg/kg I.P.
3 23 EA+DPT+FA Morphine EA 78.26
10mg/kg I.P.
<0.01
4 15 EA+DPT+FA Morphine
10mg/kg I.P.
EA 33.33
Naloxone
<0.001
10mg/kg I. P.
EA- Egg albumin 0.2ml(25mg/ml)
DPT- Triple antigen 0.5 ml (containing 20,000,X 106B. pertussis
organisms)
FA- Freund's complete adjuvant 0.2 ml
TABLE 2(i) Effect of Morphine and its Modification by Naloxone on
the Antigen Induced Histamine Release from Peritoneal
Mast Cells of Sensitized Rats in Vitro
Expt. % Histamine Release
No. Egg Albumin (EA) EA+Morphine
(0.5mg/ml) (100 µM)
EA+Morphine+Naloxone
(1 µM)
A B C
1. 16.0 31.6 4.4
2. 10.5 27.7 12.4
3. 17.4 32.4 7.3
4. 31.7 39.4 21.7
The differences between columns A and B (p<0.01) and B and C
(p<0.01 are significant by t test for paired comparison.
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TABLE 2(ii) Effect of Leu-enkephalin and its Modification by Naloxone
on the Antigen Induced Histamine Release from Peritoneal
Mast Cells of Sensitized Rats in Vitro
Expt. % Histamine Release
No. Egg Albumin(EA) EA+Leu-enkephalin EA+Leu-enkephalin+
(0.5mg/ml) (10 µM) Naloxone (1 µM)
A B C
1. 17.4 34.1 5.5
2. 10.5 24.0 12.0
3. 16.0 34.0 4.0
4. 31.7 49.6 6.7
The differences between columns A and B (p<0.001) and B and C
(p<O.05) are significant by t test for paired comparison.
TABLE 3. Effect of Naloxone on the Antigen Induced Histamine
Release from the Peritoneal Mast Cells of Sensitized Rats
in Vitro
Expt. % Histamine Release
No. Egg Albumin (EA) EA+Naloxone
(0.5 mg/ml) (1 µM)
A B
1. 11.9 4.3
2. 33.3 3.7
3. 16.0 5.0
4. 10.5 0.5
5. 17.4 6.7
6. 31.7 10.6
The difference between columns A and B is significant (p<0.01) by
t test for paired comparison.
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Table 4. Effect of Naloxone on Haemagglutination Titre to Sheep Red
Blood Cells (SRBC) in Mice
Group Pretreatment No. of Antibody Detectable Level of Hae-
Animals Not Det- magglutination titre
ectable 1/2-1/64 1/128-1/2048
1. SRBC 6 0 0 6
(1x109I.P.) (100%)
+
Normal Saline
(from day 1 to 5)
2. SRBC
+
Naloxone 6 0 6 0
(5mg/kg BD- (100%)
from day 1 to 5
Animals wre bled on 8th day after the sensitization with SRBC.
Effect on Passive Cutaneous Anaphylaxis
The detectable level of IgE antibody in the control animals was between
1/1 - 1/10 in 33.33% and up to 1/100 in 66.67% of the animals. In the
naloxone treated group, on the other hand, in 50% of the animals the
antibodies could not be detected, while in 16.67% cases it ranged
between 1/1 - 1/10 and up to 1/100 in 33.33% cases (Table 5).
Discussion
Hypothalamus and other areas of the brain have several
neurotransmitters including endogenous opioids. Recently it has been
reported that hypothalamus is activated by the immune system which by a
feed back mechanism may modulate the immune responses (Besedovsky and
Sorkin 1977; Stein et al. 1976). Opioid agonists and antagonists have
been shown to modulate the immune competence (Lancet 1984). An agent
may affect the immune system by acting atone or more than one step in
the immune mechanism. Our experimental studies were confined to
finding out the roleofendogenous opioids in humoral immune responses
in albino rats and mice using egg albumin and sheep red blood cells as
antigens and Freund's complete adjuvant and B.pertussisas adjuvants.
In the initial experiments, role of opioids in acute systemic
anaphylaxis was studied. Naloxone, an opioid antagonist when given in
a dose of 10mg/kg i.p., significantly protected animals against
anaphylactic shock. This corroborates the findings of Amir (1982) who
showed that administration of naloxone and naltrexone provided a
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TABLE 5. Effect of Naloxone on Passive Cutaneous Anaphylaxis in
Rats
Group Pretreatment No. of Antibody Detectable Level of IgE
Animals NOt Det- Antibody
ectable 1/1-1/10 1/100
1. EA+DPT+FA 6 0 2 6
+ (33.33%) (66.67%)
Normal Saline
(from day 1 to 5)
2. EA+DPT+FA
+
Naloxone 6 3 1
(mg/kg BD-
2
from day 1 to 5)
(50%) (16.67%) (33.33%)
EA- Egg albumin 0.5 ml (25mg/ml)
DPT- Triple antigen 0.5 ml (containing 20,000 x 106B. pertussis
organisms)
FA- Freud's complete adjuvant 0.5 ml
significant protection against anaphylactic shock. Morphine, an
opioid agonist, however, enhanced anaphylactic mortality which was
effectively antagonised by naloxone (Table 1). The present findings
that apparent blockade of opioid receptors protects against
anaphylactic shock suggest a role for endogenous opioids in the
pathophysiology of systemic anaphylaxis, a condition associated with
antigen antibody interaction.
To further elucidate the involvement of endogenous opioids in immune
mechanisms, experiments were done to study the effect of opioids on
histamine release, the latter being an important mediator of antigen-
antibody reaction. Opioid agonists like morphine (a µ receptor
agonist) and leu-enkephalin (a delta receptor agonist) produced a
significantincreaseintheantigen induced histamine release from the
peritoneal mast cells of sensitised rats in vitro. This increase was
effectivelyantagonised bynaloxone (Table 2(i) and 2(ii)) suggesting
thereby that the potentiating effect of opioid agonists on antigen
induced histamine release is mediated by opioid receptors and both µ
and delta receptors appear to be involved. Involvement of µ and delta
opioid receptors has also been reported for IgE mediated serotonin
release from rat mast cells (Yamasaki et al. 1982). Naloxone 'perse'
also significantly inhibited antigen induced histamine release from
peritoneal mast cells of sensitised rats in vitro (Table 3) indicating
a role of endogenous opioids in the mediation of antigen induced
histamine release. The protective effect of naloxone against
anaphylactic shock observed in the present study (Table 1) could be
because of its inhibitory effect on the mediator release.
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Experiments were also done to find out the role of endogenous opioids on
antibody production. Naloxone administration effectively reduced
haemagglutination titre to SRBC in mice (Table 4), suggesting an effect
on IgG and/IgM antibodies. Naloxone pretreatment also suppressed IgE
antibody production as measured by passive cutaneous anaphylaxis in
the present study. In the naloxone treated group antibody production
was completely inhibited in 50% of the animals (Table 5). Thus, it is
observed that apparent blockade of opioid receptors by naloxone
suppressed formation of anti SRBC and IgE antibodies,i.e.,endogenous
opioids, appear to be involved in the synthesis of these
immunoglobulins.
In conclusion, the present findings suggest that endogenous opioids
appear to be involved in the mediation of humoral immune responses.
They seem to act at various steps in the immune mechanism viz(i)
antibody production and (ii) release of mediators of hypersensitivity
reactions.
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The discovery of enkephalins by Kosterlitz and colleagues (Hughes
et al. 1975) was immediately followed by an era of synthesis of a
large number of opioid peptides. At present, a great deal of
attention is being paid to conformational analysis, receptor
biochemistry, mechanism(s) of action, addiction mechanisms, and
physiological actions of opioids. The chemistry and biology of
opioids have been extensively reviewed (Udenfriend and Meienhofer
1984; Rapaka 1986; Rapaka and Hawks 1986; Rapaka et al. 1986; Olson
et al. 1987; Dhawan and Rapaka 1988). This article is intended to
focus on selected topics only and is not a thorough review. More
detailed information is available from the above reviews. In this
article, the importance of using pure peptides and the need for
extensive characterization of these peptides is emphasized. In
addition, some of the recent advances in synthetic methodology,
rationales for some of the newly synthesized
specific ligands, conformational properties of opioids, the role of
lipids in conformational induction of llgands, and a few selected
biological aspects (such as immunomodulation by opioids) are
briefly discussed.
Numerous opioid peptides have recently been synthesized and
evaluated for various biological activities. In order to obtain
dependable data, a pure compound is essential and purity of the
compound cannot be overemphasized. Much more rigorous analytical
testing should be undertaken for commercial samples and for those
compounds that are synthesized by solid phase peptide synthesis.
As there is no way of establishing absolute purity, as many
criteria as possible should be employed to establish the purity of
the product. If the peptide is synthesized in-house, the material
is likely to be checked for purity at each stage and the end
product is therefore likely to be pure. Due to the ready
availability of new products from several commercial suppliers, and
the facilities for custom synthesis, a large number of studies now
utilize commercial samples. Recently. Brown et al. (1986) reported
on the problems associated with commercial peptides. Samples of
the tachykinin-related peptides were analyzed from several
commercial sources. Some of the problems encountered were
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these: (1) peptides had incorrect sequences; peptides might have an
incorrect residue, or material supplied might be a mixture of the
peptides; (2:) peptide content varied as much as three- to sixfold;
(3) for radiolabeled compounds, radioactivity might not be
associated with the authentic substance. These findings indicate
that results obtained with these compounds will make the data
worthless and adequate quality control checks must be made for
these compounds prior to their use. Amino acid analysis,
sequencing data, TLC data in several systems, HPLC analysis in at
least two solvent systems, elemental analysis, and any other
pertinent physicochemical data should be obtained prior to their
use. In addition, optical purity and radiochemical purity (in the
case of using labeled products) of the peptides is also critical.
A measure of optical rotation alone will not guarantee an optically
pure product. Enzyme digestions (Rapaka et al. 1976, 1977) to
establish the optical purity, along with utilization of synthetic
methods that yield optically pure products, might be helpful.
Radiochemical purity of the labeled product should be determined,
and since some of the labeled products are unstable, chemical
purity should also be determined prior to use.
Batch-to-batch variation should always be monitored. This problem
may be much more important with solid phase peptide synthesis than
with synthetic material obtained from conventional methods. All
batches should be compared with a reference standard batch.
Recently, Taylor et al. (1986) reported that anomalous binding of
DPDPE resulted due to batch variability, and the results from the
impure batch indicated a two receptor model instead of a single
receptor model. HPLC purification of the material yielded
chromatographically pure compound and gave the predicted results.
Hence, even a minor component can potentially lead to erroneous
conclusions.
The chemical complexity of peptides makes the analysis of peptides
very difficult and demands utilization of innovative, extremely
specific, and sensitive methods. In spite of the recent advances
(Desiderio et al. 1986; Fridland and Desiderio 1987; Sternson 1987)
in analytical techniques for the analysis of peptides, adequate
methodology for the analysis of extremely small amounts of opioid
peptides, their precursors and metabolites, is not currently
available. FAB-MS and LC analysis is increasingly being utilized
successfully in the area of peptide analysis (Canova-Davis et al.
1988).
The developmert of solid phase peptide synthesis (SPPS) was
instrumental in providing a large number of peptides for
structure-activity studies. Following the development of solid
phase peptide synthesis by Merrifield (1963), many other methods
have been explored to simplify and to automate the synthesis. None
of them have really been widely accepted. Recently, Houghten and
colleagues have reported a modified solid phase method that is
simple (Houghten 1985; Houghten et al. 1986a,b. 1988). This method
permits simultaneous synthesis of up to 100 or more peptides
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of up to 15 residues in length. The synthesis is fast, and these
analogs can be synthesized within a month. No special equipment is
needed, and the procedure is not labor-intensive. This method is
referred to as the simultaneous multiple peptide synthesis (SMPS),
and it involves placing the solid phase resin in a porous
polypropylene packet. Several such packets (up to 100 or so)
containing the protected amino acid resin can be deprotected
together in a Nalgene bottle. Coupling steps are performed in
different containers. After the coupling step, the resin packets
are returned to the common reaction bottle and the synthesis is
continued. At the end of the desired synthesis, the peptide can be
cleaved utilizing an apparatus that permits simultaneous cleavage
of several samples (up to 24). After the peptides are liberated
from the resin, they are purified by routine methods. Thus SMPS
permits the synthesis of a large number of peptides with reduced
time and cost, and it appears to be suitable for the synthesis and
evaluation of a large number of analogs for structure-activity
studies.
Another interesting approach to obtain complex and difficult-to-
synthesize peptides for structure-activity studies is through the
expression of synthetic genes (for a review, see Taylor, this
volume). Standard methods of peptide synthesis, either
conventional or solid phase methods, are too cumbersome for the
preparation of large numbers of peptides, their deletion analogs,
and analogs incorporating natural and unnatural amino acid
residues. The approach of utilizing synthetic genes and
recombinant DNA technology is an attractive alternative to
conventional peptide synthesis. This involves synthesis of the
desired oligonucleotide sequence and preparation of mutant gene
coding for the desired analogs followed by expression. Mutagenesis
of the synthetic gene code of the natural structure is the critical
step in the generation of the analogs. Mutagenesis may be induced
in either a random or a more controlled fashion. Chemicals such as
hydrazine, nitrous acid, and sodium bisulfite have been used, as
well as physical methods, such as UV irradiation. Other methods
include purposeful introduction of one or more restriction enzyme
recognition sites to achieve chosen mutations and oligonucleotide
directed mutagenesis. Oligotide directed mutagenesis appears to be
the most commonly used, and the phosphorothiate DNA method for
mutagenesis is one of the most efficient methods to achieve an
oligonucleotide directed mutagenesis. Methodologies for the
expression of the synthetic gene and purification of the product
have been reviewed extensively (see Marston 1986).
Numerous selective opioid analogs have been
synthesized, and several reviews have already appeared (Morley
1980; Hansen and Morgan 1984; Morley and Dutta 1986; Udenfriend and
Meienhofer 1984). Here, some of the recently synthesized analogs
are discussed briefly. One of the usual approaches was
"conformational restriction" by cyclization. Synthetic analogs,
H-Tyr-Cyclo [-D-A2bu-Gly-Phe-Leu-] (DiMaio and Schiller 1980;
DiMaio et al. 1982), homologs containing amino acid residues of
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varying chain lengths in position 2 (Schiller et al. 1985; Schiller
1986), and related retro-inverso homologs (Berman et alN 1983) were
µ-selective compounds. Later, a cyclic tetrapeptide
H-Tyr-D-Orn-Phe-Asp-NH2
was designed by Schiller et al. (1985). and pharmacological
characterization revealed that it was one of the most µ-selective
compounds.
Another approach to the development of P-receptor specific
peptides was utilized by Hruby and colleagues (1988). In this
approach, a synthetic analog related to the somatostatin fragment,
D-Phe-Cys-Phs-D-Trp-Lys-Thr-Cys-Thr(ol), which interacts weakly
with opioid receptors as well, was utilized as a template to the
development of opioid ligands of high receptor affinity. Following
a detailed structure-activity study, a number of µ-receptor
selective analogs, such as
H-D--Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 (CTP),
were developed. Some of these analogs exhibited decreased affinity
for somatostatin binding and a high specificity. This
template was further extended to analogs containing
tetrahydroisoquinoline moieties. This represents a successful
manipulation for modulation of one major physiological activity
into another activity. Conformational studies on these analogs
might shed light on conformation-receptor selectivity
relationships.
Recently, novel µ-selective analogs with antagonist activity were
reported by Judd et al. (1987). The analogs were obtained by
modifications of the Tyrl residues of D-Ala2-Met5-
enkephalinamide, and the modified tyrosine residues were m-Tyr,
ß-methyl-m-Tyr, , ß-dimethyl-Tyr and N-phenethyl-m-Tyr.
Biological evaluation of these analogs revealed that (1) shifting
of phenolic-OH from the ortho to meta position enhanced relative
antagonist activity, (2) addition of ß-CH3 to m-Tyr enhanced
P-selectivity. (3) analogs with P-selectivity had a common
energy access ble 2-3 B 11' turn, (4) , ß-dimethyl-m-OH,
Tyr1-analog had a low affinity and an N-phenylethyl analog was a
pure antagonist. A rationale for design of peptides based on
structural comparison to an opiate compound [3-(m-OH
phenyl)-piperidine] was presented.
One of the earliest successful syntheses of receptor-selective
ligands was that of a s-receptor specific compound, D-Pen2,
D-Pen5-enkephalin. Two other examples of -selective analogs
are linear herapeptides, DTLET and DSLET. and these analogs have
been extensively used as -receptor probes. Recently, Roques and
colleagues reported the synthesis of analogs of
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H-Tyr-Ser-Gly-Phe-Leu-Thr-OH and H-Tyr-Thr-Gly-Phe-Leu-Thr-OH
(Delay-Goyet et al. 1988). The three analogs reported are
[D-Ser2(0-t-butyl), Leu5] enkephalinyl-Thr6, DSTBULET;
[D-Ser2(O-t-butyl), Leu5] enkephalinyl-Thr6 (o-t-butl),
BUBU; and [D-Thr2(0-t-butyl), Leu5]-enkephalinyl-Thr6
DTTBULET. DSTBULET displays a higher affinity for rat brain
membrane preparation than DSLET and [D-Pen2, Pen5] enkephalin.
DSTBULET has a high specific binding, and it is resistant to
degradation by peptidases present in the crude rat brain membrane
preparation (a t1/2 of 1 hr, compared to t 1/2 of 10 min for
Met-enkephalin). BUBU is an even more selective -receptor
ligand. However, DTTBULET is an inactive ligand. These ligands
are apparently influenced by the large conformational changes
induced by the bulky t-butyl groups. It was suggested that these
analogs are better probes, as the other two -selective analogs,
DPDPE and DPLPE, although highly -receptor specific, have
variable affinity depending on the preparation, toxic effects are
exhibited at higher concentrations, and more important, have
comparatively lower affinity for the receptor site.
Although a large number of µ- and -selective peptides have
already been reported, very few -receptor selective peptide
ligands have been reported to date. Recently, Schiller et al.
(1988) reported conformationally restricted dynorphin analogs such
as [D-Orn2 Asp5]-dynorphin A-(1-8). However, these peptides
are no long -receptor selective, but µ-receptor selective.
This led the authors to hypothesize that these cyclizations
resulted in overall folded conformations, which are incompatible
with the conformational requirements of the -receptor.
Conformational aspects of the peptides are being actively
investigated to help design potent and receptor specific compounds,
and to understand conformation-receptor selectivity relationships.
1H NMR studies were performed on a number of -selective
penicillamine-containing enkephalin analogs by Mosberg and
colleagues (Mosberg 1987; Mosberg et al. 1987). Discrepancies of
conformation-dependent NMR parameters between DPDPE and DPLPE
(which have similar -selectivities) were observed. It appears
that the Gly residue is flexible and as such plays a crucial role,
altering its local conformation to allow similar spatial
relationships between key groups in different analogs leading to
-affinity. From NMR data, conformational features of DPDPE and
DCDPE appear very similar. However, DPDPE is much more
-selective and less potent as compared with DCDPE. This
suggests that gem-dimethyl groups of Pen2 in DPDPE lead to
adverse reaction. The adverse steric reaction may be much greater
at µ-sites than at -receptor sites. Studies on the ring
expanded analogs of DPDPE and DPLDPE revealed that increasing the
ring size led to a reduction in -receptor selectivity and that
expanded conformations favored µ-receptor binding, whereas
compact conformations are favorable for -receptor binding.
Analogs containing bulky t-Leu residue(s) revealed that bulky
substituents at residue 2 decrease affinity to -receptors and
even more so to µ-receptors.
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In a related study by Belleney et al. (1987), conformational
properties of DTLET, (H-Tyr-D-Thr-Gly-Phe-Leu-Thr-OH) and
D-Pen2, L-Pen5-enkephalin (DPLPE) were determined by 1H NMR
spectroscopy. The results, surprisingly, indicated similarities in
the overall structure for the two-folded backbone conformations for
the constrained DPLPE and the flexible peptide DTLET. Relative
orientations of the Tyr and Phe residues were found to be similar.
Interestingly, the Tyr-Phe distance was 10 A° for both the
peptides, which reflects a quasilinear backbone orientation. This
extended conformation may be associated with -receptor
selectivity. From these studies it was hypothesized that
incorporation of sterically bulky residues at positions 2 and/or 6
in DSLET and DTLET would reinforce structural analogy to DPDPE-like
peptides, thus leading to inhibition of µreceptor binding.
However, this should still permit -receptor affinity due to the
inherent flexibility of the linear hexapeptide. The above
hypothesized analogs have been recently synthesized and were shown
to have high affinity as well as high selectivity for the
s-receptor (Delay-Goyet et al. 1988). In spite of a large number
of studies, conformation-receptor selectivity relationships are not
adequately understood.
The role of the lipid phase of the membrane for the facilitation of
ligand-receptor interaction has been addressed earlier (Schwyzer et
al. 1982; Gysin and Schwyzer 1983; Erne et al. 1985; Sargent and
Schwyzer 1986; Schwyzer 1986). Erne et al. (1985) demonstrated
that interaction of dynorphln A-(1-13) with the lipid membrane
results in the formation of an -helix at the N-terminal (from
1-9, and helix formation beyond the 9th residue is inhibited by Pro
10). The N-terminal message portion is perpendicularly inserted
into the hydrophilic membrane. Recently conformational features of
dynorphin A-(1-13) and interaction of dynorphin A-(1-13) with
lipids were investigated by Renugopalakrishnan and colleagues
(Rapaka et al. 1987; Huang et al. 1988; Renugopalakrishnan et al.
1988a,b; Renugopalakrishnan and Rapaka 1988) utilizing NMR. CD,
FT-IR and Raman spectroscopy. These studies indicated that in
aqueous solution dynorphin has an open structure, and the segment
Arg6-Arg7-Ile-Argg- manifests considerable side chain
mobility on the NMR time scale and N-terminal segment may be
disordered. In the presence of lipid, a steep increase in molar
ellipticity value starting at 240nm indicated a large
conformational change. This is consistent with the observations of
Erne et al. (1985). Recently, Schwyzer (1986) estimated the
conformation, orientation, and accumulation of dynorphin A-(1-13)
on the surface of lipid membrane. Schwyzer used -helical
conformation of dynorphln as the most stable conformation
interacting with the hydrophilic phase. He calculated the Gibbs
free energy, G for the transfer of increasing number, m, of
n-terminal residues from "random" coil conformation in water to
-helical conformation in the hydrophobic phase to predict the
preferred conformation of dynorphin and its orientation and
accumulation on the surface of neutral lipid membrane. A model of
dynorphin was derived in which the hydrophobic segments of the
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lipid were in contact with the a-helical segment and the "random"
coil segment was protruding into the aqueous phase. This ingenious
study presents a plausible explanation of the events leading to the
observed interaction of dynorphln A-(1-13).
The role of neuropeptldes in general, and of oplold peptides in
particular, is being increasingly studied in the regulation of the
immune system, as the neuropeptides appear to be agents of
communication between the immune system and the brain (for reviews,
see Morley et al. 1987; Plotnikoff et al. 1986a). ACTH suppresses
-interferon production (Johnson et al. 1984). VIP inhibits the
egress of small lymphocytes (Moore 1984). substance P is
chemotactic and cross-reacts with the chemotactic receptor of
rabbit neutrophlls (Marasco et al. 1981; Ruff et al. 1985; Payan et
al. 1983), and somatostatln inhibits the proliferation of
T-lymphocytes (Payan et al. 1984). Thus, the studies to date
indicate that the neuropeptides may play an important role in
immunomodulation and that such modulation may involve the central
nervous system, the endocrine system, and the autonomic nervous
system (Plotnikoff et al. 1985; Morley et al. 1987; Wybran 1985;
Donohoe et al. 1985; Blalock and Smith 1985).
Two interesting and independent observations, one by Wybran et al.
(1979) demonstrating the presence of morphine-like and
Met5-enkephalin-like receptors on blood lymphocytes, and the
other by Hazum et al. (1979) demonstrating the presence of
ß-endorphln receptors on lymphoblastold cells, generated a great
deal of interest on the role of oplold peptldes in
immunoregulation. Human blood T cells have receptors for morphine
and enkephallns, whereas B cells have receptors for ß-endorphin.
and T and B cell involvement may be a critical factor in generating
an immune response. For researchers in the drug abuse area, study
of the role of morphine and other opiates might yield clues to the
higher Incidence of bacterial and viral infections in opiate
addicts. It has been shown that morphine decreases the abillty to
eradicate infections (Tubaro et al. 1983; for a minireview, see
Yahya and Watson 1987). Morphine injections into lateral
ventricles suppress natural klller cell activity (Shavit et al.
1986), and heroin addicts have decreased T-lymphocyte activity
(Singh et al. 1980), thus suggesting that prolonged abuse of
opiates impairs the immune system. On the other hand, enkephallns
have been shown to prolong the survival time of tumor-bearing mice,
enhance lymphocyte blastogenesis in mice, Increase size of thymus
in mice. and, in humans, to show significant increase in active T
cell rosettes and increase natural killer (NK) cell activity
(Plotnikoff et al. 1985). Similarly, ß-endorphin enhances NK
activity and active T cell rosettes. The enhancement of NK cell
activity is important for defense against bacterial and viral
infections. Here it is interesting to note that the NK cell
stimulating ablllty appears to be associated with the N-terminal
sequence of ß-endorphin (Kay et al. 1983). In addition, both
Met5-enkephalln and ß-endorphin enhance interferon production
(Mandler et al. 1986).
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Morphine depresses T cell E-rosetting (Donohoe et al. 1985), and it
was shown by Tubaro et al. (1983) that polymorphonuclear cell
activity for ohagocytosis and superoxide radical production by
polymorphonuclear cells are depressed. In contrast, ß-endorphin
and dynorphin enhance superoxide radical formation (Sharp et al.
1985). It is very interesting that the opiates and opioid peptides
act similarly at the analgesic receptors, where they appear to
mediate diffe-ent immunologic responses. It is worthwhile that a
large number of opiates and oploid peptide analogs be tested for
their actions on the immune system and to develop SAR relationships
that will lead to the design of therapeutically useful peptide
drugs. This is particularly interesting in terms of initial
encouraging results obtained with methionine enkephalin in the
treatment of AIDS patients (Plotnikoff et al. 1986b). It appears
that there is an exciting possibility of obtaining new leads for
management of this condition from centrally acting peptides.
Awareness of the important role opioid peptides may be playing in
regulation/modulation of physiological activities/behavior has been
increasing. There also appears to be a close interaction between
the enkephalirs and other naturally occurring peptides and other
putative neurctransmitters like dopamine (Radhakishun et al. 1988)
and 5-HT (Foster and Roberts 1988). It should be rewarding to
study the interaction with other neurotransmitters, particularly
the biogenic amines, in greater detail. Among the central
autonomic activities possibly regulated by the opioid peptides, the
effects on cardiovascular regulation (Said 1987) and
thermoregulation (Shukla and Dhawan, this volume) appear to be
particularly significant. The role in reaction to stress has been
extensively studied, the initial studies having been undertaken
with morphine. The recent work has been reviewed by Olson et al.
(1987).
There is evidence that some of the central effects of clonidine and
central antihypertensives like centhaquin may be mediated via the
opioid receptors (Srimal et al. 1988). Phencyclidine may be
exerting some of its effects Via µ- or -receptors,
particularly its effects on body temperature (Hiramatsu et al.
1986).
In the past few years, considerable data have been generated on the
role of opioid peptides in the control of eating, which is
stimulated by opioid agonists (Majeed et al. 1986) in several
species (Kavaliers and Hirst 1986; Yirmiya et al. 1986), as well as
that of fluid intake, perhaps through a homeostatic control of
water balance (Spencer et al. 1986). It is interesting to note
that their effects may depend on the taste. Thus agonists were
reported to enhance eating of palatable foods (Jackson and Cooper
1986). This behavior could be suppressed by naltrexone (Kirkham et
al. 1986), which also lowered pleasure rating for sweet food and
selected odors (Fantino et al. 1986). The possible role of opioids
in pathogenesis of several functional disorders of gut has been
reviewed by Dhawan et al. (1988).
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Recent evidence indicates an important role of opioid systems in
the regulation of sexual behavior in both sexes. Initial reports
suggest an inhibitory effect of opioid peptides on male sexual
behavior via the medial preoptic area (Band et al. 1986), but if
the male sex drive is low they may mediate rewards of sex (Miller
and Baum 1986). They also mediate sexual behavior in the female,
particularly the proceptive behavior (Wiesner et al. 1986). and
interaction with 5 HT in such regulatory effects has been suggested
(Allen et al. 1986).
There are several neurological disorders in whose etiology opioid
peptides may be involved (Dhawan et al. 1988). More definitive
data need to be generated in these disorders, but a major limiting
factor is the nonavailability of suitable animal models for
conditions such as Alzheimer's disease. There is an urgent need
also to develop suitable models for neurodegenerative disorders,
nerve injury, and other neurological conditions (Taylor et al.
1987). It will be useful to develop sensitive in vitro bioassay
systems involving critical biochemical parameters having predictive
capabilities.
With the increased availability of data in species other than the
rat and mouse, it has become abundantly clear that significant
species differences do exist in the effects of opioid agonists, and
these help in better understanding of their possible physiological
roles. Several investigators have in recent years included
multiple species in their studies (Davis et al. 1986; Fanselow and
Sigmundi 1986) to assess the central roles of peptides. Recently,
studies have been extended, not only to other species of laboratory
animals and nonhuman primates, but also to insects, fish, and some
unnatural ones like the bat, deer mice, and ground squirrel (Shukla
et al. 1988; see Olson et al. 1987 for additional references).
It is difficult to explain some of the results obtained with the
opioids based on the currently available data, but more comparative
studies are indicated. It is also necessary to extend studies to
different age groups of animals, since age-related changes in
modification of stress responses (Iny et al. 1986) as well as
analgesia (Hoskins et al. 1986) have been reported. It is
therefore important to carry out carefully controlled studies
before drawing firm conclusions regarding various regulatory roles
being assigned to opioid peptides.
A great deal of research work has been carried out during the past
decade on opioids, and yet the mechanisms of their various
biological actions are far from clear. It is hoped that a greater
understanding of their role will finally result in the development
of therapeutically useful drugs and help in the alleviation of pain
and human misery.
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